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“ƒ was lucky to be treated in a hospital that takes part in a study on fatigue 
They can’t do very much for me, but at least they show that 
they understand and that’s a great help ” 
(woman 51 years old, treated for breast cancer 4 years ago)
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INTRODUCTION
The Expert Centre Chronic Fatigue of the University Medical Centre Nijmegen has 
focussed on the study of chronic fatigue since 1990. In the beginning the focus was 
mainly on Chronic Fatigue Syndrome, however during the years it expanded to 
chronic fatigue in several other specific patient groups. Nowadays it is a 
multidisciplinary collaboration of physicians, paediatricians, virologists, 
neurologists, neurophysiologists, neuroscientists, oncologists, and psychologists 
from several departments in the UMC Nijmegen.
In 1997 we began to focus on fatigue complaints in cancer survivors. With ‘cancer 
survivors’ we refer to persons who have been curatively treated for cancer and are 
disease-free at the time of participation in our studies. We conducted three studies 
in the last 5 years. All of these studies dealt with the natural presence and course of 
fatigue. We did not carry out any intervention studies. In our first study we asked a 
mixed group of cancer survivors to take part. In our second study, we extensively 
investigated a group of breast cancer survivors during a two-year period. Finally, in 
our third study, we investigated patients who were treated for a bone or soft tissue 
tumour.
The current thesis presents seven articles on the subject of fatigue complaints in 
cancer survivors: one literature review and six articles that resulted from the three 
above mentioned studies.
CONTENTS OF THIS THESIS
This thesis consists of nine chapters. In Chapter 2 we start with a literature review 
of articles that were published between 1980 and 2001 on the subject of fatigue in 
cancer patients. We reviewed articles in which fatigue was investigated in patients 
in the active phase of their disease, and in disease-free patients who completed 
cancer treatment. In this review we focussed on what is known concerning: the 
prevalence of fatigue, the medical and psychosocial correlates of fatigue, and 
interventions to reduce fatigue.
In Chapter 3 results of our first study are described. The main goal of this study 
was to assess the prevalence of fatigue in disease-free cancer patients with help of 
a validated fatigue questionnaire. Furthermore, we analysed the relationship 
between severe fatigue and former treatment modalities, problems of concentration 
and motivation, physical activity, functional impairment, depression and anxiety. 
Finally, we compared severely fatigued disease-free cancer patients to patients 
with Chronic Fatigue Syndrome (CFS).
Chapter 4 presents the baseline results of our longitudinal study on fatigue 
complaints in disease-free breast cancer patients. In this chapter we investigated 
the prevalence of severe fatigue in a sample of disease-free breast cancer patients 
who completed treatment for breast cancer for a minimum of 6 months and a 
maximum of 60 months before the study commenced. Further, we studied the
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relations between severe fatigue complaints and former treatment modalities, like 
type of operation, type of adjuvant therapy, duration of treatment and time since 
treatment ended. Finally, we described the ‘severely fatigued breast cancer patient’ 
on basis of measures of psychological well-being, functional impairment in daily 
life, sleep disturbances, physical activity, neuropsychological impairment, social 
functioning, social support and self-efficacy and causal attributions with respect to 
fatigue complaints. In this study an age-matched sample of women without a 
history of cancer was included.
Chapter 5, which is also based on baseline data of our longitudinal study on fatigue 
complaints in disease-free breast cancer patients, describes the relations between 
fatigue, neuropsychological functioning and physical activity after treatment for 
breast cancer. In this article a clear distinction has been made between different 
ways to measure neuropsychological functioning and physical activity. Both 
concepts were measured with general self-report questionnaires, daily self-report 
measures and by measures of actual behaviour (neuropsychological tests and 
actometer). In this article we investigated whether severely fatigued disease-free 
breast cancer patients, non- severely fatigued disease-free breast cancer patients 
and women without a cancer history showed differences in general self-reported, 
daily self-reported and objective neuropsychological and physical functioning.
In Chapter 6, similarities and differences between severely fatigued breast cancer 
patients and matched female Chronic Fatigue Syndrome patients are described. 
The purpose of this study was to examine to what extent a patient who experiences 
severe fatigue after treatment for cancer resembled a patient with CFS. This has 
been done in a much more profound way than it has been done in the study that is 
described in Chapter 3. In this study, results were based solely on general self­
report questionnaires, while in the current study, results were based on general self­
report questionnaires, daily self-report questionnaires and on measures of actual 
behaviour (neuropsychological tests and actometer). We compared severely 
fatigued breast cancer patients and female Chronic Fatigue Syndrome patients on 
self-efficacy, psychological well-being, sleep, concentration, physical activity, 
social support, and pain. The idea behind this comparison was to determine 
whether the same cognitive behavioural intervention to reduce fatigue in CFS 
patients would be appropriate as well for severely fatigued disease-free breast 
cancer patients.
In Chapter 7 we widen our focus to fatigue complaints in patients who were treated 
for bone and soft tissue tumours, 1 to 15 years before accrual in this study. We 
thought this is of importance because this patient population has some 
characteristics that are different from our breast cancer patient population. First, 
within this population, patients have been treated for both malignant and benign 
tumours. Second, treatment for these kinds of tumours differs from treatment for 
breast cancer. Finally, time since end of treatment varied more widely within the 
investigated patient population than in our breast cancer patient population. The
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structure of this article is divided into two parts. In the first part baseline data were 
analysed. The prevalence of fatigue after treatment for malignant and benign bone 
and soft tissue tumours and the association between fatigue severity and former 
disease and treatment characteristics were described. Furthermore, we investigated 
whether patients who finished treatment relatively recently were more severely 
fatigued than patients who finished treatment longer ago. Finally we studied the 
association between fatigue severity and demographic, psychological and/or 
physical variables. In the second part we focussed on longitudinal data. In this part 
we investigated the course of fatigue during a two year period and the predictors of 
severe and heightened fatigue at follow-up.
In Chapter 8 the focus is on the follow-up of our breast cancer patient cohort 
during a two-year period. In this chapter we investigated whether severe fatigue is 
a persistent problem and whether persistent fatigue was related to former treatment 
modalities. In addition, we studied to what extent psychological well-being, 
functional impairment, sleep disturbances, physical activity, neuropsychological 
functioning, social functioning, social support, self-efficacy and causal attributions 
were able to predict persistent fatigue. Finally, we exploratory described the course 
of fatigue for those patients that developed a disease-recurrence during the two 
years of our study.
Finally, Chapter 9 entails a general discussion of the studies presented in this 
thesis. Results are summarised, and shortcomings and implications are noted.

Chapter 2
Literature review 
Fatigue in cancer patients 
during and after treatment: prevalence, 
correlates and interventions
Petra Servaes1, Stans Verhagen2, Gijs Bleijenberg1
Departments of Medical Psychology1 and Medical Oncology2 
University Medical Centre St Radboud, Nijmegen, the Netherlands
European Journal of Cancer 2002; 38: 27-43
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ABSTRACT
Research on the relationship between cancer and fatigue has increased 
considerably in recent years. In this review, we focus on fatigue observed in 
patients during and after treatment for cancer, using data from empirical studies. 
The results from these studies indicate that fatigue is mostly studied during active 
treatment for cancer, and is an important problem during this period. Studies that 
focussed on fatigue in disease-free cancer patients, although less prominent, also 
indicate fatigue is an important complaint in this time period. It is hard to draw 
conclusions with regard to the relationships between fatigue and disease- and 
treatment- related characteristics, because these relationships are seldom properly 
investigated. Relationships between fatigue and psychological, social, behavioural 
and physical factors have been established in several studies. However, most 
studies focussed on the depression-fatigue association. Finally, most intervention 
studies to reduce fatigue appear to be successful, but the follow-up analyses are 
lacking.
INTRODUCTION
Fatigue is a subjective experience that affects everybody. For healthy individuals, 
it might be a protective, sometimes even pleasant, regulatory response to physical 
or psychological stress. It seems to maintain a healthy balance between rest and 
activity. For people with specific diseases, fatigue often becomes a major 
distressing symptom and for people with cancer, fatigue has been described as a 
major concern during treatment, in the advanced stages of the disease and after 
curative treatment. Whereas healthy individuals report fatigue to be a pleasant, 
acute, normal, regulating phenomenon which helps them to schedule their daily 
rhythm and which disappears after a good night’s sleep, cancer patients speak 
about chronic, unpleasant, distressing, life and activity-limiting fatigue throughout 
the day.
In various publications, different definitions to describe fatigue in patients with 
cancer have been used. From all these different descriptions, we conclude that 
fatigue is a subjective and multidimensional concept with several modes of 
expression: physical (e.g. diminished energy, need to rest), cognitive (e.g. 
diminished concentration or attention) and affective (e.g. decreased motivation or 
interest).
In this review, we focus on what is currently known about fatigue during and after 
treatment for cancer, based on empirical studies with reliable instruments. In the 
first part of our review (fatigue during treatment for cancer), studies are included in 
which fatigue was investigated in patients in the active phase of their disease. In 
the second part (fatigue after treatment for cancer), disease-free patients who 
completed cancer treatment are included. The prevalence of fatigue and correlates
18 Chapter 2
of fatigue are discussed. In addition, the literature concerning interventions to 
reduce fatigue in cancer patients is also examined. In Tables 1-3, all of the 
reviewed studies are summarised. Study characteristics and key findings are 
described and, when possible the effect size was calculated.
METHOD
We conducted a literature search in Medline, Current Contents (CC) and Psychlit 
for the period 1980- July 2001. In the first search, 154 different articles were found 
with the keywords FATIGUE and (CANCER or HODGKIN’S or TUMOR or 
TUMOUR or MALIGN* or HAEMATOLOG* or RADIOTHERAPY or 
RADIATION or CHEMOTHERAPY or HORMONE THERAPY) in the title. In a 
second search, we combined the words CANCER (or HODGKIN’S or TUMOR or 
TUMOUR or MALIGN* or HAEMATOLOG*) and (INTERVENTION or 
EXERCISE or PSYCHOTHERAPY or GROUP or COUNSEL*) in the title and 
the word FATIGUE in the title, keyword or abstract. This search resulted in 27 
articles.
The following articles were excluded: 1) review articles, 2) editorials/ comments/ 
practical guidelines, 3) studies in which the sample size was less than 15, 4) studies 
investigating a sample of subjects other than adult cancer patients (e.g. children, 
caregivers), 5) studies in which evaluation of a fatigue-questionnaire was the only 
intention, 6) uncontrolled intervention studies, 7) studies published in a language 
other than English or Dutch and 8) studies in which fatigue was measured with 
only one or a few items from quality of life questionnaires. This last criterion was 
entered because these studies give a limited insight. The severity of the fatigue 
complaint is lacking and comparison with other groups is not possible.
Using these criteria, we had to exclude 127 articles (112 of the 154 and 15 of the 
27), resulting in 54 articles to be reviewed. We checked the internal consistency of 
the fatigue questionnaires that were used in these 54 articles and concluded that 
they are all reasonable (alpha 0.70) to good (alpha 0.97).
FATIGUE DURING TREATMENT FOR CANCER 
Description of the reviewed studies
In Table 1, 26 publications are summarised in which fatigue was investigated in a 
sample of cancer patients during or immediately after treatment for cancer1-26.
Table 1. Fatigue during treatment for cancer
Author Diagnosis and treatment Patient characteristics Number of 
measurements
Fatigue
questionnaire*
Blesch, 1991
(1)
111- and out patients (breast and lung 
cancer) receiving chemotherapy 
and/or radiotherapy (50% inpatients)
44 breast cancer patients, age 
24-69, mean 51 (sd 11)
33 lung cancer patients, age 38 
74, mean 58 (sd 9), 75% male
1 VAFS, POMS- 
fatigue
Key finding: Fatigue was present to some degree in 99% o f the patients. Two- thirds rated their level o f  fatigue as moderate to severe.
Cimprich,
1992
(2)
Breast cancer patients during 
hospitalisation for surgery (mean 3 
days after surgery)
32 patients, age 29-84, mean 
54 (sd 14)
1 Attentional fatigue: 
digit span, alphabet 
backward, symbol 
digit modification 
test, letter cancellation
Key finding: Patients had a significantly decreased capacity to direct attention in comparison to norm scores.
Glaus, 1993 (3) Patients with different cancer 
diagnoses during treatment with 
chemotherapy and/or radiotherapy
20 cancer patients age 31-85, 
mean 54 (sd 15), 30% male
30 healthy controls age 20-58, 
mean 33 (sd 10), 39% male
4 times daily during 7 
days
VAFS
Key finding: The mean fatigue score was significantly higher fo r  cancer patients than fo r  healthy controls (effect size 0.31).
Irvine, 1994A 
(4)
Patients with lung, breast and 
gynaecological cancer during 
chemotherapy or radiotherapy
54 radiotherapy, 47 chemo­
therapy, age 25-77, mean 55 
(sd 11), 3% male
53 healthy controls, mean age 
63, 0% male
2 (start and midpoint of a 
cycle of chemo-therapy 
or start and end of 
radiotherapy)
PBFFQ
Key finding 61% experienced ‘clinical fa tigue’. Cancer patients experienced a significant increase in fatigue during therapy. Their 
fatigue scores were higher than scores o f  control subjects (effect size 0.65).
Table 1. continued
Author Diagnosis and treatment Patient characteristics Number of Fatigue 
________________________________________________________________ measurements________questionnaire*
Graydon,
1995a
(5)
Key finding:
Patients with breast and 54 radiotherapy, 45 chemo- 2 (start and midpoint of a PBFFQ 
gynaecological cancer during therapy, age 25-77, mean 55 cycle of chemotherapy or 
chemotherapy or radiotherapy (sd 11 ) start and end of radio­
therapy)
At second assessment, patients were significantly more fatigued than they had been at first assessment.
Dean, 1995 
(6)
Patients with malignant melanoma 30 patients, age 20-85, mean 5 (before treatment and at 
during treatment with interferon alpha 53 (sd l7 ),67%  male the end of each two
weeks)
PFS
Key finding: Patients were significantly more fatigued mid- or post treatment than they had been at pre-treatment measurement.
Richardson,
1996
(7)
Key finding:
Patients with different cancer 129 patients, age 26-82, mean Daily during one cycle of 
diagnoses during chemotherapy 58 chemotherapy
90% reported fatigue at some point during a cycle o f  chemotherapy.
VAFS
Dimeo, 1997 
(8)
Patients with different cancer 78 patients, age 18-60, mean 1 
diagnoses in the period between 40 (sd 11), 40% male 
receiving 1 to 4 chemotherapy cycles
POMS-fatigue
and hospital admission for high-dose 
chemotherapy with stem cell 
transplantation
Key finding: A weak correlation was found between fatigue and maximal physical performance (-.30).
Table 1. continued
Author Diagnosis and treatment Patient characteristics Number of 
measurements
Fatigue
questionnaire*
Irvine, 1998 
(9)
Key finding:
Smets, 1998a 1 
(10)
Key finding:
Smets, 1998b 
(11)
Key finding:
Visser, 1998 B 
(12)
Key finding:
Breast cancer patients during 
radiotherapy and at 3 and 6 months 
follow-up
76 patients, age 33-81, mean 
60 (sd 11)
6 (before radiotherapy, 1 PBFFQ 
and 2 weeks later, during 
the last week, and 3 and 
6 months later)
Fatigue increased over the course o f  treatment, was highest at the last week o f treatment and returned to pre-treatment 
levels by 3 months after treatment.
Patients with different cancer 
diagnoses during radiotherapy
250 patients, mean age 64 (sd 
13), 58% male
MFI-202 (before start of 
treatment and 2 weeks 
after completion)
Fatigue scores after radiotherapy were significantly higher than pre-treatment scores. After treatment 46% o f the patients 
reported fatigue as among the three symptoms that caused them most distress.
MFI-20Patients with different cancer 250 patients, mean age 64 (sd 3 (before start of
diagnoses during and after 13), 58% male treatment, 2 weeks and 9
radiotherapy months after completion)
Fatigue during treatment with radiotherapy is best explained by treatment related demands (daily travel to hospital and 
confrontation with other patients) and demands o f the social environment (work, children).
Patients with different cancer 
diagnoses during and after 
radiotherapy
250 patients, mean age 64 (sd 
13), 58% male
3 (before start of 
treatment, 2 weeks and 9 
months after completion)
MFI-20
Correlations between fatigue and depression were moderate. Depression scores did not change while fatigue scores rose 
over the course o f  cancer treatment.___________________________________________________________________________
Table 1. continued
Author Diagnosis and treatment Patient characteristics Number of 
measurements
Fatigue
questionnaire*
Richardson,
1998
(13)
Patients with different cancer 
diagnoses during chemotherapy
109 patients, age 20-89, mean 
59, 46% male
daily during one cycle of 
chemo-therapy (21 or 28 
days)
VAFS
Key finding: 89% reported fatigue at some point during a cycle o f  chemotherapy.
Berger, 1998 c 
(14)
Breast cancer patients during 
chemotherapy
72 patients, age 33-69, mean 
50 (sd 9)
4 days at the start 
and 3 days at cycle 
midpoints during the first 
3 cycles of chemotherapy
PFS
Key finding: Fatigue scores were significantly higher at the day o f  chemotherapy administration than between treatment courses, but 
fatigue did not increase over time.
Miaskowski,
1999
(15)
Patients with different cancer 
diagnoses with bone métastasés during 
radiotherapy
24 patients, mean age 56 (sd 
13), 50% male
during 2 days LFS
Key finding: Patients reported moderately amounts o f  fatigue. Fatigue levels were 
morning following a night’s rest.
higher at the end o f  the day and decreased in the
Gaston-
Johansson,
1999
(16)
Breast cancer patients in the period 
between receiving chemo-therapy and 
high-dose chemotherapy with stem cell 
transplantation
127 patients, age 22-60, mean 
45 (sd 8)
1 PFS, VAFS
Key finding: 91% reported fatigue at some point.
Table 1. continued
Author Diagnosis and treatment Patient characteristics Number of 
measurements
Fatigue
questionnaire*
Stone, 1999 
(17)
Key finding:
Patients with different cancer 95 patients, age 30-89, mean 
diagnosis (advanced cancer, but 67, 43% male 
currently not receiving chemotherapy
or radiotherapy) 98 healthy controls, age 41-85,
mean 68, 38% male
Prevalence o f  ‘severe subjective fatigue ’ was found to be 75%.
2 (baseline and 2 weeks 
later)
FSS
Hann, 1999 
(18)
Key finding:
Breast cancer patients receiving high- 
dose chemotherapy with bone marrow 
transplantation
Cancer patients reported significantly j 
POMS 0.75; F S I0.61).
31 patients, age 36-74, mean 3 (prior to treatment, POMS-fatigue, FSI 
51 (sd 15) mid-treatment, near
treatment completion)
49 healthy controls, age 36-55, 
mean 51 (sd 8)
more frequent and severe fatigue than women with no cancer history (effect size
Monga, 1999 
(19)
Key finding:
Prostate cancer patients during and 36 patients, age 55-79, mean 4 (pre-, middle- and PFS 
after radiotherapy 67 completion of treatment,
and 4-5 weeks follow-up)
Fatigue scores were significantly higher during and directly after radiotherapy (25%) than at pre-treatment (8%). A t 5 
week follow-up, fatigue scores were not higher anymore than scores at pre-treatment.
Jacobsen, 1999 
(20)
Key finding:
Breast cancer patients during 54 cancer N=54, age 28-77, 
chemotherapy mean 51 (sd 10)
54 control, age 32-77, mean 54 
(sd 11)
Cancer patients experienced significant worse fatigue than women with 
and during chemotherapy (effect size POMS 0.88).
3 (before treatment and POMS-fatigue, FSI 
after completion of the 
second and third cycle)
no cancer history, before (effect size POMS 0.51)
Table 1. continued
Author Diagnosis and treatment Patient characteristics Number of 
measurements
Fatigue
questionnaire*
Berger, 1999 c 
(21)
Key finding:
Breast cancer patients during 72 patients, age 33-69, mean 
chemotherapy 50 (sd 9)
Fatigue has been found to be associated with less daytime activity.
4 days at the start and 3 
days at cycle midpoints 
during the first 3 cycles 
of chemotherapy
PFS
Stone, 2000a 
(22)
Patients with prostate cancer during 
treatment with hormone therapy
58 patients, age 55-80, median 
69
2 (day they started 
therapy, 3 months later)
FSS
Key finding: Prevalence o f  severe fatigue was found to be 14% at baseline, before treatment started. Median FSS scores increased 
significantly after 3 months treatment.
Stone, 2000b 
(23)
Key finding:
Recently diagnosed patients with 227 patients, age 30-89, 1 FSS 
breast or prostate cancer awaiting median 66, 56% male 
therapy, patients with non-small-cell
lung cancer referred for palliative 98 control, age 41-85, median 
chemo-therapy and patients with 68, 38% male 
advanced cancer (but currently not 
receiving chemo- or radiotherapy)
Prevalence o f severe fatigue was 48%). Median FSS o f  the combined patient group was significantly higher than that o f  the 
control group.
Stone, 2000c 
(24)
Patients with different cancer 
diagnosis, during different anti-cancer 
treatment
576 patients, age 18-89, 
median 59, 37% male
1 FACT-fatigue
Key finding: 58% reported that fatigue had affected them in the past month. Fatigue affected patients significantly more than any other 
symptom.
Table 1. continued
Author Diagnosis and treatment Patient characteristics Number of 
measurements
Fatigue
questionnaire*
Okuyama, 2001 Patients with advanced lung cancer 157 patients, age 27-80, mean 1 
(but currently not receiving anti-cancer 63, 71% male 
treatment)
CFS, FNS, questions 
on interference of 
fatigue with 7 
domains of daily 
activity
Key finding: 51% was found to experience clinical fatigue.
Ahsberg, 2001 
(26)
Key finding:
Patients with different cancer 
diagnosis, during and after 
radiotherapy
81 patients, age 30-70, 9% 
male
4 (before treatment, at SOFI 
the last week of 
treatment, at 1 and 3 
months after completion 
of treatment).
Patients were significantly more fatigued at the end o f  a course o f  radiotherapy than they had been before.
different studies with almost the same sample of patients.
B different studies with the same sample of patients. 
c different studies with the same sample of patients.
# Fatigue Questionnaires: CFS- Cancer Fatigue Scale; FACT- Functional Assessment of Cancer Therapy; FNS- Fatigue Numerical Scale; FSI- Fatigue 
Symptom Inventory; FSS- Fatigue Severity Scale; LFS- Lee Fatigue Scale; MFI-20- Multidimensional Fatigue Inventory; PBFFQ- Pearson Byars Fatigue Feeling 
Questionnaire; PFS- Piper Fatigue Scale; POMS- Profile of Mood States; SOFI- Swedish Occupational Fatigue Inventory; VAFS- Visual Analogue Fatigue scale
to
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These 26 publications were based on 22 studies. As indicated in Table 1, some 
studies were based on the same sample o f patients, answering different research 
questions. In ten o f these 22 studies, a homogenous group o f cancer patients was 
investigated. In six studies, the sample consisted o f breast cancer patients. In two 
studies, patients with prostate cancer were included. In one study, patients with 
malignant melanoma participated and finally, in one study, patients with advanced 
lung cancer participated. In the other 12 studies, samples consisted o f patients with 
different cancer diagnoses.
Most studies (seven) investigated fatigue during treatment with chemotherapy. In 
three o f these studies, patients were receiving high dose chemotherapy in 
combination with stem cell transplantation. More specifically, in one study patients 
were receiving high-dose chemotherapy at the moment o f investigation, while in 
two other studies patient underwent chemotherapy recently, and were waiting to 
receive high dose chemotherapy. In five studies, patients were investigated during 
treatment with radiotherapy. In two studies, the investigation took place while 
patients were treated with hormonal therapy and in four studies while they were 
undergoing either chemo- or radiotherapy, or a combination o f these treatments. 
Furthermore, in one study, in which attentional fatigue was the research subject, 
patients were investigated during hospitalisation after surgery for cancer. The idea 
behind this latter study was that the mental effort required to cope with the intense 
and competing demands imposed by a diagnosis o f cancer may lead to attentional 
fatigue. In two studies, patients had advanced cancer, but they were not receiving 
treatment at the time o f investigation and, finally, in one study, the sample 
consisted o f recently diagnosed patients awaiting therapy, patients referred for 
palliative chemotherapy and patients with advanced cancer, not receiving treatment 
at the time o f investigation.
A wide variety o f instruments were used to measure fatigue. Frequently used were 
the Piper Fatigue Scale, the Fatigue Severity Scale, the fatigue subscale o f the 
POMS and Visual Analogue Fatigue Scales.
The size of the investigated samples ranged from 20 to 576 cancer patients. The 
ages o f the patients within these samples were within a range from 18 to 89, with 
means ranging from 40 to 67. In seven studies, patients were all female, in two 
studies patients were all male. In the majority o f the other 13 studies, there was an 
equal distribution o f men and women. A control group o f healthy subjects was 
included in six studies only.
Prevalence and course of fatigue
Percentages of presence of fatigue differed in the reviewed studies. Twenty-five 
percent o f a sample o f prostate cancer patients reported fatigue during and directly 
after a course o f radiotherapy19. Forty-six percent o f a mixed sample o f cancer 
patients reported fatigue among the three symptoms that caused them the most
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distress at the end o f a course o f radiotherapy10. The prevalence o f severe fatigue 
(defined as fatigue greater than that experienced by 95% o f the control group) in a 
combined group of patients with recently diagnosed breast or prostate cancer, 
patients with inoperable non small cell lung cancer and patients receiving inpatient 
palliative care was 48%23. In a Japanese study, 51% o f a sample o f patients with 
advanced lung cancer was found to experience clinical fatigue (which means that 
they complained o f interference of fatigue with at least one domain o f daily living 
activity)25. In another study, 58% o f a sample o f cancer patients undergoing anti­
cancer therapy reported that fatigue had affected them in the past month, and that 
fatigue affected them significantly more than any other symptom24. Furthermore, 
61% of a mixed sample o f the cancer patients reported clinical fatigue (as defined 
by a score higher than the midpoint o f the fatigue questionnaire) during 
chemotherapy or radiotherapy4. Finally, the prevalence o f severe fatigue in patients 
with advanced cancer was found to be 75%17. Studies in which Visual Analogue 
Fatigue Scales were used, present even higher percentages o f fatigue. In two 
studies in which a diary was used, 89 and 90% o f the investigated patients reported 
fatigue at some point during a cycle o f chemotherapy7,13. In two other studies, with 
only one measurement time, fatigue was present to some degree in 91%16 and in 
99%1 of the investigated patients. In this last study, two thirds rated their fatigue as 
moderate to severe.
In all six studies in which cancer patients were compared with healthy control 
subjects, cancer patients reported more frequent and severe fatigue than healthy
3 4 17 18 2023control subjects ’ ’ ’ ’ ’ . In addition, in a study in which attentional fatigue was 
measured during hospitalisation for breast cancer surgery, patients had a decreased 
capacity to direct attention compared with available norm scores2. In four o f these 
studies, it was possible to calculate the effect size. The effect sizes were 0.31 3,
0.654, 0.7518 and 0.8820.
In ten studies, fatigue scores prior to treatment were compared with mid- or post­
treatment fatigue scores. Nine studies reported that patients were significantly 
more fatigued mid- or post treatment than they had been at pre-treatment 
measurement4,6’9’10’18'20’22’26. In one study, contrary results were reported. In this 
study, fatigue was found to be significantly higher on the day o f chemotherapy 
administration than between the treatment courses, but fatigue did not increase 
over time14.
The course o f fatigue during the day has been described in three studies only. In 
one study, the healthy population felt fit in the morning, with steadily increasing 
levels o f fatigue over the day. In cancer patients, the daily profile was different: 
fatigue was continuously present, they already felt fatigued in the morning and, to 
a certain degree, over the whole day, but showed lower peak levels in the evening3. 
In the other two studies, results were contradictory. The authors found that fatigue 
in cancer patients varied throughout the day, more frequently occurring in the
28 Chapter 2
afternoon and early evening13,15. These contradictions could be due to the inclusion 
o f dissimilar groups o f patients; inpatients3 versus outpatients13,15.
Correlates of fatigue
Disease related variables
Results with regard to the relationship between fatigue and disease related 
variables have been reported in several o f the reviewed studies. In seven o f the ten 
studies, severity o f fatigue appeared to be unrelated to cancer diagnosis, cancer 
stage at diagnosis, size o f original tumour, number o f nodes involved and presence
1,4,9,17,18,20,25and site o f metastases ’ ’ ’ ’ ’ ’ . However, in three studies, significant 
associations were found between fatigue and particular types o f cancer. In a sample 
o f radiotherapy patients with head and neck, gastrointestinal, gynaecological, lung, 
breast, urogenital and haematological cancer, lung cancer patients reported most 
fatigue, and patients with malignancies in the head and neck region reported least 
fatigue10. In another study, patients with small cell lung cancer were found to 
report less fatigue in contrast to patients with cholangiocarcinoma or pancreatic 
cancer, breast cancer, or a lymphoma during a cycle o f chemotherapy13. 
Considering the fact that patients with small cell lung cancer quickly feel better 
after administration o f chemotherapy, this result is not surprising. Finally, in a 
mixed sample o f cancer patients, the prevalence o f severe fatigue was found to be 
15% among patients with recently diagnosed breast cancer, 16% among patients 
with recently diagnosed prostate cancer, 50% among patients with inoperable non 
small cell lung cancer and 78% among patients receiving inpatient palliative care23.
Treatment related variables
It is generally accepted in clinical practice that fatigue complaints during treatment 
for cancer are a result o f treatment with surgery, chemotherapy, radiotherapy or 
hormonal therapy. However, the association between the severity o f fatigue and 
treatment related variables has been investigated in only a few studies. In two 
studies, fatigue scores were compared between patients receiving different kinds of 
surgery for breast cancer. No differences were found between patients who 
underwent mastectomy versus breast conservation surgery with regard to 
(attentional) fatigue2,20. Furthermore, no differences with regard to fatigue have 
been found between patients receiving chemotherapy versus radiotherapy1,25. In 
addition, in a sample o f patients undergoing radiotherapy, no associations were 
found between fatigue and radiation dose or fractionation10. It should, however, be 
noted that in this study crude categorisations were used to have large enough 
groups for meaningful statistical analyses. In two studies in which patients 
underwent chemotherapy, the relationship between fatigue and type of 
conditioning has been investigated. Results o f one study indicate that the type of 
conditioning regimen (61% received cyclophosphamide, thio-TEPA and
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carboplatin, 35 % received thio-TEPA, Novantrone and Taxol, and 4% received 
ifosfamide, carboplatin and etoposide) was unrelated to fatigue18. In the other 
study, fatigue was statistically associated with methods o f drug administration. 
Patients receiving conventional 3 to 4 week cycles o f chemotherapy experience 
high levels o f fatigue for the first 4 to 5 days after treatment, which gradually 
decline. In contrast, patients receiving weekly injections o f chemotherapy, 
experience moderate levels o f fatigue that fluctuate cyclically13.
Finally, anaemia is a frequent complication during the treatment o f cancer. 
However, in the reviewed studies, only was a weak relationship found between 
haemoglobin level and fatigue23. On the contrary, in six studies no relationship 
could be found1’3’4’9’17’25.
Demographic variables
In ten studies, relationships between the demographic variables and fatigue were 
investigated. In nine o f these studies, no relationships were found between fatigue
5101217182022 2325and age, gender, marital status, race and working status ’ ’ ’ ’ ’ ’ . Female 
patients were found to experience more fatigue in only one study3. However, this 
result has to be interpreted carefully, as the distribution o f men and women was not 
equal.
Psychological, physical, social and behavioural variables
Feeling sad, depressed, anxious, confused and angry are normal reactions to the 
whole life-threatening situation o f being diagnosed and treated for cancer. 
Emotional vulnerability and the endurance o f heavy stress over prolonged periods 
o f time may contribute to fatigue. In several studies, the intensity o f fatigue 
showed a strong correlation with indicators o f psychological distress such as 
depression, somatisation, and anxiety1’4’8’9’10’15’16’18’20’23'26. However, other studies 
present contradictory results. No correlation has been found between attentional 
fatigue and mood state after surgery for breast cancer2. Furthermore, severity of 
fatigue in patients with advanced cancer was unrelated to m ood17. This discrepancy 
may partly be explained by the nature o f the patient sample. All patients had 
advanced disease and most had multiple physical problems and a very short 
prognosis. Under these circumstances, it is probable that fatigue has a different 
origin to that occurring in patients with earlier stage disease. Finally, in three 
studies, although correlations between fatigue and depression were moderate, 
depression scores did not change while fatigue scores rose over the course of
12 19 22radiotherapy ’ and hormonal therapy .
With regard to the quality o f sleep, results were unambiguous, suggesting higher 
fatigue is associated with more sleep problems10’14’15’20’25. In addition, a change in 
sleep patterns was among the most frequently mentioned symptoms to which 
patients attributed their fatigue7. The association between fatigue and pain has very 
rarely been the subject o f investigation; in the studies we reviewed, however,
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results were similar. More severe fatigue before treatment was associated with pain 
in breast cancer patients16,20. In patients with advanced cancer, fatigue severity was
15,17,23,25also significantly associated with pain ’ ’ ’ . An association between fatigue and 
chemo- and radiotherapy side effects, like nausea, mouth sores, chills and vomiting 
has been found in two studies7,17. In addition, fatigue during treatment with 
radiotherapy is best explained by treatment related demands (daily travel to 
hospital and confrontation with other patients) and demands of the social 
environment (work, children)11.
Finally, the relationship between fatigue and physical activity has been assessed in 
three studies. Results were identical. Fatigue was found to be associated with less 
daytime activity21. In another study, activity levels were significantly different over 
time in a mirror-image pattern o f fatigue14. In addition, a weak association between 
fatigue and maximal physical performance has been found8.
Summary
From the reviewed studies, it can be concluded that fatigue is an important 
complaint during treatment for cancer. Prevalence estimates o f fatigue during 
treatment for cancer range from 25% to 75% in different samples o f cancer 
patients, measured with different fatigue questionnaires. When Visual Analogue 
Fatigue Scales were used, percentages rose up to 99%. In studies in which a control 
group o f healthy subjects was included, cancer patients reported more frequent and 
severe fatigue than healthy controls.
Most studies failed to find relationships between fatigue and disease related 
variables, such as diagnosis and stage at diagnosis. However, it is important to note 
that these negative results might be explained by the study characteristics. For 
instance, in studies investigating a small sample o f patients coupled with a wide 
variation of disease-related variables, the chance o f finding statistical differences is 
very small. However, studies o f homogenous samples o f cancer patients may also 
fail to find significant correlates of fatigue because o f a lack o f dispersion.
The relationship between fatigue and treatment related factors, such as type of 
surgery and type o f adjuvant therapy, has rarely been investigated. Therefore, no 
conclusions can be drawn. Furthermore, results regarding the relationship between 
demographic variables and fatigue were unambiguous. In nine o f the ten studies, 
no significant relationships were demonstrated. Finally, psychological distress, 
quality o f sleep and a few other variables (pain, therapy side effects, and physical 
activity) were found to be related to fatigue.
Literature review 31
FATIGUE AFTER TREATMENT FOR CANCER 
Description of the reviewed studies
In Table 2, 16 publications are summarised in which the focus was on off­
treatment fatigue2742. These 16 publications were based on 13 studies. In these 
studies, fatigue complaints have been investigated in disease-free cancer patients, 
who completed curative treatment for cancer in the (recent) past. In seven o f these 
13 studies, a sample o f breast cancer patients was investigated. In one study, 
Hodgkin’s disease survivors, in one study, lymphoma patients and in one study, 
patients treated for haematological malignancies were investigated. Finally, in 
three studies, the sample consisted o f patients treated for various kinds o f cancer. 
Mean time since completion o f cancer treatment ranged from 9 months to 12 years. 
In one study, the time since diagnosis was mentioned (mean 2.5 years). In this 
study, because some patients were diagnosed with cancer only 6 months ago, there 
is a possibility that these patients were still in active treatment at the time of 
participation in the study28.
Most studies made use o f more than one fatigue questionnaire. Frequently used 
instruments were the Fatigue Symptom Inventory, the fatigue subscale o f the 
Profile o f Mood State, the Piper Fatigue Inventory and the Fatigue Questionnaire. 
Sample sizes o f the disease-free cancer patients in the reviewed articles, ranged 
from 33 to 1975. The ages o f disease-free cancer patients ranged from 18 to 90 
years, with means ranging from 32 to 65 years. In seven studies, all o f the patients 
were female, in one study, all the patients were male and, in the other five studies, 
the distribution o f men and women was approximately equal.
In six studies, a control group was included. In five o f these studies, the control 
group consisted o f healthy subjects without a cancer history. In the sixth study, 
investigating fatigue after treatment for breast cancer, the control group consisted 
o f women who were treated for benign breast problems. Furthermore, in four
studies, norm scores were available for the fatigue questionnaire that was
used33,35,36,40.
Prevalence of ‘off treatment-fatigue’
In five studies, percentages o f patients suffering fatigue have been mentioned. In a 
study o f cancer survivors who completed treatment more than 1 year ago, 17% met 
formal diagnostic criteria for cancer related fatigue41. In a sample o f Hodgkin’s
33,39,42survivors, 26% had substantial fatigue for 6 months or longer33,39,42. This 
percentage was significantly higher than the percentage among 2214 controls 
representative o f the general Norwegian population (11%). In a study investigating 
a sample o f patients who had been treated for various kinds o f cancer, 29 percent 
experienced heightened feelings o f fatigue compared with norm scores o f healthy 
control subjects. Nineteen percent o f the total sample even experienced severe 
fatigue40. Within a large sample o f breast cancer survivors, 30 percent reported
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heightened levels o f fatigue relative to women in the general population36. Finally, 
in a sample o f cancer patients having a prior history o f chemotherapy, 30% 
experienced fatigue on a daily basis. Ninety-one percent o f those who experienced 
fatigue reported that it prevented a ‘normal life’ 38.
In six studies, fatigue scores o f disease-free cancer patients have been compared 
with scores o f control subjects. Four studies indicate that fatigue scores o f disease- 
free cancer patients long after they finished treatment were significantly higher 
than fatigue scores o f control subjects. In the first study, a group o f disease-free 
breast cancer patients reported more fatigue, more weakness and less vitality 
relative to the benign breast problem group at the initial and the 4 month follow-up 
assessments30. In the second study, comparing former breast cancer patients with 
women with no history o f cancer, patients reported more severe fatigue and worse 
quality o f life because o f fatigue31. In the third study, male patients treated for 
haematological malignancies had higher mean general fatigue, physical fatigue and 
mental fatigue scores compared with men without a cancer history34. Finally, in a 
study o f former bone marrow transplantation recipients, patients reported 
significantly more fatigue, on significantly more days in the past week, as well as 
for a significantly greater part o f the day, than the non-cancer comparison 
subjects27. The effect sizes in the above described studies range from 0.30 to 0.97. 
However, in two studies contradictory results have been described. Both o f these 
studies compared disease-free cancer patients after a course o f radiotherapy with a 
healthy control group. Results indicated that the fatigue experienced by patients 
after radiotherapy for cancer was not significantly different in intensity, duration or 
disruptiveness from fatigue experienced by healthy women29,32. In addition, three 
studies which were described in Table 1, conducted follow-up analyses o f fatigue 
scores at 1 and 3 months after radiotherapy for different kinds of cancer26, 3 and 6 
months after radiotherapy for breast cancer9 and 4-5 weeks after radiotherapy for 
prostate cancer19. All studies concluded that fatigue scores had returned to pre­
treatment levels at follow-up.
Correlates of fatigue
Disease related variables
The relationship between off-treatment fatigue and disease related variables has 
been investigated in seven studies. In these studies, it was found that cancer 
diagnosis29’34, disease stage at diagnosis27’29’31'33’37, size o f the original
27,32,37 27 33tumour ’ ’ , number o f nodes involved and having relapsed were not 
significantly related to fatigue intensity.
Table 2. Fatigue after treatment fo r  cancer
Author Diagnosis and treatment Patient characteristics Number of
measurements
Fatigue
questionnaire*
Hann, 1997 
(27)
Breast cancer patients (3.5 to 62.5 43 patients age 32-57, mean 44 1 
months, mean 20 months) after (sd 6) 
treatment with high dose chemo­
therapy with bone marrow 43 controls (noncancer) age 
transplantation 32-56, mean 47 (sd 6)
POMS-fatigue, FSI
Key finding: Women who had completed BMT reported significantly more frequent and severe fatigue than 
history (effect size POMS 0.46; FSI 0.40).
women with no cancer
Woo, 1998 
(28)
Breast cancer patients (6 months to 28 332 patients, age 31-90, mean 1
years after diagnosis, mean 30 52 (sd 10)
months). Treated with chemotherapy,
radiotherapy, hormonal therapy or a
combination
! ! a few patients could have been in 
active treatment
PFS
Key finding: Women who received combination therapy reported significant higher levels o f fatigue compared with those treated with 
radiotherapy only (effect size 0.97).
Smets, 1998c 
(29)
Key finding:
Patients with different cancer 154 patients, age 65 (sd 12), 1 
diagnoses (9 months) after treatment 57% male 
with radiotherapy
139 healthy controls, age 46 
(sd 16), 44% male
Fatigue in patients did not differ significantly from fatigue in controls.
MFI-20
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Table 2. continued
Author Diagnosis and treatment Patient characteristics Number of 
measurements
Fatigue
questionnaire*
Andrykowski,
1998
(30)
Key finding:
Broeckel, 1998 
(31)
Key finding:
Breast cancer patients (3 to 60 months, 
mean 25 months) after treatment with 
chemotherapy, radiotherapy or a 
combination of these treatments
88 patients, age 35-76, mean 
54 (sd 9)
2 (initial and 4 month 
follow-up)
MOS- vitality, CFS, 
PFS
88 controls with benign breast 
problems, age 37-76, mean 53 
(sd 9)
Breast cancer patients reported significantly more fatigue, more weakness and less vitality relative to the benign breast 
cancer patients at two assessment times (initial and 4 months follow-up) (effect size initial assessment MOS 0.30; CFS 
0.15; PFS 0.30).
1Breast cancer patients (3 to 36 months, 61 patients, age 52 (sd 11) 
mean 16 months) after treatment with 
chemotherapy (sometimes in 51 healthy controls, age 51 (sd
combination with radiotherapy) 11 )
Patients reported more severe fatigue than healthy controls (effect size POMS 0.47; FSI 0.42; MFSI 0.42).
POMS-fatigue, FSI, 
MFSI
Hann, 1998 Breast cancer patients (5 to 88 months, 45 patients, age 36-86, mean 1 POMS-F, FSI
(32) mean 22 months) after treatment with 64 (sd 13)
radiotherapy
44 healthy controls, age 47-77, 
mean 60 (sd 9)
Key finding: There were no significant differences between the groups on reported levels o f  fatigue severity, intensity, frequency, and
disruptiveness.
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Table 2. continued
Author Diagnosis and treatment Patient characteristics Number of
measurements
Fatigue
questionnaire*
Loge, 1999a 
(33)
Key finding:
Hodgkin’s disease survivors (mean 459 patients, mean age 32 (sd 1 FQ 
observation period 12 years, sd 6) 11), 56% male
26% had substantial fatigue fo r  6 months or longer This percentage was significantly higher than the percentage among 
2,214 controls representative o f  the general Norwegian population (11%) (effect size 0.51).
Howell, 2000 
(34)
Key finding:
Patients treated for haematological 66 patients, age 21-52, mean 1 MFI-20 
malignancies (1-21 years, mean 8 40, 100% male 
years) after chemotherapy (sometimes
in combination with radiotherapy) 44 healthy controls, age 20-59,
mean 40, 100% male
Fatigue scores were higher in men treatedfor haematological malignancies in comparison to healthy men.
Knobel, 2000
(35)
Key finding:
Lymphoma patients (median 6 years) 33 patients, age 18-59, mean 1 
after high dose therapy supported by 39, 55% male 
autologous bone marrow 
transplantation
Lymphoma patients were more fatigued than the Norwegian reference population.
FQ
Bower, 2000 
(36)
Key finding:
Breast cancer patients (12 to 60 1975 patients, mean age 55 1
months, mean 35 months) after
treatment with chemotherapy,
radiotherapy or a combination of these
treatments
30% did report heightened levels o f  fatigue relative to women in the general population.
Rand 36- 
energy/fatigue
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Table 2. continued
Author Diagnosis and treatment Patient characteristics Number of
measurements
Fatigue
questionnaire*
Okuyama, 2000 Breast cancer patients (mean 20 134 patients, age 28-86, mean 1 
(37) months) after treatment with surgery, 55 (sd 10) 
chemotherapy, radiotherapy or a 
combination of these treatments
Key finding: Fatigue was significantly correlated with dyspnea, insufficient sleep and depression.
CaFS
Curt, 2000b 
(38)
Key finding:
Cancer survivors who completed 379 patients, mean age 63, 1 Telephone interview, 
treatment for chemotherapy 21% male 50 questions on 
(sometimes in combination with fatigue 
radiotherapy) more than 1 year ago
30% experienced fatigue on a daily basis. 91% o f those who experienced fatigue reported that it prevented a ‘normal life’.
Loge, 2000a 
(39)
Key finding:
Hodgkin’s disease survivors 421 patients, age 19-74, 56% 1 
(observation period 3 to 23 years) males
Fatigued HDS had higher levels o f  anxiety and depression than non-fatigued HDS.
FQ
Servaes, 2001 
(40)
Patients with different cancer 85 patients, age 21-74, mean 1 
diagnoses (6 months to 12.5 years, 48 (sd 14), 60% male 
mean 36 months) after treatment with 
chemotherapy and/or radiotherapy
CIS
Key finding: 19% o f a sample o f disease-free cancer patients experienced severe fatigue. Their mean fatigue score is significantly 
higher than a reference score o f healthy adults (effect size 0.30).
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Table 2. continued
Author Diagnosis and treatment Patient characteristics Number of 
measurements
Fatigue
questionnaire*
Celia, 2001b 
(41)
Cancer survivors who completed 
treatment for chemotherapy 
(sometimes in combination with 
radiotherapy) more than 1 year ago
379 patients, mean age 63, 
21% male
1 Telephone interview, 
50 questions to 
establish cancer- 
related-fatigue
Key finding: 17% met formal diagnostic criteria for cancer related fatigue.
Knobel, 2001A 
(42)
Hodgkin’s disease survivors after 
radiotherapy (sometimes in 
combination with chemotherapy), 
mean observation time 9 years (sd 3)
92 patients, age 23-56, mean 
37, 59% male
1 FQ
Key finding: Pulmonary dysfunction is associated with fatigue in HDS. Cardiac sequelae was not associated with fatigue in HDS.
A different studies with almost the same sample of patients 
B different studies with the same sample o f patients
# Fatigue Questionnaires: CaFS- Cancer Fatigue Scale; CFS- Chalder Fatigue Scale; CIS-20- Checklist Individual Strength; FQ- Fatigue Questionnaire; FSI- 
Fatigue Symptom Inventory; MFI-20- Multidimensional Fatigue Inventory; MFSI- Multidimensional Fatigue Symptom Inventory; MOS- Medical Outcome 
Studies; PFS- Piper Fatigue Scale; POMS- Profile of Mood States.
Literature 
review
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Treatment related variables
Relationships between off-treatment fatigue and certain treatment related variables 
were investigated in all the reviewed studies. No differences were found with 
regard to off-treatment fatigue between patients who underwent mastectomy versus 
patients who underwent breast conservation surgery31’37.
The extent of adjuvant therapy patients underwent was unrelated to fatigue severity 
in eight articles in which this relationship was studied29-34’37’40. Current tamoxifen 
use turned out to be unrelated to fatigue severity as well27’31’32’36’37. In contrast’ in 
two studies’ severity of post treatment fatigue was related to the extent of 
treatment. In these studies’ former chemotherapy patients (sometimes in 
combination with radiation and/or hormonal therapy) reported higher levels of 
fatigue compared with those treated with radiotherapy28’36. It should be noted’ 
however’ that in the study by Bower’ the association between fatigue and type of 
treatment was only moderate. Treatment did not emerge as a significant predictor 
of fatigue in the regression analysis36. Furthermore’ as noted before’ in the study by 
Woo there is a possibility that some patients were still in active treatment at the 
time of participation in the study28.
Time since treatment completion was unrelated to fatigue severity in eight of the
nine studies in which this was investigated30-34’36’37’40. In the study that did reveal a
relation between fatigue and time since treatment completion’ this was the opposite 
of what was to be expected. The longer the time since treatment completion’ the 
more severe was the fatigue reported27.
Finally’ possible long-lasting side effects of cancer treatment were investigated in 
two studies35’42. Hodgkin’s disease survivors with pulmonary dysfunction were 
more fatigued than those with normal pulmonary function. Thyroid dysfunction 
and cardiac sequelae were not associated with fatigue in this patient population42. 
Furthermore’ no statistical endocrinological or immunological association with 
fatigue could be demonstrated35.
Demographic variables
In nine studies the relationships between off-treatment fatigue and age’ educational 
level’ marital status and ethnicity have been investigated. The authors of three 
studies found that none of the investigated demographic variables were
27’31’32significantly related to fatigue ’ ’ . The association between gender and fatigue 
was investigated in three studies’ in which a sample of both men and women was 
investigated. In one study’ no differences were found between men and women39’ 
however in two studies women were found to experience more fatigue than men 
do29’ 35. In three studies’ fatigued breast cancer survivors were slightly younger than 
survivors in the non fatigued group28’36’37. An explanation could be that younger 
women are more often employed and often have the responsibility of caring for 
their families and young children.
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Psychological, social, physical and behavioural variables
State and trait anxiety and depressive symptoms were significantly and positively 
correlated to fatigue severity in all studies. However’ in one of the studies’ the 
breast cancer group and benign breast problems group did not differ with regard to 
depressive symptoms’ while they did differ with respect to fatigue scores30.
Sleep quality was assessed in six studies. In all of these studies’ poorer sleep 
quality was significantly related to fatigue27’29-31’36’37. Pain was registered in only 
two studies. In these studies fatigue was significantly associated with the pain 
rating29’36.
Unlike in the studies investigating fatigue during treatment for cancer’ the level of 
activity has hardly been studied in studies of off-treatment fatigue. An exception is 
one study’ in which a negative relationship was found between fatigue and physical 
activity40. Furthermore’ negative associations have been found between fatigue and 
physical functioning32 and functional ability29. Finally’ it is reported that severe 
fatigue among patients was significantly related to dyspnoea37’ menopausal 
symptoms31’36’ and the use of catastrophising as a coping strategy31.
Summary
Studies of off-treatment fatigue mainly focussed on disease-free breast cancer 
patients. The majority of these studies conclude that fatigue is an important 
problem for approximately one third of the cancer survivors. With regard to the 
correlates of severe fatigue’ it can be concluded that previous disease and treatment 
characteristics were unrelated to fatigue. Furthermore’ only a few studies found 
that demographic variables (gender’ age) were related to fatigue. Finally’ fatigue 
turned out to be related to anxiety and depression’ sleep quality’ and a few physical 
variables (pain’ dyspnoea’ menopausal symptoms and physical activity/ physical 
functioning).
INTERVENTIONS TO REDUCE FATIGUE 
Description of the reviewed studies
In Table 3’ 12 controlled intervention studies are summarised. In five of these 
studies fatigue was the main dependent variable48’50-52’54. In the other seven studies’ 
fatigue was one of the investigated outcome measures43-47’49’53. All studies took 
place while patients were undergoing treatment for cancer or’ in one study’ just 
after treatment for cancer had finished (surgery’ without adjuvant therapy) To the 
best of our knowledge’ no intervention studies have been conducted to reduce 
fatigue complaints long after treatment for cancer has finished.
With respect to the content of the interventions’ three studies investigated the effect 
of a walking- or exercise program50-52. In these studies’ patients walk or perform 
exercises on three to seven days a week for approximately 30 minutes. Five other
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studies described the effect of individual counselling by professionals44’45’49’53 or by 
former cancer patients46. Contents of these individual sessions included preparatory 
information’ improving coping skills’ psychological support’ health education’ 
stress management’ cognitive restructuring and relaxation. Two studies conducted 
an intervention study in which the effect of supportive group meetings43 and 
psychiatric group meetings47 were investigated. Furthermore’ in one study the 
effect of an intervention to minimise attentional fatigue through regular 
participation in activities that engage fascination and have other restorative 
properties was investigated48. Finally’ in one study’ a virtual reality system was 
used. This system made patients feel that they were somewhere else in a virtual 
world’ while they were given chemotherapy. Patients could chose a content (lake’ 
forest’ country town) and an aromatic essential oil54.
The sample of patients in the reviewed studies’ consisted mainly of breast cancer 
patients (in five studies). Other studies investigated patients with gynaecologic 
cancer’ malignant melanoma or samples of patients with different cancer 
diagnoses. The POMS-fatigue was the most frequently used measurement of 
fatigue.
Effect of intervention
The studies that investigated the results of sports or walking programmes during 
treatment with radiotherapy or chemotherapy’ reported positive results50-52. All 
studies found that after the end of the intervention patients felt less fatigued in 
comparison to patients who did not participate in the sports or walking program. 
None of these studies presented follow-up results.
In addition’ in the four studies in which the effect of individual counselling by 
professionals on fatigue severity was investigated’ positive results were found 
directly after the intervention44’45’49’53. Patients in the intervention groups reported 
significantly less fatigue than patients in the control group. In two studies these 
results lasted’ at three49 and six months follow-up44 but’ in the other study’ the 
benefit was no longer present at a 4-week follow-up45. A study in which the results 
of counselling by former cancer patients was investigated failed to find a reduction 
in fatigue46.
Furthermore’ the studies in which the effects of a group intervention were tested’ 
also reported positive results with regard to a reduction in fatigue43’47. In one study’ 
the focus was on the effect of health education’ enhancement of problem solving 
skills’ stress management (e.g. relaxation) and psychological support. It was found 
that the intervention group reported less fatigue than a control group six months 
after the end of the intervention47. The other study compared a group of patients 
who were following weekly supportive group meetings compared with a group of 
patients who did not follow these meetings. Results indicate that the first group 
reported less fatigue than the second group43.
Table 3. Interventions to reduce fatigue
Author Diagnosis and treatment Intervention Patient
characteristics
Number of Fatigue 
measurements questionnaire*
Spiegel, 1981 
(43)
Key finding:
4 (initial, and 4, 
8, 12 months 
later)
POMS-fatiguePatients with metastatic breast Weekly supportive group 16 intervention, mean 
cancer meetings, during one age 54
year
14 control, mean age 55
Those who participated in the weekly group sessions experienced significantly less fatigue at all measurements than 
controls.
Worden, 1984 Patients with different cancer 6 week individual 59 intervention 3 (pre- POMS-fatigue
(44) diagnoses, shortly after the training to lower intervention, 2
time of initial diagnosis emotional distress and 58 control and 6 months
improve coping follow-up)
Patients were at risk for 
emotional distress and 
poor coping
Key finding: Two and six months after the intervention, the intervention group was significantly less fatigued than the control group.
Forester, 1985 Patients with different cancer Individual 48 intervention, age 23- 5 (before psycho- SADS-fatigue
(45) diagnoses, during radiotherapy, psychotherapy, weekly 78, mean 62, 54% men therapy, week 3,
10 times week 6 (end of
52 control, age 25-81, radiotherapy),
mean 62, 46% men week 10, week 14)
Key finding: The intervention group reported significantly less fatigue directly after intervention, but the difference disappeared at
follow-up (4 and 8 weeks later).
Table 3. continued
to
Author Diagnosis and treatment Intervention Patient
characteristics
Number of 
measurements
Fatigue
questionnaire*
Houts, 1986 
(46)
Key finding:
Gynaecologie cancer patients, Individual counselling by 14 intervention, mean 3 (initial and 6 
shortly after the time of initial former cancer patients age 48 and 12 weeks 
diagnosis (telephone), 10 weeks after entering the
18 control, mean age 51 study)
There were no differences in fatigue between the two groups at 6 and 12 weeks after beginning treatment.
POMS-fatigue
Fawzy, 1990 
(47)
Key finding:
Patients with malignant 6 week psychiatric group 38 intervention, mean 3 (pre, post 
melanoma directly after intervention, postsurgical age 46, 47% male intervention and 
surgery (no adjuvant therapy) (health education, 6 months follow-
enhancement of problem 28 control, mean age up) 
solving skills, stress 38, 47% male 
management and 
psychological support)
Directly after the intervention, there were no differences in fatigue scores. At 6 month follow-up patients 
group reported less fatigue than patients in the control group (effect size 0.61).
POMS- fatigue
in the intervention
Cimprich,
1993
(48)
Breast cancer patients during 
treatment (radiotherapy/ 
chemotherapy/ antihormonal)
Regular participation in 
activities that engage 
fascination
16 intervention, age 29- 
84, mean 57 (sd 16)
16 control, age 32-77, 
mean 51 (sd 13)
4(3, 18, 60 and 
90 days after 
surgery)
Total Attention 
Score (sum of 
standardised 
objective 
attentional tests), 
Attentional 
Function Index
Key finding:. There was an interaction o f experimental intervention and time on attentional capacity. Subjects in the intervention group 
showed significant improvement in attention capacity over the four time points.
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Table 3. continued
Author Diagnosis and treatment Intervention Patient
characteristics
Number of 
measurements
Fatigue
questionnaire*
Fawzy, 1995 
(49)
Key finding:
Newly diagnosed patients with Nursing intervention, 3 29 intervention, mean 3 (baseline, 6 POMS-fatigue 
malignant melanoma hours of individual age 42, 52% male weeks and 3
teaching on two months after the 
occasions (health 33 control, mean age intervention) 
education, stress 46, 58% male 
management, coping)
Patients in the intervention groups reported significantly less fatigue than patients in the control group 3 months after the 
intervention (effect size 0.40).
Mock, 1997 
(50)
Key finding:
Breast cancer patients during 20- 30 minutes walking 4 22 exercise, mean age 
treatment with radiotherapy to 5 times a week 48 (sd 5)
24 control, mean age 50, 
(sd 8)
The intervention group reported less fatigue than the control group immediately after
3 (pre, mid, and 
post exercise 
program)
intervention.
PFS
Dimeo, 1999 
(51)
Key finding:
Patients with different cancer Exercise program, 30 27 exercise, age 21-59, 2 (at hospital POMS-fatigue 
diagnoses during minutes daily mean 40 (sd 11 ), 33 % admission and 
hospitalisation for high dose male hospital 
chemotherapy with stem cell discharge) 
transplantation 32 control, age 20-56,
mean 40 (sd 10), 40% 
male
By the time o f  hospital discharge, fatigue had increased significantly in the control group but not in the training group.
4^
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Table 3. continued
Author Diagnosis and treatment Intervention Patient
characteristics
Number of Fatigue 
measurements questionnaire*
Schwartz,
2000
(52)
Key finding:
Patients with breast cancer, 
during the first 3 cycles of 
chemotherapy
8-week home-based 
exercise program, 3 to 4 
days a week, 15 to 30 
minutes
16 exercise, age 25-57, 
mean 47
2 (pre- and post VAFS 
exercise program)
11 control
Women who adopted exercise experienced fewer days o f high fatigue levels than women who did not exercise.
Gaston-
Johansson,
2000
(53)
Breast cancer patients 
undergoing autologous bone 
marrow transplantation 
(ABMT)
Comprehensive coping 
strategy program 2 
weeks before hospital 
admission (preparatory 
information, cognitive 
restructuring, and 
relaxation)
52 intervention, age 
21% 22-40, 50% 41-50, 
29% >51
58 control, age 30% 22- 
40, 56% 41-50, 14% >51
2 (2 days before 
ABMT and 7 
days after 
ABMT)
VAFS
Key finding: Patients in the intervention group reported significantly less fatigue than patients in the control group (effect size 0.35).
Oyama, 2000 
(54)
Key finding:
Patients during a cycle of 
chemotherapy
15 intervention, age 29- 
73, mean 54, 20% male
15 control, age 29-73, 
mean 51, 20% male
2 (before chemo­
therapy and 3-5 
days after 
chemotherapy)
CFS, VAFSBed Wellness System -  
virtual reality: patients 
chose a preferred 
aromatic essential oil and 
content (lake, forest, 
country town)
Patients in the intervention group were statistically less fatigued three to five days after chemotherapy than patients in the 
control group.
# Fatigue Questionnaires: CFS- Cancer Fatigue Scale; PFS- Piper Fatigue Scale; POMS- Profile of Mood States; SADS- Schedule of Affective Disorders 
and Schizophrenia; VAFS- Visual Analogue Fatigue scale.
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Furthermore, in the study that investigated an intervention to minimise attentional 
fatigue, the authors found that the intervention group improved significantly more 
than the control group48. Finally, patients who were in the virtual reality 
intervention group during the administration of chemotherapy, were statistically 
less fatigued three to five days after chemotherapy than patients in the control
54group .
Summary
All intervention studies were conducted with patients who were undergoing 
treatment or had just finished treatment at the time o f the study. The interventions 
included individual counselling (5 studies), a walking- or exercise program (3 
studies) or group meetings (two studies). In 10 o f the 12 studies, positive effects on 
fatigue complaints were reported immediately after the intervention. Follow-up 
results were presented in only four studies. In three o f these studies, the positive 
effect o f the intervention was still apparent at three or six months follow-up.
DISCUSSION
In the last ten years, the amount of research on the relationship between cancer and 
fatigue has increased considerably. To give an indication, from the 181 articles we 
found using Medline, Current Contents and Psychlit, 20 were published between 
1980 and 1990, and 161 were published between 1991 and 2001. From these 161 
studies, 32 were published between 1991 and 1995 and 129 were published 
between 1996 and 2001. The conducted research has focussed mainly on fatigue 
complaints during treatment for cancer, while up to now only a few studies have 
attempted to investigate fatigue in cancer survivors.
The reviewed studies clearly indicate that fatigue is a problem for many cancer 
patients undergoing treatment for cancer. In studies that compared cancer patients 
to healthy control subjects, cancer patients have been found to report more frequent 
and severe fatigue than healthy controls. In addition, many studies reported a 
significant rise in fatigue when cancer patients are assessed just before treatment 
and again during or immediately after treatment. However, the percentages of 
fatigue during treatment for cancer showed broad variation, obviously depending 
on the way fatigue has been measured. Percentages o f fatigue range from 25 
percent to 99 percent in the reviewed studies. In studies in which a VAS scale was 
used to measure fatigue, the highest percentages were observed, indicating that 
fatigue is a problem for nearly all patients undergoing treatment for cancer. 
However, these percentages only indicate the amount o f patients who experience 
fatigue to some degree. All patients who report fatigue on a VAS, no matter to 
which degree (a score greater than 0) are considered as fatigued. Thus, the meaning
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is limited, because is does not give an indication about the severity o f the 
experienced fatigue.
Percentages o f severe fatigue in disease-free cancer patients after they have 
finished curative treatment have been mentioned in only four studies and vary from 
17 to 30 percent. The reason for this varying prevalence estimates probably has to 
do with the lack o f consensus about what constitutes a case o f severe fatigue after 
treatment for cancer.
Eight o f the ten reviewed studies in which a control group or norm scores were 
available reported that fatigue scores were significantly higher for cancer survivors 
in comparison to control subjects without a cancer history or to norm scores. 
However, two studies reported contrary findings. In these studies, fatigue does not 
seem to be an important complaint for cancer patients (long) after they have 
finished treatment. In addition, in three studies fatigue scores had returned to pre­
treatment levels at follow-up. A possible explanation for this contradiction, 
proposed by the authors o f one o f these studies, is a problem that has been denoted 
a “response shift” . This means that the experience o f fatigue during treatment for 
cancer, could have changed a patient’s standard o f measurement concerning 
fatigue. What has been perceived to be intense fatigue before treatment may be 
labelled ‘slightly’ fatigued after having experienced exhaustion during treatment. 
The term “response shift” thus refers to the change in a person’s internal standard 
for determining his or her level o f functioning on a given dimension55. However, if  
this hypothesis is right, it remains unclear why in most studies fatigue scores were 
significantly higher for cancer survivors in comparison to control subjects.
Another explanation could be that all five studies that did not find fatigue to be a 
serious problem after treatment for cancer, investigated a sample o f patients who 
had received radiotherapy only. Moreover, in the studies in which it is was 
concluded that fatigue remained a problem long after cancer treatment, all patients 
were treated with chemotherapy, or with a combined anti-cancer therapy including 
chemotherapy.
Is it the receipt o f chemotherapy or a combination o f  multiple therapies, that 
account for severe fatigue long after treatment? The results o f two studies suggest 
that this might be the case28,36. However, eight studies did not find a relation 
between off-treatment fatigue and type/extent o f former treatment. In addition, no 
relation has been found between fatigue and time since treatment. Obviously more 
controlled research should be conducted in the future in order to clear up these 
contradictions within the existing research.
For the disease related variables, in most studies, both during and after treatment 
for cancer, fatigue appeared to be unrelated to disease variables (e.g. cancer 
diagnosis, cancer stage at diagnosis, size o f the original tumour, number o f nodes 
involved and presence and site o f metastases). However, as we have indicated 
before, certain study characteristics might explain these negative results.
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Apart from the relationships between fatigue and disease- and treatment related 
variables, we looked at psychological, social, behaviour and physical correlates of 
fatigue. The results o f many o f the studies indicated that both during and after 
treatment for cancer, fatigue is associated with a negative affect. In addition, 
intervention studies which focussed on psychological well-being reported positive 
results with regard to fatigue. Still, the data are far from definitive in this regard. 
Most research has focused on the depression-fatigue association, which is a 
complex one. Feelings of depression may results from the fact that one has (or had) 
a possibly fatal disease, and a depressed state o f mind may induce fatigue. 
However, depression could also be a result o f persistent feelings o f fatigue56 
probably especially when treatment for cancer has ended some time ago. Although, 
the depression-fatigue association cannot be ruled out as an explanation for the 
experience o f fatigue during and after treatment for cancer, it is clearly an 
incomplete description o f the underlying process. We found three indications in the 
reviewed studies to support this view. First, although correlations between fatigue 
and depression were moderate, depression scores did not change while fatigue
12 19 22scores rose over the course o f cancer treatment ’ ’ . Second, although breast 
cancer survivors differed with respect to fatigue scores from women with benign 
breast problems, the two groups did not differ with regard to depressive 
symptoms30. Thirdly, within a group o f severely fatigued disease-free cancer 
patients, only 19% could be considered as clinically depressed40.
An additional problem with regard to the relation between fatigue and depression is 
that most measures o f depression contain items which overlap with items o f fatigue 
questionnaires (for instance an item like ‘I have to push myself very hard to do 
anything’). High correlations between fatigue and depression may be due to these 
overlapping items.
The relationship between fatigue and physical activity has been investigated 
scarcely, and only during active treatment for cancer. There seems to be a negative 
relationship between physical activity and fatigue. In addition, sports or walking 
programs during treatment for cancer reported positive results. However, follow-up 
analyses were absent. In clinical practice, cancer patients are often being advised to 
reduce activities and take a lot o f rest. With the discussed studies as a basis it 
would be better to encourage patients to maintain activity levels balanced with 
efficient rest periods. After treatment for cancer, rest may even be more ineffective 
in order to relieve chronic fatigue40.
Disturbances in sleep have been found to be linked with fatigue, both during as 
well as after cancer. Causes o f sleep problem have not been extensively 
investigated. It is possible that sleep problems are a result o f the experience of 
tension, fear and anxiety that is related to the disease, the treatment and the 
uncertainty regarding the future. Furthermore, patients who are inactive, often have 
insomnia, which causes further fatigue complains. Finally, in breast cancer 
patients, who become menopausal because o f chemotherapy, an increased
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frequency of night-time vasomotor symptoms (i.e. night sweats) could produce 
disruptive effects on sleep.
A few studies have reported correlations between fatigue and pain. The authors of 
the studies in which this relation was investigated did not however specify whether 
fatigue was caused by the pain itself or by pain medication. Therefore, this remains 
unclear.
A concept that has not been studied in the reviewed studies is the concept o f social 
support. However, resource-related factors such as the perceived level o f social 
support may be vital. It is important to understand the role social support plays in 
the perception and management o f symptoms such as fatigue.
Finally, findings regarding the role o f catastrophising suggest that the strategies 
patients use to cope with fatigue may also explain differences in fatigue severity. In 
our opinion, this is an area which deserves more attention in the future.
In this review, we decided to exclude studies in which fatigue has been measured 
with one or a few items within a quality o f life instrument, because these measures 
are not suitable for in-depth studies o f fatigue. However, we realise that many of 
the self-report fatigue scales that were used in the reviewed studies have 
shortcomings as well. More specific, most o f the instruments are unidimensional 
(they simply measure fatigue intensity) opposite to multidimensional instruments 
(they attempt to gauge the quality o f the symptoms as well as its severity). 
Examples o f unidimensional fatigue scales are the Rhoten Fatigue Scale, the 
Pearson & Byars Fatigue Feeling Checklist, the Fatigue Questionnaire, the Visual 
Analogue Fatigue Scale and the fatigue scale o f the Profile o f Mood State. 
Examples o f multidimensional fatigue scales are the Chalder Fatigue Scale, the 
Piper Fatigue Scale, the Fatigue Symptom Inventory, the Multidimensional Fatigue 
Inventory and the Checklist Individual Strength.
In future research, use o f valid and reliable multidimensional fatigue instruments is 
recommended because fatigue is a subjective state with multiple dimensions 
(physical, cognitive and motivational). Fatigue questionnaires for which norm 
scores o f healthy subjects and/or other patient populations are available should 
preferably be used. Another possibility is the inclusion o f a matched control group. 
Otherwise there is no reliable way o f ascertaining whether fatigue is any different 
for cancer patients than for healthy individuals or for patient with diseases other 
than cancer. Finally, longitudinal studies will better indicate factors that are 
correlated with the initiation or persistence o f fatigue in cancer patients.
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ABSTRACT
The goal o f our work was to assess fatigue in disease-free cancer patients with help 
o f a validated fatigue questionnaire. Furthermore, we wished to analyse the 
relationship between severe fatigue and former treatment modalities, problems of 
concentration and motivation, physical activity, functional impairment, depression 
and anxiety and finally, to compare severely fatigued disease-free cancer patients 
and patients with Chronic Fatigue Syndrome (CFS).
The participants were 85 adult cancer patients and 16 patients with CFS. The 
cancer patients were all disease-free and had been off treatment for a minimum of 
6 months. They were asked to participate in this study by their physician when they 
came to the hospital for control visits. Patients who were willing to participate, 
completed four questionnaires. The Checklist Individual Strength was used to 
measure fatigue. In addition the Beck Depression Inventory, the Spielberger Trait 
Anxiety Inventory and the Nottingham Health Profile were used.
Results indicate that 19% o f the disease-free cancer patients were severely 
fatigued. Their fatigue experience is comparable to that o f patients with CFS. 
Severe fatigue is associated with problems o f concentration and motivation, 
reduced physical activity, emotional health problems and pain. Furthermore, a 
relation was found between fatigue and depression and anxiety. No relation was 
found between fatigue and type o f cancer, former treatment modalities, duration of 
treatment and time since treatment ended.
In conclusion, for one fifth o f a group o f disease-free cancer patients fatigue is a 
severe problem long after treatment. In addition to fatigue, these patients 
experience several psychological and physical problems.
INTRODUCTION
Fatigue is symptom that is frequently encountered in cancer patients, due to their 
illness or their treatment. The prevalence of fatigue in cancer patients undergoing 
chemotherapy and/or radiotherapy has been estimated to range from 70 to 96
percent16,18.
Recently, several quality o f life (QOL) studies in disease-free cancer patients also 
mention fatigue as a frequent complaint long after treatment has finished. Most of 
these studies investigate patients treated for Hodgkin’s disease and breast cancer. 
The time elapsed since treatment varies from 1 to 10 years, and percentages of 
fatigue from 32% to 76%4-6"8-11"14"17"23.
While these studies suggest the existence o f off-treatment fatigue in cancer 
patients, they have been limited by rather crude, single-item measures o f fatigue. In 
some o f these studies fatigue has been scored on a yes/no format, in others on a 
four-point scale from ‘not at all’ to ‘very much’. This might be an explanation for 
the variation in fatigue percentages.
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Another limitation is the lack o f comparisons with other patient groups or healthy 
control subjects. Both o f these limitations were taken into account in five
17 12 13 19studies ’ ’ ’ ’ . In these studies, fatigue has been measured in disease-free cancer 
patients and in subjects without a history o f cancer, using specific fatigue 
questionnaires. Results indicate that disease-free cancer patients, following 
treatment for cancer respectively 28, 15 and 20 months before, report more fatigue 
than control subjects do1,7,12. However, in two studies no differences in fatigue 
scores were found between cancer patients, following treatment respectively 22 
and 9 months before, and healthy comparison subjects1319.
The role o f former treatment modalities in predicting post-treatment fatigue 
remains unclear in the studies mentioned above. In one study, former radiotherapy 
patients had significantly greater problems with decreased stamina than patients 
treated with chemotherapy4. In another study, fatigue was worse for patients who 
received a combination o f radiotherapy and chemotherapy than in those who 
underwent radiotherapy only10. In contrast, in other studies no relations were found
17131719between present fatigue and former type and extent o f treatment .
A relation between time since treatment and post-treatment fatigue was absent in 
four studies which investigated disease-free breast cancer patients1,7,13 and patients 
after stem cell transplantation14. However, in another study the time since treatment 
in survivors o f Hodgkin’s disease who still suffered energy loss was less than in 
those with normal energy levels10. On the contrary, Hann et al. found that the 
longer the time since bone marrow transplantation for breast cancer, the more 
severe fatigue reported12.
The relation between post-treatment fatigue and depression and anxiety in disease- 
free cancer has only been investigated in a few studies. A significant and positive 
correlation between anxiety and depressive symptoms and post-treatment fatigue
1710121319has been found ’ ’ , , , . It is possible that fatigue is a symptom o f depression or 
anxiety. Long after treatment, cancer patients could be clinically depressed as a 
result o f being confronted with a life threatening illness or be anxious about the 
possibility o f a relapse. Alternatively, prolonged fatigue in itself can lead to 
depression or anxiety.
Finally, other related problems o f fatigue, such as problems with regard to 
concentration, motivation and physical activity, have never been investigated in the 
literature.
In the present study the prevalence of fatigue in a group o f disease-free cancer 
patients is described, using a validated questionnaire. This questionnaire has been 
used extensively in research with patients with Chronic Fatigue Syndrome (CFS). 
This means it is possible to compare fatigue in disease-free cancer patients with 
fatigue in patients with CFS.
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In this study the following research questions are addressed:
• How many disease-free cancer patients are severely fatigued long after 
treatment?
• Is fatigue severity long after treatment influenced by former treatment 
modalities?
• Is severe fatigue related to depression and anxiety?
• Is severe fatigue related to problems o f concentration, motivation, physical 
activity and functional impairment?
• In what way(s) are severely fatigued disease-free cancer patients comparable to 
patients with CFS?
METHODS
Patients
The study used a cross-sectional design to assess fatigue in disease-free cancer 
patients in comparison to patients with CFS. Disease-free cancer patients were 
recruited from the Departments o f Medical Oncology, Surgery and Gynaecology at 
the University Hospital Nijmegen in The Netherlands. The ethics committee o f the 
hospital approved the study. During a period o f 7 months in 1997, cancer patients 
who had been off treatment for a solid tumour for a minimum o f 6 months were 
asked by their physicians to participate in this study when they came to the hospital 
for control visits. Patients who were willing to participate were asked to complete 
four questionnaires at home. After filling in the questionnaires, they were asked to 
send the questionnaires to the Department o f Medical Psychology. Because 
physicians did not keep a record o f patients who were unwilling to participate, the 
response rate in this study is unknown. Patients with breast cancer were not 
approached for participation because they are included in a longitudinal study 
concerning the course of post-treatment fatigue specifically in disease-free breast 
cancer patients.
For comparison, 16 patients with CFS, matched for age and gender with severely 
fatigued disease-free cancer patients (N=16) were recruited from the Department of 
Internal Medicine at the University Hospital Nijmegen.
Questionnaires
Participating patients were asked to complete the following four questionnaires.
The Checklist Individual Strength (CIS)21. This 20-item questionnaire is designed 
to measure four aspects o f fatigue during the last 2 weeks: fatigue severity (8 
items), concentration (5 items), motivation (4 items) and physical activity (3 
items). Each item is scored on a 7-point Likert scale. High scores indicate a high 
level o f fatigue, a high level o f concentration problems, low motivation and a low 
level o f physical activity. Reference scores recorded in several groups o f patients
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(CFS, MS, CVA, Cambodia- veterans) and healthy controls are available22. Based 
on research into CFS, a score o f 35 or higher on the subscale ‘fatigue severity’ 
indicates severe feelings o f fatigue21. Bases on scores in healthy controls, a score 
between 27 (mean score for healthy adults plus 1 sd) and 35 indicates a heightened 
experience o f fatigue22.
The Beck Depression Inventory (BDI)2. This standardised self-report questionnaire 
measures depression. A score of 16 or more is indicative o f a clinical depression. 
For analyses o f the data, also the Beck Depression Inventory for primary care 
(BDI-PC) was used, which has 7 items and is composed o f cognitive and affective 
symptoms3.
The Spielberger Trait Anxiety Inventory (STAI)20. This standardised self-report 
questionnaire measures trait anxiety. A score o f 50 or more is considered indicative 
o f clinical anxiety.
The Nottingham Health Profile (NHP)15. This questionnaire measures perceived 
physical, social and emotional health problems. It consists of six sub-scales: energy 
(3 items), pain (8 items), emotional reactions (9 items), sleep (5 items), social 
isolation (5 items) and physical mobility (8 items). All items use a yes/no answer 
format.
Statistical analyses
Analyses involved descriptive statistics for description o f the sample. T-tests, chi- 
square and analyses o f variance (ANOVA) were performed to test differences 
between groups.
RESULTS
Description of the sample
The sample in this study consists o f 85 disease-free cancer patients, 48 men and 37 
women. Their mean age is 47.5 (sd 14) years. Their education levels were 
determined according to a Dutch standardised scoring system (range 1-7). Thirty- 
seven patients (54%) completed elementary education (1-4), while 32 patients 
(46%) completed higher education (data about education were lacking for 16 
patients). Data on the distinct cancer diagnoses (n=76), treatment modalities 
(n=80), duration of treatment (n=75) and time since treatment stopped (n=75) are 
listed in Table 1.
Seventy-eight patients (98%) underwent surgery. Sixty-three percent o f these 78 
patients also received adjuvant therapy. This adjuvant therapy was chemotherapy, 
radiotherapy, corticosteroids, immunotherapy, or a combination o f two or more of 
these therapies. The mean duration o f treatment was 5.8 months (sd 9.6) and the 
mean time since treatment stopped was 2.9 years (range 0.5 - 12.5).
The sample o f 16 patients with CFS consists o f 8 men and 8 women. Their mean 
age is 48.1 (sd 12) years.
Fatigue in disease-free cancer patients compared with fatigue in patients with CFS 59
Table 1. Cancer- and treatment related variables
Cancer diagnoses Testis carcinoma 19 (25 %)
Colorectal carcinoma 18 (23 %)
Sarcoma 15 (20 %)
Other 24 (32 %)
Treatment modalities Surgery 78 (98 %)
Chemotherapy 38 (48 %)
Radiotherapy 18 (23 %)
Corticosteroids 27 (34 %)
Immunotherapy 6 ( 8 %)
Duration of treatment 1 month 29 (39 %)
Between 2 and 6 months 27 (36 %)
Between 6 months and 1 year 9 (12 %)
More than 1 year 10 (13 %)
Time since treatment finished Less than 1 year 16 (21 %)
Between 1 and 2 years 19 (25 %)
Between 2 and 3 years 12 (16 %)
Between 3 and 4 years 9 (12 %)
Between 4 and 5 years 11 (15 %)
More than 5 years 8 (11 %)
* Most patients are included in more than one treatment modality, because they received a 
combination of treatments.
Severe fatigue in disease-free cancer patients
The sample o f 85 disease-free cancer patients has a mean score o f 21.06 (sd 13.69) 
on the fatigue severity subscale o f the CIS. Twenty-five patients (29%) score 27 or 
higher on this sub-scale, and 16 patients (19%) score 35 or higher. Twenty-five 
patients thus experience heightened feelings o f fatigue compared with healthy 
control subjects. Sixteen patients even experience severe fatigue, comparable to 
fatigue patients with CFS experience.
Effect of former treatment on fatigue severity
Severely fatigued disease-free cancer patients (CIS-fatigue >= 35) are compared 
with non-severely fatigued disease-free cancer patients (CIS-fatigue < 35) to 
investigate whether severe fatigue was influenced by the duration o f treatment and 
the time since treatment stopped (Table 2).
Results indicate no significant differences between severely fatigued disease-free 
cancer patients and non-severely fatigued disease-free cancer patients with regard 
to the mean time since treatment stopped and the mean duration o f treatment.
Data about the impact o f former treatment modalities on severe fatigue can be 
found in Figure 1.
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Table 2. Effect o f  duration o f  treatment and time since end o f  treatment on fatigue severity
Severely fatigued 
disease-free cancer 
patients 
(n=16)
Non-severely fatigued 
disease-free cancer 
patients 
_______(n=69)_______
Mean (sd) Mean (sd)
p-value
Duration of treatment 
(months)
Time since treatment 
finished (years)
6.88 (7.18) 
3.39 (2.56)
5.57 (10.32) 
2.80 (2.20)
0.637
0.363
Figure 1. Relation between form er treatment modalities and severe fatigue
In this figure, percentages of patients suffering severe fatigue following different 
treatment modalities are shown. The highest frequency o f severe fatigue is found in 
patients treated with radiotherapy. Forty percent o f the patients who received 
radiotherapy report severe fatigue while only 15 percent o f the patients who did not 
receive radiotherapy report severe fatigue (Chi- Square, p=0.06).
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Depression and anxiety in relation to severe fatigue
CIS-fatigue scores are significantly correlated with scores on the BDI (Spearman 
correlation=0.73), BDI-PC (Spearman correlation=0.58) and the STAI (Spearman 
correlation=0.60).
Table 3 compares mean depression and anxiety scores for non-severely fatigued 
disease-free cancer patients, severely fatigued disease-free cancer patients and 
patients with CFS. Severely fatigued disease-free cancer patients had significantly 
higher mean scores for depression and anxiety than non-severely fatigued disease- 
free cancer patients. There was no significant difference between severely fatigued 
disease-free cancer patients and patients with CFS with regard to mean depression 
scores.
Table 3 Mean depression and anxiety scores
Non-severely 
fatigued disease-free 
cancer patients 
(n=69)
Severely fatigued 
disease-free cancer 
patients 
(n=16)
Patients 
with CFS 
(n=16)
Mean (sd) Mean (sd) Mean (sd)
BDI-PC 0.43 (0.87) 2.25 (1.81)** 2.63 (1.82)
STAI 30.94 (9.37) 37.79 (10.97)* no available data
* Significantly different from non-severely fatigued disease-free cancer patients, p<0.05 
** Significantly different from non-severely fatigued disease-free cancer patients, p<0.01 
CFS: Chronic Fatigue Syndrome, BDI: Beck Depression Inventory, STAI: Spielberger Trait Anxiety 
Inventory
Fatigue related problems (problems of concentration, motivation, physical 
activity and functional impairment)
To investigate whether fatigue was associated with other problems, comparisons 
were made between severely fatigued disease-free cancer patients and non-severely 
fatigued disease-free cancer patients. Three sub-scales o f the CIS measure 
problems with concentration, motivation and physical activity. Scores on these 
three subscales were also compared against scores o f patients with CFS. Functional 
impairment was measured by the NHP. Data are presented in Tables 4 and 5. 
Severely fatigued disease-free cancer patients had more problems with 
concentration and reduced motivation and had a lower level o f physical activity 
than non-severely fatigued disease-free cancer patients. Severely fatigued disease- 
free cancer patients also experienced more emotional health problems and pain 
than non-severely fatigued disease-free cancer patients. On the other hand, they did 
not experience more physical impairment (although there was a trend), sleep 
problems and social isolation.
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Severely fatigued disease-free cancer patients were comparable to patients with 
CFS with regard to motivation problems and physical activity. However, patients 
with CFS experienced more problems with concentration.
Table 4. Fatigue related problems; concentration, motivation and physical activity _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Non-severely fatigued Severely fatigued Patients with
disease-free cancer disease-free cancer CFS
patients patients
(n=69) (n=16) (n=16)
Mean (sd) Mean (sd) Mean (sd)
CIS-concentration 
CIS-motivation 
CIS-physical activity
10.18 (5.94) 
7.51 (4.11) 
5.88 (3.93)
15.81 (8.80)* 
15.38 (6.71)* 
15.12 (5.38)*
24.69 (8.05)** 
17.94 (5.81) 
16.38 (3.96)
* significantly different from non-severely fatigued disease-free cancer patients, p<0.01 
** significantly different from severely fatigued disease-free cancer patients, p<0.01 
CIS: Checklist Individual Strength
Table 5. Fatigue related problems; functional impairment
Non-severely 
fatigued disease-free 
cancer patients 
(n=69)
Severely fatigued 
disease-free cancer 
patients 
(n=16)
p-value
Mean (sd) Mean (sd)
NHP- energy 0.19 (0.50) 1.75 (0.86) 0.000
NHP- pain 0.10 (0.52) 1.12 (1.89) 0.049
NHP- emotion 0.47 (1.04) 1.68 (1.40) 0.000
NHP- sleep 0.32 (0.85) 1.00 (1.51) 0.101
NHP- social 
interaction
0.13 (0.38) 0.38 (0.62) 0.151
NHP- physical 0.26 (0.64) 1.06 (1.57) 0.063
NHP- total 1.49 (2.58) 7.00 (3.90) 0.000
NHP: Nottingham Health Profile
DISCUSSION
This study shows that a considerable proportion o f a sample o f disease-free cancer 
patients were severely fatigued years after treatment. The severity of fatigue 
experienced by these patients was comparable to the severity o f fatigue in patients 
with CFS. In addition, severe fatigue was associated with problems of 
concentration, reduced motivation, reduced physical activity, pain, and emotional 
health problems. The direction o f the relation between these problems remains
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unclear. It is possible that fatigue causes the problems mentioned above: however, 
the relationship might also be the other way around, fatigue being a consequence of 
the problems mentioned above. Finally, for certain problems both can be true. For 
instance, because o f fatigue, patients often reduce their level o f physical activity. 
Because o f a low level o f physical activity, physical condition deteriorates and 
leads to even higher levels o f fatigue.
There seems to be no relation between initial disease and treatment factors and 
severe fatigue in this study. First, the type o f cancer is not associated with levels of 
post-treatment fatigue. Second, the duration o f treatment and time since treatment 
finished are not associated with levels o f post-treatment fatigue. This lack of 
association between fatigue and time since the end o f treatment is in accordance 
with the results described in the majority o f the studies mentioned in the 
Introduction1,7’13’14. Finally, no relation was found between former treatment 
modalities and fatigue. However, a strikingly high proportion o f patients who had 
received radiotherapy were severely fatigued. Thus, radiotherapy might be a risk 
factor for severe fatigue long after treatment. This trend between radiotherapy and 
post-treatment fatigue should be interpreted with caution. As mentioned in the 
Introduction, results in studies that have investigated this relationship are 
contradictory. In addition, only a small proportion o f the disease-free cancer 
patients in the current study (n=18) did receive radiotherapy, and some o f these 
patients also underwent additional adjuvant therapy.
In accordance with results in the literature, severe fatigue is related to depression 
and anxiety. Results o f this study reveal a significant difference between severely 
fatigued disease-free cancer patients and non-severely fatigued disease-free cancer 
patients with regard to mean depression and anxiety scores, severely fatigued 
disease-free cancer patients having the higher mean scores. The strength o f the 
association between fatigue and depression is interesting considering that the 
measure o f depression used in this study (BDI-PC) includes items that reflect 
cognitive and affective symptoms o f depression but not somatic symptoms. Thus, 
the relationship can not be explained as overlap o f the physical aspects o f fatigue 
with somatic symptoms o f depression. As a result o f the cross-sectional design of 
this study no conclusions can be drawn about the direction o f the causal relation 
between fatigue severity and depression and anxiety. However, even if  depression 
and anxiety are causal factors in severe fatigue, other factors also play a part. In the 
group o f severely fatigued disease-free cancer patients, only 19 percent can be 
considered to have been clinically depressed (BDI>16) and 14 percent clinically 
anxious (STAI>50). Severe fatigue thus cannot be fully explained by depression 
and anxiety.
When fatigued disease-free cancer patients are compared with patients with CFS 
there seem to be many similarities. The problems severely fatigued disease-free 
cancer patients experience in terms o f depression, motivation and reduced physical
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activity are comparable in extent to the problems experienced by patients with 
CFS. However, patients with CFS report more problems with concentration.
The results presented in this study should be considered with some caution, since 
the number of disease-free cancer patients is small and the sample does not 
represent a well balanced disease-free cancer population. Also, there might be a 
selection bias because patients were asked by their physicians to take part. In the 
future, studies with a longitudinal design should focus on predictors o f fatigue 
complained o f long after treatment. Cancer and treatment for cancer might well 
lead to fatigue, but these factors seem not to explain levels o f fatigue long after 
treatment. Anxiety and depression probably play a role in the maintenance of 
fatigue, but severe fatigue can not be fully explained by these factors. More 
knowledge, about (psychological) factors causing fatigue long after the end of 
treatment, will be useful in the development o f interventions for severely fatigued 
cancer patients.
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ABSTRACT
Quality o f life after cancer treatment becomes more important as the number of 
long-term survivors increases. This study aimed to investigate complaints of 
fatigue after treatment for breast cancer. The study patients were 150 women who 
had finished curative treatment for breast cancer by a mean o f 29 months before 
commencement o f this study. Measurements included computerised questionnaires 
and a daily Self Observation List. Thirty-eight percent o f the sample were severely 
fatigued, compared with 11% in a matched sample o f women without a history of 
cancer. No association was found between fatigue and former treatment. The 
‘severely fatigued disease-free breast cancer patient’ scored more ‘problematic’ on 
psychological well-being, functional impairment, sleep disturbance, physical 
activity, social support, neuropsychological and social functioning compared with 
the ‘non-severely fatigued disease-free breast cancer patient’. Furthermore, the 
severely fatigued patients had a lower sense o f control with respect to their fatigue 
complaints and stronger breast cancer- and psychologically- related attributions 
with regard to the causes o f fatigue compared with the non-severely fatigued 
patients. Regression analyses indicated that sleep disturbance, physical activity and 
causal attributions contributed significantly to the subjective experience of fatigue. 
In conclusion, severe fatigue is a problem for almost 40 percent o f the sample of 
breast cancer survivors. Severe fatigue is related to physical, psychological, social, 
cognitive and behavioural factors.
INTRODUCTION
Fatigue is a subjective experience that affects everybody. For healthy individuals it 
might be a protective, sometimes even pleasant regulatory response to physical or 
psychological stress. It seems to maintain a healthy balance between rest and 
activity. Controversially, for people with specific diseases fatigue often becomes a 
major distressing symptom. Based on results o f research with patients with Chronic 
Fatigue Syndrome, Multiple Scleroses and other chronic diseases we know that 
fatigue is a multidimensional phenomenon, which consists o f physical, 
psychological, social, cognitive and behavioural aspects1,2.
For patients with cancer, fatigue has been described as a major concern during 
treatment and in advanced stages o f the disease3,4. In recent (quality o f life) studies, 
fatigue has also been mentioned as a frequent complaint by disease-free cancer 
patients (long) after curative treatment for cancer has ended513. Furthermore, in 
three studies1416 patients who had been treated for breast cancer 20, 28 and 16 
months before, respectively, scored significantly higher than non-cancer 
comparison subjects on standardised self-report measures o f fatigue. In addition, in 
a large sample o f breast cancer survivors, there was a subgroup o f survivors who 
did report heightened levels o f fatigue relative to women in the general
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population17. Contrary to these results, no differences in fatigue scores were found 
in two other studies1819 comparing disease-free cancer patients 9 and 22 months, 
respectively, following radiotherapy with healthy controls.
The possible causes o f fatigue, long after treatment for cancer has finished, are still 
unknown. It is a logical expectation that fatigue can be predicted by preceding 
illness or former treatment modalities. However, most studies do not support a 
relationship between off-treatment fatigue and type o f treatment, time since 
diagnosis, or treatment and disease-stage at diagnosis7"9’13’15’16’18"20. Nevertheless, 
these results have to be interpreted with caution because results might have been 
influenced by the research design. For instance, in a sample o f patients who were 
all treated with radiotherapy, it is hard to demonstrate a relationship between off­
treatment fatigue and radiotherapy.
Physical, psychological, social, cognitive and behavioural factors might also be 
related to fatigue, and play a role in the perpetuation o f fatigue, long after treatment 
for cancer has finished. These relationships have been the object o f investigation in 
only a few studies. In those studies post treatment fatigue seemed to be related to 
depression, anxiety, quality o f sleep, use o f catastrophizing as a coping strategy 
and menopausal symptoms15-20.
In assessing chronic fatigue in patients with several chronic diseases, a 
multidimensional assessment method has identified nine dimensions, namely 
fatigue severity, psychological well-being, functional impairment in daily life, 
sleep disturbance, physical activity, neuropsychological impairment, social 
functioning/ social support, self-efficacy and causal attributions1. These 
dimensions appear to be relatively independent, meaning that each dimension 
uniquely contributes to the description o f a patient. Based on clinical experience 
and indications in the literature, the object o f the current study is to assess these 
nine dimensions o f fatigue in a group o f disease-free breast cancer patients. In 
addition, an age-matched sample o f women without a history o f cancer is included. 
In this article we will answer the following four research questions. 1) How many 
disease-free breast cancer patients experience severe fatigue (long) after treatment 
for cancer was finished; 2) Is fatigue severity in disease-free breast cancer patients 
associated with former treatment modalities (type of operation, type o f adjuvant 
therapy, duration o f treatment and time since treatment ended); 3) How can the 
‘severely fatigued disease-free breast cancer patient’ be described, with use o f the 
above mentioned dimensions and 4) What is the contribution o f the physical, 
psychological, social, cognitive and behavioural dimensions to the fatigue severity 
dimension in disease-free breast cancer patients?
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PATIENTS AND METHODS 
Sample
To select a relatively homogeneous group o f patients, all patients had to be treated 
according to the protocol o f the Comprehensive Cancer Centre East for 
premenopausal breast cancer patients. Furthermore, they had to be younger than 50 
by the time o f primary diagnosis and had to have completed treatment for breast 
cancer for a minimum o f 6 months and a maximum o f 70 months before the study 
commenced. They also had to have no evidence o f disease recurrence at the time of 
participation. Finally, all patients had been checked for side effects of previous 
anti-cancer treatment within three months after treatment. None o f the patients 
included in the study were anaemic at the time.
Most participating patients (120 o f the 150) were asked to bring along a female 
family member, friend, or colleague who was not more than five years younger or 
older than the patient. This woman had to be healthy (no chronic disease) and had 
never to have been treated for cancer in the past.
Recruitment procedure
Patients were recruited from one university hospital and 6 regional hospitals. At 
the university hospital and three regional hospitals, all patients who met the 
eligibility criteria were initially informed about the study by mail with an 
introductory letter from their oncologist. A t the other three regional hospitals, 
patients were informed by their oncologist during control-visits. In the following 
week, patients were contacted by telephone by the psychologist-researcher (P.S.). 
Those patients who agreed to take part in the study were invited to the department 
o f Medical Psychology o f the University Hospital Nijmegen. The ethics committee 
o f all participating hospitals agreed with the study.
Measurement
Patients and their female friends were invited to the research institute where they 
were asked to fill out several computerised questionnaires. In addition, they filled 
out a daily Self Observation List (SOL) during a period o f 12 days. Severity of 
fatigue was reported four times a day in this list. Furthermore, quality o f sleep, 
level o f activity, hours o f household activities and hours o f work outside the house 
were reported once a day.
Each o f the nine investigated dimensions was represented by several measures. The 
reason behind this lies in the fact that each instrument contributed uniquely to a 
certain dimension.
Fatigue severity was measured by the fatigue severity subscale (CIS-fatigue) o f the 
Checklist Individual Strength (CIS)1. The CIS is a 20-item questionnaire which 
was designed to measure four aspects o f fatigue during the previous two weeks, 
namely: fatigue severity (8 items), concentration (5 items), motivation (4 items) 
and physical activity (3 items). Each item was scored on a 7-point Likert scale.
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High scores indicated a high level o f fatigue, a high level o f problems with regard 
to concentration, low motivation and a low level o f physical activity. Based on 
research with Chronic Fatigue Syndrome patients, a score o f 35 or higher on the 
subscale fatigue severity indicates severe feelings o f fatigue1. Based on scores of 
healthy controls, a score between 27 (mean score for healthy adults plus one 
standard deviation (sd)) and 35 indicated heightened experience o f fatigue21. In 
addition fatigue was measured with the Daily Observed Fatigue (DOF) score o f the 
SOL22. DOF was reported four times a day on a 5-point scale (0-4). Total scores 
range from 0 to 16. Available norm scores o f 53 healthy subjects indicated that 
healthy adults have a mean DOF score of 1.6 (sd=1.4)2.
Psychological well-being was been measured with the Beck Depression Inventory 
for primary care (BDI-PC), the Spielberger Trait Anxiety Inventory (STAI) and the 
Rosenberg Self Esteem Scale (RSE). The BDI-pc was used in analysing the data, 
to prevent an overlap between the physical aspects o f fatigue with the somatic 
symptoms o f depression. This shortened version o f the BDI23 had 7 items and was 
composed of cognitive and affective symptoms only24. A score of 4 or more was 
indicative o f clinical depression. The STAI is a standardised self-report 
questionnaire designed to measure trait anxiety25. A score of 50 or more was 
considered indicative o f clinical anxiety26. The RSE measured global self-esteem 
and consists o f ten items27. Furthermore, the anxiety, agoraphobia, depression, 
somatisation, obsessive-compulsive behaviour, interpersonal sensitivity and 
hostility subscales o f the Symptom Checklist (SCL-90) were used28. Finally, the 
emotional functioning subscale o f the Quality o f Life Questionnaire-C30 o f the 
European Organisation for Research and Treatment o f Cancer (QLQ-C30) was
included29.
Functional impairment was measured with the subscales home management, work, 
and recreation and pastimes from the Sickness Impact Profile (SIP)30. Furthermore, 
the role functioning subscale o f the QLQ-C30 was used. In addition, hours o f work 
(outside the home and household activities) were registered in the SOL.
Sleep disturbance was measured with the Groninger Sleep Quality Scale (GSQS)31. 
This questionnaire consisted o f 14 items on problems with falling asleep, restless 
sleep, early awakenings in the morning and general quality o f sleep. Each item was 
scored on a yes/no format. A total score of sleep disturbances was derived from 
this questionnaire. Furthermore, the sleep/rest subscale o f the SIP and the sleep 
subscale o f the SCL were used. Finally, quality o f sleep (general quality o f sleep, 
difficulties falling asleep, restless sleep and early awakenings) was registered daily 
in the SOL.
Physical activity was measured with the physical functioning subscale o f the QLQ- 
C30, the physical activity subscale o f the CIS, and the mobility and ambulation 
subscales of the SIP. In addition, physical activity was registered once a day in the 
SOL.
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Neuropsychological functioning was measured with the cognitive functioning 
subscale o f the QLQ-C30, the concentration subscale o f the CIS and the alertness 
behaviour subscale o f the SIP.
Social functioning/ Social support was measured with the social functioning 
subscale o f the QLQ-C30, the social interaction subscale o f the SIP and the van 
Sonderen Social Support Inventory (SSL)32. The SSL was divided into the SSL-I 
(amount o f social support), the SSL-D (discrepancies between amount o f social 
support and desired amount o f social support), and the SSL-N (amount o f negative 
interactions).
Self efficacy, a sense o f control over fatigue symptoms, was measured with the 
subscale ‘internal locus o f control’ o f the Multidimensional Health Locus of 
Control (MHLC) and the Self Efficacy Questionnaire (SEQ). The MHLC 
measured control beliefs with respect to health in general33,34. The SEQ consisted 
o f five questions that measured sense o f control with respect to fatigue35.
Causal attributions with regard to fatigue complaints were measured with the 
Causal Attribution List (CAL). This questionnaire consisted o f 9 items divided 
over two subscales, psychological (e.g. ruminate, sleep problems) and breast 
cancer related attributions (e.g. surgery for breast cancer, adjuvant therapy for 
breast cancer). For each item, patients were asked to indicate their opinion 
regarding the cause o f their fatigue complaints on a 4 point scale (1 very applicable 
to 4 not at all applicable). Internal reliability o f this questionnaire was good. The 
subscales psychological- and breast cancer related attributions had alpha’s o f .81 
and .79, respectively.
Statistical analysis
Data analysis was performed using SPSS (version 8.0). Descriptive statistics were 
used for description o f the sample. T-tests, chi-square and general linear model 
(GLM)-general factorial were performed testing the differences between groups. In 
order to examine the contribution o f the physical, psychological, social, cognitive 
and behavioural dimensions to the dimension of fatigue severity, linear regression 
analyses (enter-method) was performed.
RESULTS
Description of the samples
Two-hundred and sixty-three disease-free breast cancer patients were contacted for 
this study. Most o f these patients (248) were sent an introductory letter from their 
oncologist while only 15 patients were contacted during control visits. One 
hundred and fifty-five patients (59%) agreed to participate in the study. N on­
participants did not differ from the participants with regard to age, type o f surgery, 
radiotherapy and time since treatment completion. However the non-participants 
received chemotherapy less often: 41% compared with 66% (chi-square; p<0.001).
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Therefore, duration o f treatment was significantly lower for non-participants (4 
compared with 6 months for participants; t-test; p<0.001). Reasons for non­
participation were: participation takes to much time (n=24), too emotional to 
participate (n=12), wanting to move on with their lives (n=12), did not feel like 
taking part (n=9), concurrent major health problems (n=8), not able to contact 
(n=7), problems with transport (n=6), too tired to participate (n=1), other reasons 
(n=6) and unknown (n=23).
Table 1. Demographic characteristics o f  both samples
Disease-free Women without
breast cancer patients a cancer history
n 1 5 ) n II )
Mean age 45.9 (sd 6.3) 48.1 (sd 6.2)
Marital status
married 130 (87%) 67 (86%)
unmarried 7 ( 4%) 3 ( 4%)
divorced 10 (7%) 5 ( 6%)
widowed 3 ( 2%) 3 ( 4%)
Higher education (>= 12 years) 57 (38%) 32 (41%)
Employment
work outside home 92 (61 %) 52 (67%)
voluntary work 33 (22%) 17 (22%)
disablement insurance act 18 (12%) 2 ( 3%)
partial disablement insurance act 20 (13%) 2 ( 3%)
sick leave 5 ( 3%) 1 ( 1%)
Table 2. Medical characteristics o f  the patient sample
Disease-free breast cancer patients
(n=150)
Mastectomy / Lumpectomy 95 (63%) / 55 (37%)
Adjuvant therapy
none 20 (13%)
radiotherapy only 31 (21%)
chemotherapy only 33 (22%)
radio- and chemotherapy 66 (44%)
Duration of treatment (months) Mean=6 (sd=3)
Time since diagnosis (months) Mean=35 (sd=17)
Time since treatment (months) Mean=29 (sd=17)
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Five o f the 155 participants were excluded for analyses since they dropped out 
during baseline assessment. One had concurrent major health problems (thyroid 
gland disorder), one had disease recurrence, one had medical problems with regard 
to breast reconstruction and two had major psychological problems.
Seventy-eight patients brought a female family member, friend, or colleague along 
to the hospital. Information about demographic characteristics o f the two samples 
is listed in Table 1. The sample o f disease-free breast cancer patients was 
comparable to the sample o f control women with regard to age, marital status, 
education and employment. However, the percentage o f disablement insurance act 
was higher in former breast cancer patients than in women without a cancer 
history.
Information about medical characteristics o f the patient sample is listed in Table 2. 
The majority o f the participating women were treated with mastectomy. A small 
group (13%) did not receive any adjuvant therapy while the others received 
radiotherapy, chemotherapy or both. Duration o f treatment was defined as the 
period from the time o f surgery until the end o f adjuvant therapy. Time since 
diagnosis was defined as the day o f diagnosis until the day o f participation in the 
current study. Finally, time since treatment was defined as the period from the end 
o f adjuvant therapy until the day o f participation in the current study.
Research questions
How many disease-free breast cancer patients experience severe fatigue (long) 
after treatment for cancer was finished?
The mean CIS-fatigue score o f the total patient sample was 28.5 (sd=13.6) 
compared with 19.4 (sd=11.0) in the sample o f women without a history o f cancer 
(t-test, p<0.001). Fifty- seven patients (38%) met the “cut-off” criteria for severe 
fatigue (i.e., CIS-fatigue >= 35) while an additional 24 patients (16%) had a score 
between 27 and 35. The group o f patients who had a CIS-fatigue o f 35 and higher 
will be referred to as “severely fatigued disease-free breast cancer patients”, from 
now on. The other patients will be referred to as “non-severely fatigued disease- 
free breast cancer patients”. In the control group, 9 women (11%) met the “cut-off” 
criteria for severe fatigue.
The mean DOF score o f the total patient sample was 2.9 (sd=2.2, min=0 max=9.5). 
In comparison, the mean DOF score was 1.6 (sd=1.3, min=0, max=4.5) in the 
sample o f women without a history o f cancer (t-test, p<0.001). The mean DOF 
score o f the severely fatigued disease-free breast cancer patients was 4.6 (sd=2.1) 
and that o f the non-severely fatigued disease-free breast cancer patients was 1.9.
Is fatigue severity associated with former treatment modalities?
To test the association between fatigue severity on the one hand, and type of 
operation (lumpectomy or mastectomy) and type o f adjuvant therapy (no adjuvant 
therapy, radiotherapy, chemotherapy or both) on the other hand, a GLM-general
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factorial was conducted. Dependent variable was the CIS-fatigue. Fixed factors 
were the variables type o f operation and type o f adjuvant therapy. Results indicated 
that there was no main effect o f type o f surgery (p=0.281), no main effect of 
adjuvant therapy (p=0.852) and no interaction effect (p=0.912). This meant that 
mean fatigue severity scores did not differ significantly for those patients who 
underwent mastectomy (mean CIS-fatigue 27) and those who underwent 
lumpectomy (mean CIS-fatigue 31). Furthermore, mean fatigue severity scores 
were equal for those patients who received radiotherapy (CIS-fatigue 28), 
chemotherapy (CIS-fatigue 28), both radiotherapy and chemotherapy (CIS-fatigue 
29) and those who did not receive adjuvant therapy (CIS-fatigue 28).
The association between severe fatigue and length o f treatment (1, 2-6 or more 
than 6 months) and time since treatment (6-12, 13-24, 25-36, 37-48, 49-60, or more 
than 60 months) was also tested with a GLM-general factorial. The dependent 
variable was the CIS-fatigue. Fixed factors were the variables length o f treatment 
and time since treatment. No main effect o f length o f treatment (p=0.387), no main 
effect o f time since treatment (p=0.938) and no interaction effect (p=0.950) were 
found.
How can the ‘severely fatigued disease-free breast cancer patient’ be described?
In Table 3, comparisons have been made between severely fatigued disease-free 
breast cancer patients, non-severely fatigued disease-free breast cancer patients and 
women without a history of cancer, with regard to the dimension o f psychological 
well-being, functional impairment in daily life, sleep disturbance, physical activity, 
neuropsychological impairment, social functioning, self-efficacy and causal 
attributions.
Results with regard to the psychological well-being dimension are consistent. 
Severely fatigued disease-free breast cancer patients have a lower mean score of 
emotional functioning, they are significantly more depressed and more anxious 
than non-severely fatigued disease-free breast cancer patients. In addition, severely 
fatigued disease-free breast cancer patients have a lower self-esteem and higher 
scores on the agoraphobia, somatisation, obsessive-compulsive behaviour, 
interpersonal sensitivity and hostility subscales o f the SCL, compared with the 
non-severely fatigued disease-free breast cancer patients. clinically depressed and 
19 percent as both clinical depressed and anxious. These percentages are 2, 3, and 
1%, respectively, for the group o f non-severely fatigued disease-free breast cancer 
patients. Non-severely fatigued disease-free breast cancer patients are comparable 
with regard to psychological well-being to women without a cancer history.
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Table 3. Dimensions o f  fatigue; comparisons between severely fa tigued disease-free breast 
cancer patients, non-severely fa tigued disease-free breast cancer patients and control 
women (General Linear Model-general factorial) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
A B C
Severely Non-severely Control p-value
fatigued fatigued women
patients patients
(n=57) (n=93) (n=78)
Mean (sd) Mean (sd) Mean (sd)
Psychological well-being
Emotional functioning 71.2 (21.8) 86.4 (15.0) - <0.001
(QLQ-C30)1
Depression (BDI- PC) 2.8 (2.8)bc 0.7 (1.4)a 0.8 (1.3)a <0.001
Trait anxiety (STAI) 42.3 (11.0)bc 31.7 (7.7)a 31.2 (8.7)a <0.001
Self-esteem (RSE) 36.6 (7.3)bc 42.2 (5.2)a 40.8 (5.9)a <0.001
Depression (SCL) 28.9 (9.7)bc 20.4 (4.7)a 20.4 (4.7)a <0.001
Anxiety (SCL) 16.1 (6.3)bc 12.1 (2.8)a 12.5 (3.1)a <0.001
Agoraphobia (SCL) 8.8 (3.7)bc 7.3 (0.8)a 7.8 (1.5)a 0.004
Somatisation (SCL) 23.4 (6.8)bc 16.9 (5.0)a 16.3 (4.0)a <0.001
Obsessive-comp. behaviour (SCL) 18.5 (7.2)bc 12.4 (3.8)a 12.7 (3.3)a <0.001
Interpersonal sensitivity (SCL) 29.0 (12.5)bc 22.5 (4.9)a 23.3 (4.8)a <0.001
Hostility (SCL) 8.3 (3.8)bc 6.8 (1.1)a 7.0 (1.2)a <0.001
Functional impairment 
in daily life
Role functioning (QLQ-C30)1 71.4 (22.7) 89.3 (15.7) - <0.001
Home management (SIP)2 98.6 (64.5)bc 52.0 (64.6)ac 8.8 (32.0)ab <0.001
Work (SIP)2 91.4 (115.1)c 63.1 (116.5)c 12.7 (64.4)ab <0.001
Recreation and pastimes (SIP)2 72.4 (51.9)bc 33.7 (46.6)ac 6.7 (21.7)ab <0.001
Number of days working (SOL) 3.6 (3.4) 4.1 (3.4) 4.7 (3.4) ns
Hours of work a day (SOL) 3.2 (3.1)c 3.9 (3.1)c 5.6 (2.1)ab <0.001
Number of days with household 10.3 (2.2) 10.1 (2.4) 10.4 (2.2) ns
activities (SOL)
Hours of household activities 3.4 (1.9) 3.9 (2.1) 3.6 (1.9) ns
a day (SOL)
Sleep disturbances
Sleep disturbances (GSQS) 6.6 (4.0)bc 3.5 (3.6)a 3.6 (3.5)a <0.001
Sleep/ rest (SIP)2 65.8 (49.0)bc 28.3 (43.8)ac 11.4 (26.0)ab <0.001
Sleep (SCL) 7.1 (3.4)bc 5.2 (2.6)a 4.8 (1.9)a <0.001
Daily general quality of sleep 0.58 (0.26)bc 0.72 (0.25)a 0.71 (0.28)a 0.001
(SOL)
Daily difficulties falling asleep 0.20 (0.26)bc 0.10 (0.17)a 0.11 (0.20)a 0.007
(SOL)
Daily restless sleep (SOL) 0.30 (0.24)bc 0.20 (0.21)a 0.18 (0.24)a 0.012
Daily early awakenings (SOL) 0.18 (0.21) 0.15 (0.22) 0.14 (0.24) ns
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Table 3. continued
A
Severely 
fatigued 
patients 
(n=57) 
Mean (sd)
B
Non-severely 
fatigued 
patients 
(n=93) 
Mean (sd)
C
Control
women
(n=78) 
Mean (sd)
p-value
Physical activity
Physical functioning (QLQ-C30)1 72.6 (18.8) 87.0 (13.4) - <0.001
Physical activity (CIS)2 12.1 (5.9)bc 6.8 (3.8)a 5.9 (3.7)a <0.001
Mobility (SIP)2 16.5 (41.5)bc 4.9 (17.5)a 1.5 (8.7)a 0.003
Ambulation (SIP)2 25.4 (40.6)bc 6.9 (18.0)a 0.0 (0.0)a <0.001
Daily activity score (SOL) 2.51 (0.52)bc 2.27 (0.46)a 2.29 (0.49)a 0.009
Neuropsychological impairment
Cognitive functioning 
(QLQ-C30)1
73.7 (24.0) 88.8 (15.8) - <0.001
Concentration (CIS)2 20.3 (7.6)bc 14.1 (7.2)a 13.1 (7.5)a <0.001
Alertness behaviour (SIP)2
Social functioning and 
social support
150.9 (150.0)bc 56.5 (90.4)a 15.4 (78.8)a <0.001
Social functioning (QLQ-C30)1 82.5 (22.8) 94.6 (12.1) - <0.001
Social interaction (SIP)2 173.5 (172.5)bc 64.3 (99.7)ac 9.0(26.9)ab <0.001
Amount of social support (SSL-I) 168.1 (26.3) 170.3 (26.5) 165.7 (21.4) ns
Amount of negative interactions 
(SSL-N)
10.54 (3.0)bc 9.4 (2.1)a 9.4 (1.9)a 0.005
Discrepancies social support 
(SSL-D)
47.89 (13.0)bc 42.3 (9.1)a 42.9 (8.1)a 0.002
Self-efficacy
Self-efficacy (SEQ)* 17.3 (3.2) 19.2 (3.2) - 0.002
Internal locus of control 
(MHLC-I)
13.9 (4.6) 13.8 (4.2) - ns
Causal attributions
Psychological attributions 
(CAL)*3
2.9 (0.7) 3.3 (0.6) - 0.001
Breast cancer related attributions 
(CAL)* 3
2.1 (0.6) 2.7 (0.8) - <0.001
The QLQ-C30, SEQ, MHLC-I and CAL were not filled out by women in the control group.
1 higher scores represent better functioning
2 higher scores represent more impairment
3 higher scores present less strong attributions
a significantly different from group A, Bonferroni p<0.05 
b significantly different from group B, Bonferroni p<0.05 
c significantly different from group C, Bonferroni p<0.05
* n=133 (these questionnaires have not been filled out by those patients who report that they never 
experience fatigue)
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On the subscales o f the QLQ-C30 and SIP that were used to measure functional 
impairment in daily life, severely fatigued disease-free breast cancer patients 
reported being more functionally impaired than did non-severely fatigued disease- 
free breast cancer patients. Furthermore, both patients groups (severely fatigued 
and non-severely fatigued) reported more functional impairment in daily life than 
women without history o f cancer. On the SOL, no significant differences were 
found with regard to number o f days working, number o f days with household 
activities and hours o f work or household activities per day within a 2-week period, 
between the three different samples. However, controls worked more hours per day 
in comparison with both patient groups.
On the sleep disturbance dimension, severely fatigued disease-free breast cancer 
patients report having more problems with sleep than non-severely fatigued 
disease-free breast cancer patients. The two groups did not differ in the frequency 
o f early awakenings. Scores o f non-severely fatigued disease-free breast cancer 
patients were comparable with scores o f women without a cancer history, except 
for the sleep/rest subscale o f the SIP. Non-severely fatigued disease-free breast 
cancer patients scored more problematic on this subscale in comparison with 
control women.
With regard to the physical activity dimension, severely fatigued disease-free 
breast cancer patients reported less physical functioning on all used measures 
compared with non-severely fatigued disease-free breast cancer patients. Non- 
severely fatigued disease-free breast cancer patients were comparable with respect 
to physical activity with women without a history of cancer.
The same applies for the dimension representing neuropsychological impairment. 
Scores on all subscales indicated that severely fatigued disease-free breast cancer 
patients reported having more problems with regard to memory and concentration 
than non-severely fatigued disease-free breast cancer patients. This latter group had 
comparable scores to women without a history o f cancer.
On the social functioning/ social support dimension, severely fatigued disease-free 
breast cancer patients reported less social functioning and more impairment with 
regard to social interactions than non-severely disease-free breast cancer patients. 
In comparison with the control group, both patient groups reported significantly 
more problems on the social interaction scale o f the SIP. With regard to social 
support all three groups reported having the same amount o f social support. 
However, severely fatigued patients experience more negative interactions and a 
higher discrepancy between amount o f social support and desired amount o f social 
support than did the non-severely fatigued patients and control women. That is to 
say, severely fatigued patients wished they were receiving more social support than 
they felt they are actually receiving.
Within the self-efficacy dimension, no differences were found between severely 
fatigued disease-free breast cancer patients and non-severely fatigued disease-free 
breast cancer patients with respect to the internal locus o f control o f health in
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general. This means that patients in both groups believed to the same extent that 
they would remain healthy or ill as a result o f their own behaviour. However, 
severely fatigued patients had a lower sense o f control with respect to fatigue than 
non-severely fatigued patients. Thus, severely fatigued patients thought to a lesser 
extent, than non-severely fatigued patients, that they could exert influence on their 
fatigue complaints.
Finally, on the dimension of causal attributions, severely fatigued disease-free 
breast cancer patients, reported more psychological and more breast cancer-related 
attributions with regard to fatigue complaints than did non-severely fatigued 
disease-free breast cancer patients. In other words, patients who experienced severe 
fatigue attributed their fatigue complaints, more often, to the fact that they were 
diagnosed and treated for breast cancer in comparison with those who experienced 
only moderate fatigue. In addition, they also more often indicated that their fatigue 
complaints could be a result of the fact that they often ruminate, experience trouble 
sleeping etc.
Table 4. Linear regression analysis to predict fatigue_________________________________
Dependant variables
CIS-fatigue severity Daily Observed Fatigue
(DOF)
___________________________________ Beta_______ p________ Beta________ p
Independent variables
SCL-depression 0.227 0.033 0.173 0.140
QLQ-C30-role functioning -0.152 0.140 -0.041 0.720
SIP-sleep/rest 0.213 0.008 0.202 0.024
QLQ-C30-physical functioning -0.072 0.384 -0.209 0.025
CIS-physical activity 0.317 <0.001 0.058 0.514
CIS-concentration 0.139 0.111 0.122 0.222
QLQ-C30-social functioning 0.177 0.098 0.123 0.305
SIP-social interaction -0.043 0.645 0.023 0.829
SEQ-self efficacy -0.061 0.448 -0.117 0.186
CAL-breast cancer related attributions -0.205 0.023 -0.272 0.006
Total R2 (adjusted) 0.523 0.427
What is the contribution o f  the physical, psychological, social, cognitive and 
behavioural dimensions to the fatigue severity dimension in disease-free breast 
cancer patients?
Regression analyses have been performed to examine the contribution of 
psychological well-being, functional impairment in daily life, sleep disturbance, 
physical activity, neuropsychological impairment, social functioning, self-efficacy
Determinants of chronic fatigue in disease-free breast cancer patients 81
and causal attributions to fatigue severity. Two analyses were done, one with the 
CIS-fatigue severity score as the dependent variable, and the other using the DOF 
score as the dependent variable. Independent variables were those questionnaires 
or subscales o f questionnaires within the other eight dimensions that correlated 
highest with one o f the dependent variables. For the dimensions physical activity 
and social functioning two measures were selected for the regression analyses, 
because within these dimensions one measure correlated highest with the CIS- 
fatigue severity score and the other one with the DOF. Within all the other 
dimensions, one measure correlated highest with both the CIS-fatigue severity 
score and the DOF score.
Results indicate that in both analyses, questionnaires representing the dimensions 
o f sleep disturbance (SIP-sleep/rest), physical functioning (CIS-activity or QLQ- 
C30-physical functioning) and causal attributions (breast cancer-related 
attributions) contributed significantly to the fatigue severity dimension. 
Furthermore, the dimension o f psychological well-being (SCL-depression) 
contributed significantly to the CIS-fatigue severity score. In total, 52% o f the 
fatigue severity subscale o f the CIS were predicted, and 43% o f the DOF score 
(Table 4).
DISCUSSION
In this study, a strikingly large part (38%) of a group o f women who were treated 
for breast cancer in the past turned out to be severely fatigued. This is significantly 
higher than the percentage in a matched control group o f women without a history 
o f cancer. Although severe fatigue might have been associated with treatment 
modalities while patients were undergoing treatment, this association could not be 
found long after treatment for breast cancer was completed. Results failed to find 
significant associations between severe fatigue on the one hand, and type of 
operation, type o f adjuvant therapy, length o f treatment and time since treatment on 
the other hand. As mentioned in the Introduction, these results correspond to the 
majority o f recent findings in the literature.
In an attempt to describe ‘the severely fatigued disease-free breast cancer patient’ 
on several dimensions, we found that severe fatigue long after completion of 
treatment for breast cancer is associated with several physical, psychological, 
social, cognitive and behavioural factors. The strength o f the association observed 
between fatigue and depressive symptomatology is interesting in light o f the fact 
that one o f the measures o f depression used in this study (BDI-pc) includes items 
that reflect cognitive and affective symptoms o f depression but not somatic 
symptoms. Thus, the relationship cannot be explained as overlap o f the physical 
aspects o f fatigue with somatic symptoms o f depression. However, our results 
suggest that, although in some patients the depression-fatigue association cannot be
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ruled out as a possible explanation for the experience of fatigue after treatment for 
cancer, it is an incomplete description o f the underlying process. Within the group 
o f severely fatigued disease-free breast cancer patients, 69 percent can not be 
considered as clinical depressed.
From results o f the dimension ‘functional impairment’ it can be concluded that 
severely fatigued disease-free breast cancer patients see themselves as more 
impaired with regard to role functioning, home management and recreation and 
pastimes than do non-severely fatigued disease-free breast cancer patients. 
However, on the SOL, severely fatigued disease-free breast cancer patients 
reported the same amount o f household activities and work outside the house as 
non-severely fatigued disease-free breast cancer patients. These results probably 
indicate that disease-free breast cancer patients have to resume their household 
activities, no matter whether they feel fatigued or not. Furthermore, it could be that 
it is very important for women in our society to resume their work outside the 
home after treatment for cancer (for financial or social reasons).
With regard to sleep disturbances, it seems logical that when one does not sleep 
well, fatigue complaints are maintained. Causes o f sleep problems have not been 
extensively investigated. It is possible that sleep problems are a result of the 
experience o f tension, fear and anxiety that is related to the uncertainty regarding 
the future. Furthermore, in breast cancer patients, who often become menopausal 
because o f chemotherapy, an increased frequency of night-time vasomotor 
symptoms (i.e. night sweats) could produce disruptive effects on sleep36. 
Additional research is needed to clarify this issue.
The relationship between fatigue and physical activity has rarely been investigated 
in the literature, and only during active treatment for cancer37 39. Results suggest a 
negative relation between physical activity and fatigue. In addition, sports or 
walking programmes during treatment for cancer report positive results, although 
follow-up analyses are absent40,41. Results from our study also suggest that after 
treatment for cancer lower physical activity is related to more severe fatigue.
On the dimension o f social support we found that severely fatigued disease-free 
breast cancer patients experienced less social support than they would like. This 
perceived lack o f social support may result from the fact that family and friends do 
not expect their wife, mother or friend to experience fatigue or any other 
complaints more than a year after treatment for breast cancer.
In general, non-severely fatigued disease-free breast cancer patients are 
comparable to women without a cancer history on the above described dimensions. 
The only differences between these two groups were found on several subscales of 
the SIP (namely home management, work, recreation and pastimes, sleep/rest and 
social interaction) and on one subscale o f the SOL (hours o f work a day).
On the ‘self-efficacy’ dimension, severely fatigued disease-free breast cancer 
patients had a lower sense o f control with respect to their fatigue complaints than 
did non-severely fatigued disease-free breast cancer patients. This finding is
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consistent with results o f studies with chronic fatigue syndrome patients and 
multiple sclerosis patients. In these patient populations, a negative self-efficacy 
was found to have a direct negative causal effect on fatigue severity35.
In summary, results from this study indicate that severe fatigue is a problem for 
nearly 40 percent o f the disease-free breast cancer patients. Furthermore, there are 
no indications for a relationship between off-treatment fatigue and former 
treatment modalities. Finally, severe fatigue is associated with several physical, 
psychological, social, cognitive and behavioural factors. Regression analyses 
indicated that depression, physical inactivity, the need to sleep and rest during the 
day and the tendency to attribute fatigue complaints to the breast cancer 
experience, contribute significantly to the severity of fatigue.
Nevertheless, it is important to note that there are also many breast cancer 
survivors who have comparable scores to women without a history o f cancer with 
respect to fatigue severity, psychological well-being, sleep disturbances, physical 
activity, neuropsychological impairment, social functioning and social support. 
These women thus seem to function quite well about two years after treatment for 
breast cancer.
The strengths o f this study include the use o f a comprehensive multidimensional 
assessment o f fatigue and the reliance upon different self-report measures for each 
dimension. In addition, use of the SOL in which fatigue is registered four times a 
day, and sleep, activity and work are registered once a day, constituted an advance 
over entire reliance upon retrospective measures. Furthermore, we could use an 
empirically validated cut-off point for severe fatigue, based on norm scores of 
fatigue from several groups o f patients and healthy controls21. Finally, the inclusion 
o f an age and gender matched control group leads to useful results.
In the future, specific attention should be paid to the way physical, psychological, 
social, cognitive and behavioural factors contribute to the course o f fatigue after 
successful treatment for cancer, using a longitudinal design. More knowledge 
about the perpetuating factors o f off-treatment fatigue will enable us to develop 
interventions to reduce fatigue complaints in severely fatigued disease-free cancer 
patients.
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ABSTRACT
Previous research indicates that disease-free breast carcinoma survivors who 
experienced severe fatigue also had many problems with regard to 
neuropsychological functioning and physical activity, measured with general self­
report questionnaires. Both neuropsychological functioning and physical activity 
can be measured with daily self-report measures in addition to measures of 
objective behaviour. The main objective o f this study was to examine the relations 
between 1) fatigue and 2) daily self-reported and objective measures of 
neuropsychological functioning and physical activity. Disease-free breast 
carcinoma survivors and age-matched women with no history o f breast carcinoma 
filled out a daily self-observation list and wore an actometer during a period o f 12 
days. Furthermore, they performed two standardised tests to assess 
neuropsychological functioning. No differences were found between severely 
fatigued disease-free breast carcinoma survivors, non-severely fatigued disease- 
free breast carcinoma survivors, and women in a control group with regard to daily 
self-reported and objective physical activity. The severely fatigued disease-free 
patients reported more impairment in neuropsychological functioning on daily 
questionnaires compared with non-severely fatigued disease-free patients and 
women in the control group. However, no differences were found between these 
three groups on a standardised concentration task. On a standardised reaction time 
task, no significant differences were found between the two groups o f disease-free 
breast carcinoma survivors: However, women in the severely fatigued group had a 
significantly longer reaction time compared with women in the control group. We 
conclude that fatigue is correlated strongly with daily self-reported 
neuropsychological functioning, but not with objective neuropsychological 
functioning, in a laboratory setting. In the current study, fatigue was not correlated 
with daily self-reported and objective physical activity.
INTRODUCTION
During recent years, several articles have been published about fatigue complaints 
in disease-free patients long after curative treatment for malignant disease1-9. 
Although the results are not unambiguous, the majority o f those studies concluded 
that fatigue is an important problem for about one-third o f survivors o f malignant 
disease.
Recently, our research group conducted a study to investigate fatigue in a sample 
o f 150 disease-free breast carcinoma survivors10. The results indicated that 38% of 
these women experienced severe fatigue. Furthermore, it was found that, among 
this group o f disease-free breast carcinoma survivors, severely fatigued patients 
experienced significant more problems in neuropsychological functioning 
(concentration and memory problems) and physical activity compared with non-
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severely fatigued patients and with a group o f women who had no history o f breast 
carcinoma, as measured with validated general self-report questionnaires.
There are several studies in which neuropsychological impairment is described in 
disease-free patients who previously had malignant disease1113, in patients 
undergoing treatment for malignant disease1416, in patients with terminal malignant
17-19 20,21disease " , and in survivors o f childhood malignancies ’ . However, with the 
exception o f one article, the relation between fatigue and neuropsychological 
functioning was never investigated12. In that study, the patients who showed most 
impairment with respect to neuropsychological functioning also reported the most 
fatigue.
The relation between fatigue and physical activity has been investigated scarcely 
and only during active treatment for malignant disease22-25. During this period of 
active treatment, there seems to be a negative relation between physical activity 
and fatigue. In addition, patients with malignancies who participate in walking or 
exercise intervention programs report positive effects on fatigue26,27. No data are 
available concerning the relation between fatigue and physical activity in survivors 
o f malignant disease.
In the current study, data are presented on the relation between 1) fatigue and 2) 
both neuropsychological functioning and physical activity. Results o f general self­
report questionnaires were reported previously10. However, neuropsychological 
functioning and physical activity can be measured as well with a daily self­
observation list and by measures o f objective behaviour. It is important to combine 
these different ways o f measurement, because there is evidence that general self­
report measures, daily self-report measures, and measures o f objective behaviour 
do not always lead to the same conclusion28.
To interpret data, an age-matched control group o f women with no history o f breast 
carcinoma was included. Furthermore, because clinical evidence suggests that 
radiotherapy of the breast can cause damage indirectly to the lungs, and because 
chemotherapy can have an effect on the nervous system, we investigated the 
influence o f previous treatment on physical activity and neuropsychological 
functioning.
Three specific research questions were investigated: 1) Do severely fatigued 
disease-free breast carcinoma survivors, non-severely fatigued disease-free breast 
carcinoma survivors, and women with no history of breast carcinoma show 
differences in daily self-reported and objective neuropsychological functioning; 
2) Do these three groups differ with regard to daily self-reported and objective 
physical activity; 3) Are the results o f daily self-report measures and objective 
measures o f neuropsychological functioning and physical activity consistent with 
the results o f general self-report measures and 4) Are general self-reported, daily 
self-reported, and objective neuropsychological functioning and physical activity 
influenced by previous treatment for breast carcinoma?
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METHODS
Sample
To select a relative homogeneous group of patients, all patients had to be treated 
according to the protocol o f the Comprehensive Cancer Center East for 
premenopausal breast carcinoma. Furthermore, women had to be age < 50 years by 
the time o f primary diagnosis and had to have completed treatment for breast 
carcinoma a minimum o f 6 months and a maximum o f 70 months prior to study 
entry. Finally, they could have no evidence o f disease recurrence at the time of 
participation.
Participating patients were asked to bring along a female family member, friend, or 
colleague who was not > 4 years younger or > 4 years older than the patient. This 
woman had to be healthy (no chronic disease) and was never treated for malignant 
disease in the past.
Recruitment Procedure
Women were recruited from one university hospital and from six regional 
hospitals. At the university hospital and at three regional hospitals, all patients who 
met the eligibility criteria initially were informed about the study by mail with an 
introductory letter from their oncologist. A t the other three regional hospitals, 
patients were informed by their oncologist during control visits. In the following 
week, patients were contacted by telephone by the psychologist-researcher (P.S.). 
The patients who agreed to take part in the study were invited (with their female 
family member, friend, or colleague) to the Department o f Medical Psychology of 
the University Medical Center Nijmegen. The psychologist-researcher and one 
psychological assistant administered all measures. This was done during the period 
between January 1998 and June 1999. From all patients and control participants, 
informed consent was obtained. The ethics committee o f all participating hospitals 
agreed with the study.
Measurement
Fatigue severity was measured with the Fatigue Severity subscale o f the Checklist 
Individual Strength (CIS)29. The CIS is a 20-item questionnaire that was designed 
to measure fatigue severity (8 items), concentration (5 items), motivation (4 items), 
and physical activity (3 items). Each item is scored on a 7-point Likert scale, with 
high scores indicating a high level o f fatigue, a high level o f concentration 
problems, low motivation, and a low level o f physical activity. Based on research 
with patients who have chronic fatigue syndrome, a score 35 on the Fatigue 
Severity subscale indicates severe feelings o f fatigue30.
Patients registered daily complaints o f neuropsychological functioning and 
physical activity at home during a 12-day period in a daily self-observation list31. 
Memory and concentration both were registered four times daily (0, no; 1, yes). 
Total daily scores ranged from 0 to 4, with a higher score indicating more
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problems with memory and concentration. In addition, physical activity was 
registered 4 times daily, from 0 (not at all active) to 4 (very active). Total scores 
ranged from 0 to 16, with a higher score indicating more daily physical activity. 
Objective physical activity was measured with the actometer, which is an apparatus 
about the size o f a matchbox that was worn around the ankle both day and night 
during a 12-day period28. Specialised software was used to calculate several 
parameters. A general physical activity score reflected the physical activity level 
over the 12-day period and was expressed as the average number o f accelerations 
per 5-minute period. Furthermore, the program calculated the 10 largest activity 
peaks. Both the average peak duration and average peak amplitude o f these 10 
largest peaks were calculated. Finally, the average duration o f rest periods after 
these 10 largest peaks was calculated32.
Objective neuropsychological functioning was measured with the Complex 
Reaction Time Task (CRT)33 and the Symbol Digit subtest o f the Wechsler Adult 
Intelligence Scale (WAIS)34. The CRT measures the speed of information 
processing and is comprised o f three consecutive tasks. On a response board, five 
target buttons are situated in an arch around a start button. The target buttons are 
placed at equal distances from the start button. Each target button contains a 
stimulus light. In all tasks, the participant keeps the start button pressed until a 
stimulus button lights up. In the first task, only one stimulus button (the middle) 
can light up. In the second task, three different stimulus buttons (the middle three) 
can light up in random order. In the third task, three different stimulus buttons (the 
three buttons on the left) can light up in random order. In this task, participants are 
asked not to press the stimulus button that lights up (the first two tasks are 
considered the obvious response) but to press the button to the right o f the stimulus 
button. Each task consists o f 30 trials. To prevent anticipation effects, the time that 
elapses between pushing the start button and the lighting o f the stimulus is varied 
between 0.5 seconds and 2.5 seconds (in random order). In the CRT, reaction time 
(speed o f information processing) is registered by the computer. Reaction time is 
defined as the time elapsed between the moment the stimulus lights up and the 
moment the start button is released.
The Symbol Digit subtest of the WAIS assesses the ability to concentrate. This test 
consists o f pairing numbers with nonsense symbols as quickly as possible. The 
higher the score on this test, the better a person is able to concentrate.
It should be noted that concentration and reaction time tap specific facets o f 
neuropsychological functioning. These domains do not represent the complete area 
o f cognitive functioning. The reason for choosing to focus on these domains is that 
previous research indicates that these domains often are problematic in long-term 
survivors o f malignant disease11,13,35.
General self-reported neuropsychological functioning was measured using the 
Concentration subscale of the CIS. Furthermore, the Alertness and Intellectual 
Functioning subscale o f the Sickness Impact Profile (SIP-8) was used36. General
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self-reported physical activity was measured with the Physical Activity subscale of 
the CIS and the Mobility and Ambulation subscales o f the SIP-8.
Statistical Analyses
Data analysis was performed using SPSS software (version 8.0; SPSS, Inc., 
Chicago, IL). Descriptive statistics were used to describe the samples. Chi-square 
tests and general linear model (GLM)-General Factorial tests were performed to 
determine differences between groups. In instances of an overall significance, the 
Bonferroni correction was applied to compare the three individual groups.
Table 1. Demographic characteristics
Severely 
fatigued disease- 
free patients 
with breast 
carcinoma
(n=57)
Non-severely 
fatigued disease- 
free patients 
with breast 
carcinoma
(n=93)
Women without 
a history 
of carcinoma
(n=78)
Mean age 45.2 (sd=6.2) 46.4 (sd=6.3) 48.1 (sd=6.2)
Marital status
married 81% 90% 86%
unmarried 5% 4% 4%
divorced 10% 4% 6%
widowed 4% 1% 4%
Higher education (>=12 years) 37% 39% 41%
Employment
work outside home 53% 67% 67%
voluntary work 14% 27% 22%
disablement insurance act 19% 7% 3%
partial disablement insurance act 21% 9% 3%
sick leave 7% 1% 1%
RESULTS
Description of the Sample
One hundred fifty disease-free breast carcinoma survivors participated in this 
study. The numbers o f women who did not participate and their reasons for 
nonparticipation were described in an earlier publication10. Seventy-eight patients 
brought a female family member, friend, or colleague along to the hospital.
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The sample of disease-free breast carcinoma survivors was divided into two 
groups: severely fatigued patients (i.e., a score 35 on the Fatigue Severity subscale 
o f the CIS) and non-severely fatigued patients. Information about demographic 
characteristics o f these two groups and the group o f control women is listed in 
Table 1. No significant differences were found with regard to age, marital status, 
education, and employment between the three groups. However, the percentage of 
women on (partial) disability insurance was higher in the group o f severely 
fatigued breast carcinoma survivors compared with the group o f non-severely 
fatigued breast carcinoma survivors and the group o f women with no history of 
breast carcinoma (GLM-General Factorial; p<0.002).
Information on the medical characteristics o f the breast carcinoma survivors can be 
Information on the medical characteristics o f the breast carcinoma survivors can be 
found in Table 2. Duration o f treatment was defined as the period from the time of 
surgery until the end o f adjuvant therapy. Time since diagnosis was defined as the 
month o f diagnosis until the month o f participation in the current study. Finally, 
time since treatment was defined as the period from the end o f adjuvant therapy 
until the month o f participation in the current study.
Table 2. Treatment characteristics
Severely fatigued 
disease-free patients 
with breast carcinoma
(n=57)
Non-severely fatigued 
disease-free patients 
with breast carcinoma
(n=93)
mastectomy vs. lumpectomy 54% vs 46% 68% vs 32%
no adjuvant therapy 12% 14%
only radiotherapy 19% 21%
only chemotherapy 21% 23%
radiotherapy and chemotherapy 48% 42%
mean duration of treatment (months) 6 (sd 3) 6 (sd 3)
mean time since treatment (months) 27 (sd 16) 30 (sd 18)
Research Questions
Do severely fatigued disease-free breast carcinoma survivors, non-severely 
fatigued disease-free breast carcinoma survivors, and women with no history o f  
breast carcinoma show differences in daily self-reported and objective 
neuropsychological functioning?
Results o f daily self-reports (Table 3) indicated that severely fatigued disease-free 
breast carcinoma survivors (mean "  standard deviation CIS Fatigue Severity score, 
43.0 "  5.5) reported more daily concentration problems and more daily memory 
problems compared with non-severely fatigued disease-free breast carcinoma
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survivors (mean "  standard deviation CIS Fatigue Severity score, 19.6 "  8.4) and 
women with no history of breast carcinoma. However, the difference between 
severely fatigued disease-free breast carcinoma survivors and non-severely 
fatigued disease-free breast carcinoma survivors with regard to daily memory 
problems did not reach significance (p<0.06). Non-severely fatigued disease-free 
breast carcinoma survivors and women with no history o f breast carcinoma had 
equal scores.
Table 3. Neuropsychological functioning
A B c
Severely Non-severely Women p-value
fatigued fatigued without a
disease-free disease-free history of
patients with patients with carcinoma
breast breast
carcinoma carcinoma
(n=57) (n=93) (n=78)
Mean (sd) Mean (sd) Mean (sd)
Daily self-report
concentration 0.36 (0.79)bc 0.14 (0.37)a 0.04 (0.10)a 0.000
memory 0.22 (0.75)c 0.06 (0.27) 0.02 (0.08)a 0.016
Actual behaviour
concentration (symbol 54.5 (10.4) 55.7 (11.5) 55.4 (8.9) 0.795
digit)
reaction time (CRT1) 0.32 (0.06)c 0.30 (0.05) 0.29 (0.05)a 0.004
reaction time (CRT2) 0.36 (0.05)c 0.36 (0.14 )c 0.32 (0.04)ab 0.009
reaction time (CRT3) 0.47 (0.08)c 0.45 (0.07) 0.42 (0.07)a 0.001
General self-report
concentration (CIS)* 20.3 (7.6)bc 14.1 (7.2)a 13.1 (7.5)a 0.000
alertness behaviour 150.9 (150.0)bc 56.5 (90.4) a 15.4 (78.8)a 0.000
(SIP)*
GLM-general factorial
b significantly different from group A, Bonferroni p<0.05 
significantly different from group B, Bonferroni p<0.05 
# significantly different from group C, Bonferroni p<0.05 
also reported in Servaes et al.10
Furthermore, the speed o f information processing (CRT) was slower for severely 
fatigued disease-free breast carcinoma survivors compared with for women in the 
control group. In addition, on one o f the three subtests o f the CRT, non-severely 
fatigued disease-free breast carcinoma survivors also were significantly slower 
compared with women in the control group. Severely fatigued disease-free breast
96 Chapter 5
carcinoma survivors and non-severely fatigued disease-free breast carcinoma 
survivors did not have significantly different scores. Finally, the ability to 
concentrate, as measured with the Symbol Digit subtest o f the WAIS, did not 
reflect any differences between the three groups (Table 3).
Table 4. Physical activity
A B c
Severely Non-severely Women p-value
fatigued fatigued without a
disease-free disease-free history of
patients with patients with carcinoma
breast breast
carcinoma carcinoma
(n=57) (n=93) (n=78)
Mean (sd) Mean (sd) Mean (sd)
Daily self-report
physical activity 5.27 (1.71) 5.90 (2.04) 5.82 (1.88) 0.131
Actual behaviour
general physical activity 76.1 (22.5) 79.1 (20.8) 76.9 (15.5) 0.613
(actometer)1
peak amplitude (actometer)1 182.0 (29.7) 182.1 (23.1) 177.6 (22.3) 0.452
peak duration (actometer)2 125.7 (46.0) 136.7 (51.7) 129.5 (39.0) 0.344
rest duration after peak 71.2 (31.7) 63.9 (30.2) 68.2 (31.7) 0.369
(actometer)2
General self-report
physical activity (CIS)3 12.1( 5.9)bc 6.8 ( 3.8)a 5.9 ( 3.7)a 0.000
mobility (SIP)3 16.5 (41.5)bc 4.9 (17.5)a 1.5 ( 8.7)a 0.003
ambulation (SIP)3 25.4 (40.6)bc 6.9 (18.0)a 0.0 ( 0.0)a 0.000
GLM-general factorial
b significantly different from group A, Bonferroni p< 0.05 
significantly different from group B, Bonferroni p< 0.05 
1 significantly different from group C, Bonferroni p< 0.05
activity levels are expressed in the number of accelerations per 5-minute period 
3 peak and rest durations are expressed in minutes 
3 also reported in Servaes et al.10
Do severely fatigued disease-free breast carcinoma survivors, non-severely 
fatigued disease-free breast carcinoma survivors, and women with no history o f  
breast carcinoma differ with regard to measures o f daily self-reported and 
objective physical activity?
During a 12-day period, severely fatigued disease-free breast carcinoma survivors 
reported the same daily activity as non-severely fatigued disease-free breast 
carcinoma survivors and women in the control group. In addition, the three groups
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had equal scores for general physical activity, peak amplitude, peak duration, and 
duration o f rest after an activity peak, as measured with the actometer (Table 4).
Are the results o f  daily self-report measures and objective measures o f  
neuropsychological functioning and physical activity consistent with the results o f  
general self-report measures?
In our previous publication, we found that severely fatigued disease-free breast 
carcinoma survivors experienced more impairment in neuropsychological 
functioning and in physical activity compared with non-severely fatigued disease- 
free breast carcinoma survivors and women with no history o f breast carcinoma on 
all general self-report measures. Non-severely fatigued disease-free breast 
carcinoma survivors and women with no history o f breast carcinoma had equal 
scores (see Tables 3 and 4). The results o f daily self-reports of neuropsychological 
functioning were consistent with the previous results. Severely fatigued disease- 
free breast carcinoma survivors reported more daily problems with regard to 
neuropsychological functioning compared with non-severely fatigued disease-free 
breast carcinoma survivors and women with no history o f breast carcinoma. 
Results o f objective measurements o f neuropsychological functioning were not 
entirely consistent with the results obtained by general self-report measures. 
Reaction time was longer for severely fatigued disease-free breast carcinoma 
survivors compared with women who had no history o f breast carcinoma but not 
compared with non-severely fatigued disease-free breast carcinoma survivors. 
Furthermore, no differences were found between the three groups on the 
standardised concentration task.
The results o f daily self-report and objective measurement o f physical activity 
were not consistent at all with general self-reported physical activity results. 
Severely fatigued disease-free breast carcinoma survivors experienced more 
impairment in physical activity compared with non-severely fatigued disease-free 
breast carcinoma survivors and women with no history o f breast carcinoma on all 
general self-report measures, as mentioned above. However, no differences 
between the three groups were found on daily self-reported activity or on the 
different parameters o f the actometer.
Are general self-report, daily self-report, and objective neuropsychological 
functioning and physical activity influenced by previous treatments fo r  breast 
carcinoma?
Neither general self-report, daily self-report, nor objective neuropsychological 
functioning and physical activity were influenced by previous treatment modalities. 
Patients who did not receive adjuvant therapy, patients who received chemotherapy 
only, patients who received radiotherapy only, and patients who received both 
chemotherapy and radiotherapy did not differ from one another on any o f the 
general self-report, daily self-report, or standardised measures (Tables 5 and 6).
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Table 5. Neuropsychological functioning fo r  different form er treatment
both no chemo- radio- p-
radio- and adjuvant therapy therapy value
chemotherapy therapy only only
(n=66) (n=20) (n=33) (n=31)
Mean (sd) Mean (sd) Mean (sd) Mean (sd)
General self-report
concentration (CIS) 17.5 (17.5) 14.9 (6.1) 15.6 (8.3) 15.9 (8.3) 0.460
alertness behaviour 105.1 (143.7) 87.4 (85.5) 78.33 (100.1) 83.48 (123.2) 0.729
(SIP)
Daily self-report
concentration 0.24 (0.55) 0.10 (0.18) 0.19 (0.42) 0.31(0.89) 0.620
memory 0.17 (0.64) 0.24 (0.75) 0.05 (0.15) 0.02 (0.08) 0.346
Actual behaviour
concentration (symbol 55.7 (10.3) 52.2 (10.8) 55.9 (8.6) 55.5 (14.8) 0.629
digit)
reaction time (CRT1) 0.30 (0.05) 0.31 (0.07) 0.32 (0.06) 0.31 (0.05) 0.671
reaction time (CRT2) 0.36 (0.17) 0.36 (0.05) 0.36 (0.04) 0.36 (0.05) 0.997
reaction time (CRT3) 0.45 (0.08) 0.45 (0.07) 0.46 (0.06) 0.47 (0.08) 0.815
GLM-general factorial
Table 6. Physical activity fo r  different form er treatment modalities
both no chemo- radio- p-
radio- and adjuvant therapy therapy value
chemotherapy therapy only only
(n=66) (n=20) (n=33) (n=31)
Mean (sd) Mean (sd) Mean (sd) Mean (sd)
General self-report
physical activity (CIS) 8.9 (5.5) 9.6 (4.9) 8.4 (5.5) 8.5 (5.3) 0.879
mobility (SIP) 9.5 (30.33) 3.6 (16.1) 10.5 (31.2) 11.2 (33.0) 0.822
ambulation (SIP) 16.8 ( 30.37) 1.8 (7.8) 8.6 (19.9) 21.5 (42.4) 0.073
Daily self-report
physical activity 5.8 (2.0) 5.9 (1.6) 5.6 (2.0) 5.3 (1.8) 0.639
Actual behaviour
general physical activity 77.8 (19.6) 78.5 (22.0) 80.2 (24.9) 75.7 (21.5) 0.873
(actometer)1
peak amplitude 185.8 (25.9) 177.9 (28.2) 182.9 (24.6) 175.8 (24.0) 0.290
(actometer)1
peak duration 131.2 (46.7) 134.3 (56.6) 136.6 (55.3) 130.2 (47.5) 0.952
(actometer)2
rest duration after peak 67.8 (29.9) 63.3 (26.8) 65.0 (31.2) 68.0 (36.0) 0.923
(actometer)2
1GLM-general factorial
2 activity levels are expressed in number of accelerations per 5-minute period 
2 peak and rest durations are expressed in minutes
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DISCUSSION
This study was an attempt to expand knowledge of the relation between fatigue, 
neuropsychological functioning, and physical activity among disease-free breast 
carcinoma survivors by including daily self-report and standardised measures of 
neuropsychological functioning and physical activity in addition to general self­
report measures o f neuropsychological functioning and physical activity. With 
regard to neuropsychological functioning, it can be concluded that severely 
fatigued breast carcinoma survivors reported more impairment compared with non- 
severely fatigued breast carcinoma survivors and women with no history of breast 
carcinoma both on general measures and on daily self-report measures. 
Furthermore, severely fatigued breast carcinoma survivors had a slower speed of 
information processing compared with women in the control group and women in 
the group o f non-severely fatigued breast carcinoma survivors. However, the 
differences between severely and non-severely fatigued breast carcinoma survivors 
did not reach significance. In the standardised concentration task, no differences 
were found between the two groups of breast carcinoma survivors and the 
comparison group. However, it should be noted that this standardised concentration 
task was done in a laboratory setting: The task has a duration o f 90 seconds, so it 
does not measure the ability to concentrate during a longer period. In other words, 
we cannot draw conclusions about the possible differences between severely 
fatigued and non-severely fatigued disease-free breast carcinoma survivors and 
women with no history of breast carcinoma with respect to the endurance o f the 
ability to concentrate.
With regard to the measurement o f neuropsychological functioning, a few things 
have to be noted. First, we did not control for overall intelligence quotient (IQ), 
because we did not collect data pertaining to this variable. However, there is no 
reason to expect differences in IQ between the three groups; in addition, there were 
no differences with respect to education between the three groups. Second, it is 
important to note that the concentration task we used measures not only 
concentration but also incidental learning and visuomotor speed. Finally, it should 
be noted that we used only two tests of objective neuropsychological functioning; 
therefore, our conclusions with respect to objective neuropsychological functioning 
are limited to the concepts that were measured by these two tests.
No relation was found between type o f previous treatment for breast carcinoma and 
neuropsychological performance. Patients who received chemotherapy had equal 
scores on general self-report, daily self-report, and standardised 
neuropsychological measures compared with patients who received radiotherapy 
and patients who did not receive any adjuvant therapy. This result is contrary to 
what was expected according to previous studies. In those studies, the types of 
treatment that affected the central nervous system (e.g., chemotherapy and 
prophylactic cranial irradiation) led to more neuropsychological impairment 
compared with antitumor treatments that did not affect the central nervous system
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directly12,141618’37. However, there is an important difference between those studies 
and the current study. The samples investigated in the studies mentioned above 
consisted o f patients who were undergoing treatment at the time o f the study as 
well as terminal carcinoma survivors. In our study, all patients were disease-free 
and had finished treatment for breast carcinoma a mean o f 2.5 years prior to the 
current investigation. Thus, it is possible that there was a relation between 
treatment and neuropsychological functioning during the period when patients 
were receiving treatment for breast carcinoma. However, this relation has 
disappeared over time.
With regard to physical activity, we knew previously that severely fatigued 
disease-free breast carcinoma survivors perceived themselves as more limited with 
regard to physical activity compared with non-severely fatigued disease-free breast 
carcinoma survivors and women in the control group. However, in a daily self­
observation list, severely fatigued patients did not perceive themselves as less 
active compared with the two other groups. In addition, their objective physical 
activity pattern matched the pattern o f the other groups. The expectation that 
patients who received radiotherapy were the most physically impaired was not 
confirmed. On all measurements (general self-report, daily self-report, and 
actometer), no differences were found between the four treatment groups.
What can explain the lack o f correspondence between 1) general self-report 
measures and 2) daily self-report and standardised measures o f physical activity? 
In other words, why do severely fatigued breast carcinoma survivors report less 
physical activity compared with non-severely fatigued breast carcinoma survivors 
and women in a healthy control group, although they seemed to function just as 
well as the other two groups during a 12-day period? One hypothesis that explains 
this lack o f correspondence is that, due to the effort necessary to continue their 
physical activities, severely fatigued disease-free patients may experience 
themselves as less active. It is possible to imagine that, when a breast carcinoma 
survivor experiences severe fatigue, and when physical activity requires a lot of 
effort, the patient may perceive herself as physically less active compared with her 
activity level before she was diagnosed with breast carcinoma. In fact, she may 
have the same level o f physical activity as a non-severely fatigued breast 
carcinoma survivor and a healthy control woman. In addition, it is possible that 
fatigued breast carcinoma survivors are too demanding o f themselves. Thus, 
although they are just as active physically as non-severely fatigued breast 
carcinoma survivors and women in a healthy control group, they are not satisfied 
with their level o f activity and, thus, perceive themselves as inactive. Finally, 
another possibility is that complaints o f physical inactivity are indicative of 
emotional distress rather than actual reduced physical activity. In our data, 
relations between self-reported inactivity and emotional distress (measured with 
the Beck Depression Inventory and the Symptom Checklist) were significant 
statistically. Conversely, no significant relations were found between actual
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physical activity and emotional distress. The same was true for complaints of 
neuropsychological functioning. Statistically significant relations were found 
between self-reported neuropsychological problems and emotional distress, 
whereas there were no relations between actual neuropsychological functioning 
and emotional distress. In addition, in the literature, it is a common finding that 
objective test results and subjective reports o f cognitive functioning are not related, 
whereas subjective reports of cognitive functioning are related strongly to anxiety 
and depression12,38. More data on emotional functioning in samples o f disease-free 
breast carcinoma survivors can be found elsewhere10.
To conclude, we want to emphasise that it is important to include different ways of 
measurement when possible. In our study, the inclusion o f daily self-report and 
actual measurement, in addition to general self-report, provided better inside into 
fatigue and related problems.
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ABSTRACT
Fatigue is investigated in 57 severely fatigued disease-free breast cancer patients 
and in 57 gender- and age-matched patients with Chronic Fatigue Syndrome (CFS) 
using multidimensional and multimethod assessment. A comparison between these 
groups o f patients is important to determine whether a cognitive behavioural 
intervention to reduce fatigue in CFS patients would be appropriate as well for 
severely fatigued disease-free breast cancer patients. Measurement included 
computerised questionnaires and a standardised neuropsychological test. 
Furthermore, patients filled out a daily Self-Observation List (SOL) and wore an 
actometer during a period o f 12 days. Results indicate that in comparison to 
severely fatigued disease-free breast cancer patients, CFS patients score more 
problematic with regard to the level of fatigue, functional impairment, physical 
activity, pain and self-efficacy. However, a subgroup o f severely fatigued disease- 
free breast cancer patients reports the same amount o f problems as CFS patients 
with regard to psychological well-being, sleep and concentration. Finally, CFS 
patients and severely fatigued breast cancer patients score equal on measures of 
social support. In conclusion, there seem to be some similarities but also many 
differences between severely fatigued breast cancer survivors and females with 
CFS. Therefore, cognitive behaviour therapy (CBT) to reduce fatigue after 
treatment for cancer should also differ in certain aspects from cognitive behaviour 
therapy as it has been developed for patients with CFS.
INTRODUCTION
Fatigue is a complaint that is often reported by cancer patients while they are 
undergoing treatment for cancer1. In the last few years, several studies have 
demonstrated that many patients also experience fatigue (long) after curative 
treatment for cancer has been terminated211. At this moment, little is known about 
the factors that may cause or perpetuate fatigue. However, it seems that 
characteristics o f the disease and treatment are not related to the severity o f fatigue 
long after treatment has ended. A treatment for fatigue long after treatment for 
cancer is not available.
Another patient population with severe fatigue complaints, for which up until now 
no physical explanation has been found, are patients with chronic fatigue syndrome 
(CFS). CFS is characterised by persistent or recurrent fatigue that lasts for 6 or 
more consecutive months. Fatigue is not the result o f constant exertion, does not 
improve by rest and has leaded to substantial decrease o f former standards of 
professional, social and personal functioning12. There is increasing evidence that 
cognitive behaviour therapy (CBT) is effective for patients with CFS13,14.
Our research group has developed a multidimensional assessment method to 
measure fatigue in patients with CFS15. Factor analyses has identified nine
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dimensions, namely fatigue severity, functional impairment, psychological well­
being, sleep disturbances, neuropsychological impairment, physical activity, social 
support, causal attributions and self-efficacy. These dimensions appeared to be 
relatively independent, meaning that each dimension uniquely contributes to the 
description o f a patient.
Using this assessment method, we are able to examine to what extent a patient who 
experiences severe fatigue after treatment for cancer resembles a patient with CFS. 
The purpose o f this study is to compare, where possible, a group o f severely 
fatigued disease-free cancer patients with a group o f CFS patients on the above­
described dimensions. We added the dimension "pain" in this study, because pain 
is a frequent complaint, besides fatigue, o f CFS patients. A comparison between 
these groups o f patients is important to determine whether a cognitive behavioural 
intervention to reduce fatigue in CFS patients would be appropriate as well for 
severely fatigued disease-free breast cancer patients.
The specific research questions we would like to answer are the following:
1) How many severely fatigued disease-free breast cancer patients fulfil the criteria 
(severity o f fatigue and functional impairment) for CFS; 2) Do severely fatigued 
disease-free breast cancer patients (those who fulfil the criteria for CFS and those 
who do not fulfil these criteria) differ from CFS patients on the dimensions self­
efficacy, psychological well-being, sleep, concentration, physical activity, social 
support and pain?
METHODS 
Patients
In a longitudinal study investigating the course o f fatigue after treatment for breast 
cancer, 150 disease-free breast cancer patients were included33. One o f the 
inclusion criteria was that patients had to be treated according to the protocol o f the 
Comprehensive Cancer Centre East in the Netherlands for premenopausal breast 
cancer patients. Furthermore, they had to be younger than 50 by the time of 
primary diagnosis and had to have completed treatment for breast cancer a 
minimum o f 6 months and a maximum o f 70 months before. Finally, they had to 
have no evidence o f disease recurrence at the time o f participation. On the basis of 
a cut-off score o f 35 on the subscale "severity o f fatigue" o f the Checklist 
Individual Strength (CIS), 57 patients (38%) could be considered as severely 
fatigued 6-70 months (mean 2 years) after the end o f treatment for cancer. Data of 
these severely fatigued disease-free breast cancer patients have been used for the 
present study.
In an intervention study, in which the effect o f cognitive behaviour therapy on 
fatigue has been investigated, 270 patients with CFS participated (n=270)14. 
Participants had to be between the age o f 18 and 60 years old. Furthermore,
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patients were selected for this intervention study on the basis o f the operational 
criteria for CFS. This means a score o f 40 or higher on the subscale "fatigue 
severity" o f the CIS and a score o f 800 or more on eight subscales o f the Sickness 
Impact Profile (SIP-8). Finally, patients were excluded if  they had participated in 
previous CFS research. From this sample o f 270 patients, we selected 57 patients 
matched on age and gender with the 57 severely fatigued disease-free breast cancer 
patients.
From both samples, baseline data are used for the current study. The collected data 
consist o f computerised questionnaires. Patients were asked to complete the self­
report questionnaires mentioned below by computer at our department. 
Furthermore, patients performed a standardised neuropsychological test and filled 
out a daily Self-Observation List (SOL) during a period o f 12 days. They also wore 
an actometer during this 12-day period.
Measures per dimension
Fatigue severity has been measured by the "fatigue severity" subscale of the CIS 
and the "Daily Observed Fatigue" (DOF) o f the SOL. The CIS15,16 is a 20-item 
questionnaire. Each item is scored on a seven-point Likert scale. The questionnaire 
was designed to measure four aspects o f fatigue during the last 2 weeks, namely 
fatigue severity (eight items; 7-56), concentration (five items; 5-35), motivation 
(four items; 4-28) and physical activity (three items; 3-21). High scores indicate a 
high level o f fatigue, a high level of concentration problems, low motivation and a 
low level o f physical activity. The CIS has good reliability (Cronbach's alpha's 
varying from 0.83 to 0.92) and discriminative validity1517. In the SOL, Daily 
Observed Fatigue is reported four times a day on a five-point scale (0-4). Total 
scores range from 0 to 1618.
Functional impairment has been measured with eight subscales o f the SIP-8: home 
management, mobility, alertness behaviour, sleep/rest, ambulation, social 
interactions, work and recreation and pastimes19,20. The SIP is a widely used 
measure with good reliability and content validity21.
Self-efficacy is measured with the Self-Efficacy Scale (SES)22. The SES consists 
o f five questions that measure sense o f control with respect to fatigue complaints. 
A total score ranges from 5 to 25, a higher score reflecting more sense o f control.
14,22,23Cronbach's alpha reliability coefficients range from 0.70 to 0.77 , , . 
Psychological well-being has been measured with the Beck Depression Inventory 
for primary care (BDI-PC)24 and with the subscales depression, anxiety, 
somatisation, interpersonal sensitivity and obsessive-compulsive behaviour o f the 
Symptom Checklist (SCL-90)25. Lower scores reflect less problems in these 
subscales. The SCL-90 is widely used and the reliability and discriminating 
validity are good. The BDI-PC has seven items and is composed o f cognitive and 
affective symptoms only. We used this shortened version o f the BDI to prevent an 
overlap between the physical symptoms o f chronic fatigue and the physical
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symptoms o f depression. The BDI-PC has high internal consistency (Cronbach's 
alpha=0.86) and displays convergent validity24.
Sleep has been measured with the sleep subscale o f the SCL-90. Furthermore, 
quality o f sleep (general quality o f sleep, difficulties falling asleep, restless sleep 
and early awakenings) is registered daily (1=yes, 0=no) in the SOL. Concentration 
has been measured with the concentration subscale o f the CIS. Additionally, the 
ability to concentrate has been assessed with the Symbol Digit subtest o f the 
Wechsler Adult Intelligence Scale (WAIS)26. The test consists o f pairing numbers 
with nonsense symbols as quickly as possible. The higher the score on this test, the 
better a person is able to concentrate.
Physical activity has been measured in three ways. Self-reported physical activity 
has been measured with the physical activity subscale o f the CIS. In addition, 
physical activity is registered four times a day, on a five-point scale (0-4), in the 
SOL [Daily Observed Activity (DOA), range 0-16]. Finally, actual physical 
activity has been measured with the actometer. The actometer is a motion sensing 
device attached to the ankle and worn continuously for 12 days27. Specialised 
software was used to calculate several parameters. A general physical activity 
score reflects the physical activity level over the 12-day time period and is 
expressed in the average number o f accelerations per 5-min period. Furthermore, 
the program calculates the 10 largest activity peaks. Both the average peak 
duration and average peak amplitude o f these 10 largest peaks are calculated. In 
addition, the average duration o f rest periods following these 10 largest peaks is 
calculated. Finally, pervasively passive patients were defined as those patients 
whose average daily physical activity scores stayed below the reference score (the 
mean general activity score o f a sample of 277 CFS patients) in at least 11 o f the 
12 assessment days28.
Social support has been measured with the van Sonderen Social Support Inventory 
(SSL)29. The SSL is divided into the SSL-I (amount o f social support), the SSL-D 
(discrepancies between amount and desired amount o f social support) and the SSL- 
N (amount o f negative interactions). The SSL has good reliability (Cronbach's 
alpha=0.93 (SSLI) and 0.95 (SSLD)) and content validity29.
Pain has been measured with the SOL. The presence and intensity o f pain is scored 
four times a day on a 0-4 scale (range 0-16). In addition, patients register the 
presence o f a headache or joint or muscle pain four times a day (1=yes, 0=no; max 
score=4).
Statistics
Data analysis was performed using SPSS (version 8.0). Descriptive statistics have 
been used for description of the samples. Differences between CFS patients, 
severely fatigued breast cancer patients who fulfil the CFS criteria and severely 
fatigued breast cancer patients who do not fulfil the CFS criteria, have been tested
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with GLM general factorial. In case o f an overall significance, the Bonferroni 
correction was applied to compare the three individual groups.
RESULTS
Description of the patient samples
The group severely fatigued disease-free breast cancer patients consists o f 57 
women with a mean age of 45 (sd=6.2, range 29-55). Mean time since the ending 
o f cancer treatment is 27 months (sd=16, range 6-70). The gender- and age- 
matched group o f CFS patients (n=57) has a mean age o f 45 (sd=6.3, range 29-59). 
The mean duration o f complaints in this group is 90 months (sd=89, range 7-378). 
Despite the fact that the two groups were not matched on level o f education, the 
mean level o f education is equal for both groups.
Table 1. Comparisons with regard to fa tigue severity and functional impairment (GLM- 
general factorial)_______________________________________________________________
A B C
CFS patients Severely fatigued Severely fatigued F-
disease-free disease-free value
breast cancer breast cancer
patients patients
CFS criteria no CFS criteria
(n=57) (n=14) (n=43)
Mean (sd) Mean (sd) Mean (sd)
Fatigue
52.1 (4.1)bcCIS-fatigue severity 45.4 (3.9)a 42.2 (5.8)a 42.64**
SOL-daily fatigue 7.9 (2.2)bc 5.3 (2.4)a 4.3 (1.9)a 36.34**
Functional impairment
(SIP-8)
81.0 (53.2)abHome management 218.3 (117.5)c 152.7 (67.8)c 26.99**
Work 127.6 (149.5) 139.9 (101.3) 75.7 (116.0) 2.31
Mobility 168.4 (121.0)bc 41.3 (62.7)a 8.4 (28.4)a 41.02**
Ambulation 153.4 (96.7)bc 33.4 (48.5)a 22.8 (23.0)a 42.21**
Recreation and pastimes 180.2 (76.0)bc 110.8 (55.4)ac 59.9 (44.6)ab 44.43**
Sleep/ rest 163.9 (95.5)bc 103.7 (53.0)ac 54.7 (41.5)ab 26.38**
Alertness behaviour 353.2 (212.0)c 281.9 (188.6)c 108.3 (101.1)ab 24.16**
Social interaction 378.9 (205.6)c 331.4 (196.7)c 122.1 (129.1)ab 25.89**
Total 1744 (579.7)bc 1195 (275.8)ac 532.9 (247.9)ab 89.13**
** p<0.01
b significantly different from group A, Bonferroni p<0.05 
significantly different from group B, Bonferroni p<0.05 
significantly different from group C, Bonferroni p<0.05
112 Chapter 6
Research questions
How many severely fatigued disease-free breast cancer patients fulfil the criteria 
fo r  the CFS?
As described in the Methods, CFS patients are selected on a score o f 40 or higher 
on the subscale "fatigue severity" o f the CIS and a score o f 800 or more on the SIP. 
Severely fatigued disease-free cancer patients are selected on basis of a score o f 35 
or higher on the subscale "fatigue severity" o f the CIS.
Within the group o f 57 severely fatigued disease-free breast cancer patients, 14 
patients have a score o f 40 or higher on the subscale "fatigue severity" o f the CIS 
and a score o f 800 or more on the SIP. This means that only 25% o f the severely 
fatigued disease-free breast cancer patients fulfilled the fatigue severity and 
impairment criteria for CFS. The other 43 severely fatigued disease-free breast 
cancer patients do not fulfil these criteria and thus automatically experience less 
severe fatigue and functional impairment than the CFS patients. In Table 1, mean 
scores o f these three different groups are presented. In this table, you can see that 
the severely fatigued disease-free cancer patients who fulfil the criteria for CFS 
also have lower scores with regard to fatigue and functional impairment in 
comparison to the CFS patients. In addition, severely fatigued disease-free cancer 
patients who fulfil the criteria for CFS experience the same amount o f fatigue but 
more functional impairment than severely fatigued disease-free cancer patients 
who do not fulfil the criteria for CFS, except on restless sleep.
Do severely fatigued disease-free breast cancer patients (those who fulfil the 
criteria for CFS and those who do not fulfil these criteria) differ from CFS patients 
on the dimensions self-efficacy, psychological well-being, sleep, concentration, 
physical activity, social support and pain?
In Table 2, mean scores o f the three different groups, on the measures that were 
used to describe the above-mentioned dimensions, are presented.
In the first place, severely fatigued disease-free breast cancer patients have a higher 
sense of control with respect to fatigue than CFS patients do. Secondly, severely 
fatigued disease-free breast cancer patients who fulfil the criteria for CFS score 
highest on depression, interpersonal sensitivity and obsessive-compulsive 
behaviour. These differences are significant in comparison to severely fatigued 
disease-free breast cancer patients who do not fulfil the criteria for CFS but not 
significant in relation to CFS patients. Further, CFS patients score highest on 
somatisation. Their score is significantly higher than the score of severely fatigued 
disease-free breast cancer patients who do not fulfil the criteria for CFS but not 
significantly different to the score o f severely fatigued disease-free breast cancer 
patients who fulfil the criteria for CFS.
Comparisons with regard to anxiety indicate that severely fatigued disease-free 
breast cancer patients have a comparable score to CFS patients. The score of
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severely fatigued disease-free breast cancer patients who fulfil the criteria for CFS 
is somewhat heightened in comparison to the two other groups. However, this 
difference is not significant (p<0.08).
Further, with regard to sleep and sleep quality, CFS patients and severely fatigued 
disease-free breast cancer patients who fulfil the criteria for CFS experience more 
problems than severely fatigued disease-free breast cancer patients who do not 
fulfil the criteria for CFS, except on restless sleep.
Table 2. Comparisons with regard to self-efficacy, psychological well-being, sleep, 
concentration, physical activity, social support and pain (GLM-general factorial)_________
A
CFS patients
(n=57) 
Mean (sd)
B
Severely fatigued 
disease-free 
breast cancer 
patients
CFS criteria 
(n=14) 
Mean (sd)
C
Severely fatigued 
disease-free 
breast cancer 
patients
no CFS criteria 
(n=43) 
Mean (sd)
F- value
Self-efficacy with regard 
to fatigue
15.3 (3.3)bcSelf Efficacy Scale 17.4 (3.4)a 17.3 (3.1)a 5.45**
Psychological well-being
BDI-PC 3.3 (2.6) 4.2 (3.9) 2.3 (2.2) 3.33*3
SCL-depression 31.6 (8.0)c 36.9 (10.9)c 26.3 (7.9)ab 9.94**
SCL-anxiety 15.7 (5.0) 19.1 (7.0) 15.2 (5.9) 2.63
SCL-somatisation 29.8 (6.8)c 26.9 (8.0) 22.2 (6.1)a 15.7**
SCL-interpersonal
sensitivity
28.1 (7.3) 35.0 (18.1)c 27.0 (9.5)b 3.52*
SCL-obsessive-compulsive
behaviour
23.6 (5.4)c 23.9 (8.9)c 16.8 (5.7)ab 17.23**
Sleep
SCL-sleep 7.22 (3.1) 9.3 (4.1)c 6.3 (2.8)b 4.60*
SOL-general quality of 
sleep
0.5 (0.3) 0.5 (0.3) 0.6 (0.2) 3.15* 3
SOL-difficulties falling 
asleep
0.4 (0.3)c 0.4 (0.3)c 0.2 (0.2)ab 12.13**
SOL-restless sleep 0.3 (0.2) 0.4 (0.2) 0.3 (0.2) 1.98
SOL-early awakenings 0.3 (0.3)c 0.2 (0.2) 0.2 (0.2)a 3.96*
Concentration
CIS-concentration 27.5 (7.4)c 23.4 (6.0) 19.2 (7.8)a 15.31**
WAIS-symbol digit 52.3 (10.6) 54.1 (12.8) 54.6 (9.7) 0.62
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Table 2. continued
A
CFS patients
(n=57) 
Mean (sd)
B
Severely fatigued 
disease-free 
breast cancer 
patients
CFS criteria 
(n=14) 
Mean (sd)
C
Severely fatigued 
disease-free 
breast cancer 
patients
no CFS criteria 
(n=43) 
Mean (sd)
F- value
Physical activity
CIS-physical activity 17.5 (3.9)bc 13.1 (7.0)a 11.7 (5.6)a 16.95**
SOL-daily observed activity 4.3 (0.2)bc 5.5 (0.5)a 5.2 (0.3)a 5.43**
Actometer-mean activity
score1
62.4 (18.0)c 71.8 (23.3) 77.5 (22.3)a 6.72**
Actometer-peak
amplitude1
183.0 (29.7) 183.0 (34.0) 192.7 (31.1) 1.19
Actometer-peak duration2 136.1 (49.2)c 150.0 (53.3) 165.6 (63.5)a 3.39**
Actometer-duration rest 
after peak2
89.9 (52.1) 73.7 (38.9) 73.7 (36.4) 1.35
Social support
SSLI-total 166.2 (23.3) 172.1 (29.1) 166.2 (23.3) 0.32
SSLI-negative interactions 11.2 (3.2) 11.6 (3.8) 10.2 (2.6) 1.97
SSLD-total 51.1 (13.2) 49.3 (14.1) 47.4 (12.7) 0.96
Pain
SOL-pain 5.8 (3.0)bc 3.7 (2.5)a 2.9 (2.8)a 13.35**
SOL-joint- or muscle pain 2.7 (1.4)bc 0.7 (1.1)a 0.5 (0.9)a 45.39**
SOL-headache 1.3 (1.2)c 0.8 (0.9) 0.5 (0.7)a 8.84**
** p<0.01 
* p<0.05
b significantly different from group A, Bonferroni p<0.05 
significantly different from group B, Bonferroni p<0.05 
significantly different from group C, Bonferroni p<0.05
1 activity levels are expressed in number of accelerations per 5 minute period
2 peak and rest duration are expressed in minutes
3 in the post-hoc analyses no significant differences were found
CFS patients report the most problems with regard to concentration. Their mean 
score on the CIS concentration is significantly different from the mean score of 
severely fatigued disease-free breast cancer patients who do not fulfil the criteria 
for CFS but not significantly different to the mean score o f severely fatigued 
disease-free breast cancer patients who fulfil the criteria for CFS. This result does 
not come to the fore on the standardised concentration task (symbol digit WAIS). 
On this test, all groups have equal scores.
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In reference to physical activity, severely fatigued disease-free breast cancer 
patients are more physically active than CFS patients are. On the self-report 
instruments, severely fatigued disease-free cancer patients report less problems 
with regard to activity than CFS patients do. In addition, measured with the 
actometer, they have a higher mean activity score and a longer peak duration in 
comparison to CFS patients. Also, the percentage o f pervasively passive patients 
differs between the three groups. About 28% o f the patients with CFS can be 
considered as pervasively passive compared to 23% in the group of severely 
fatigued disease-free breast cancer patients who fulfil the criteria for CFS and only 
8% in the group o f severely fatigued disease-free breast cancer patients who do not 
fulfil the criteria for CFS (F=9.98, p=0.041). Mean peak amplitude and mean 
duration o f rest after a peak are equal for all groups.
The subscales o f the social support list indicate that amount o f social support, 
amount o f negative interactions and discrepancies between amount and desired 
amount o f social support are equal for the three different groups.
Finally, concerning daily observed pain, results indicate that severely fatigued 
disease-free cancer patients experience significantly less pain than CFS patients do. 
Large differences can be seen as well when looking at the percentage o f patients 
who do not experience pain at all during a period o f 12 days. Within the sample of 
CFS patients, 2% does not experience pain (general), 9% does not experience joint 
or muscle pain and 5% does not experience a headache at all. For severely fatigued 
disease-free breast cancer patients who fulfil the criteria for CFS, these percentages 
are 7%, 43% and 14%, respectively. Finally, for severely fatigued disease-free 
breast cancer patients who do not fulfil the criteria for CFS, these percentages are 
14%, 50% and 33%, respectively (F=5.77, p=0.056; F=21.91, p<0.001; F=13.70, 
p=0.001).
DISCUSSION
In this study, multidimensional and multimethod assessment indicate that severely 
fatigued former breast cancer patients differ from CFS patients on certain 
important aspects. It is important to note that differences were found not only on 
general self-report questionnaires but also on daily self-report measures and when 
measured with the actometer. The only measure that did not reveal differences was 
the standardised concentration task. It should, however, be noticed that this 
concentration task was done in a laboratory setting. This task has a duration o f 90 
seconds, so it does not measure the ability to concentrate during a longer period of 
time. In other words, we cannot draw conclusions about the possible differences 
between severely fatigued former breast cancer patients and CFS patients with 
respect to the endurance o f the ability to concentrate.
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The group that we identified as severely fatigued disease-free breast cancer 
patients experiences fatigue to a lesser extent than a group o f female CFS patients. 
In addition, the first-mentioned group experiences less limitations in several areas 
o f daily life than the group o f CFS patients. Within the group o f severely fatigued 
breast cancer patients, only 25% fulfil criteria for CFS.
Further comparisons indicate that patients with CFS and severely fatigued breast 
cancer patients score equal on measures o f social support. However, both groups 
experience more negative interactions and a higher discrepancy between the 
amount o f social support and the desired amount o f social support in comparison to 
a group o f healthy women33.
With regard to physical activity, pain and self-efficacy, patients with CFS score 
more problematic in comparison to severely fatigued breast cancer patients. In 
reference to sleep and concentration, the subgroup o f severely fatigued disease-free 
breast cancer patients who fulfils the criteria for CFS reports the same amount of 
problems as CFS patients. However, all three groups score equal on the 
standardised concentration task (symbol digit). Nevertheless, these scores are 
significantly lower than mean scores (64.2) o f healthy controls30.
Depression and anxiety are somewhat heightened for severely fatigued disease-free 
breast cancer patients who fulfil the criteria for CFS in comparison to CFS patients. 
These differences are, however, not significant, probably due to the small sample 
size o f the severely fatigued disease-free breast cancer patients who fulfil the 
criteria for CFS. It is possible that these former cancer patients interpret persistent 
feelings o f severe fatigue as a sign o f a disease-recurrence, associated with feelings 
o f depression and anxiety and increasing fatigue. In the current group o f severely 
fatigued disease-free breast cancer patients who fulfil the criteria for CFS, 50% had 
a score on the BDI-PC that is indicative o f a clinical depression. In the group of 
CFS patients, this percentage is lower (35%).
As indicated in the Introduction, the findings of these study are important within 
the framework o f the development o f interventions to reduce fatigue. For patients 
with CFS, cognitive behaviour therapy has proven be to successful in reducing 
fatigue14,31,32. In one o f these studies14, cognitive behaviour therapy was based on a 
statistically tested model o f perpetuating factors in CFS22. In this model, focussing 
on bodily symptoms, low physical activity and low sense o f control contribute to 
increasing severity o f fatigue and functional impairment. Cognitive behaviour 
therapy for patients with CFS is directed at these perpetuating factors.
It is very likely that a model o f perpetuating factors for fatigue after treatment for 
cancer will differ from the CFS model. Based on the results o f this current study, 
depression, sleep and concentration problems could possibly play important roles 
in this model. Therefore, cognitive behaviour therapy to reduce fatigue after 
treatment for cancer should also differ in certain aspects from cognitive behaviour 
therapy as it has been developed for patients with CFS. In addition, because there 
seem to be larger differences within the group o f severely fatigued cancer patients
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than within the group o f CFS patients, cognitive behaviour therapy to reduce 
fatigue after treatment for cancer should be adapted to each individual ex-cancer 
patient.
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ABSTRACT
Fatigue has been mentioned as an important complaint in several groups of 
disease-free patients after curative treatment for cancer. However, it has never been 
investigated in a sample o f patients who have been treated for a bone or soft tissue 
tumours in the past. In the current study these patients participated. Measurement 
included posted questionnaires at baseline and at follow-up (two years later). 
Baseline results indicate that fatigue is a severe problem for 28 percent o f the 
investigated patients. Percentages were equal for patients who were treated for 
malignant or benign tumours. Fatigue complaints seem to be most severe for 
patients who finished treatment relatively recently, and for patients who had to 
undergo more than one operation. In addition, fatigue is associated with several 
psychological and physical variables. At follow-up, the majority o f all patients who 
were severely fatigued at baseline continued to be severely fatigued. Severe fatigue 
at follow-up is predicted by oncological complications after initial treatment, less 
optimism and more somatisation. It can be concluded that fatigue is an important 
problem for more than a quarter o f a sample o f patients who have been treated for a 
malignant or benign bone or soft tissue tumour in the past.
INTRODUCTION
The number o f long-term survivors o f bone and soft tissue tumours has gone up in 
the last decades. Because cancer treatment tends to produce troublesome long-term 
side effects, quality o f life assessment after treatment for bone and soft tissue 
tumours becomes more important. Although most studies still solely concentrate 
on oncological and functional results, a few studies have been published recently in 
which quality o f life has been assessed in survivors o f bone sarcoma18.
Fatigue is an important aspect o f quality o f life, which has been mentioned recently 
in several groups o f disease-free patients long after they have finished treatment for 
cancer919. However, as far as we know, fatigue has never been investigated in a 
sample o f disease-free patients who were treated for bone and soft tissue tumours. 
In addition, up till now no longitudinal studies have been published on the course 
o f fatigue after successful treatment for cancer.
In the present prospective longitudinal study we will focus on fatigue complaints in 
a population o f disease-free patients who were treated for bone and soft tissue 
tumours in the past. This patient population has a few specific characteristics that 
are different from cancer populations in which post-treatment fatigue complaints 
have been investigated up till now. First, within this population, patients have been 
treated for both malignant and benign tumours. It will be o f interest to find out 
whether fatigue complaints differ between these two groups o f patients. Second, 
treatment for these kinds o f tumours differs from treatment for other kinds of 
tumours. Patients more often undergo extensive surgery that often leads to a certain
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level o f physical impairment. In addition, although adjuvant chemotherapy is often 
utilised in osteo- and Ewing sarcoma, it is not used in chondrosarcoma and benign 
tumours. Furthermore, radiation therapy is used in soft tissue tumours and Ewing 
sarcoma but not curative in osteosarcoma or benign tumours. Finally, time since 
end of treatment varied widely within the investigated patient population. This 
makes it possible to compare the severity o f fatigue complaints for patients who 
finished treatment relatively recently, versus patients who finished treatment longer 
ago.
The structure in this article is divided into two parts. In the first part baseline data 
will be analysed. The following specific research questions will be answered 1) 
What is the prevalence o f fatigue after treatment for malignant and benign bone 
and soft tissue tumours, 2) Is fatigue severity associated with former disease and 
treatment characteristics, 3) Are patients who finished treatment relatively recently 
more severely fatigued than patients who finished treatment longer ago and 4) Is 
fatigue severity associated with demographic, psychological and/or physical 
variables?
In the second part we will focus on longitudinal data. In this part we will answer 
two more questions: 5) What is the course o f fatigue during a two year period, and 
finally 6) Which variables are able to predict severe and heightened fatigue at 
follow-up?
METHODS
Patients
All patients who finished treatment for a bone or soft tissue tumour (malignant and 
benign) between 1 and 15 years ago at the University Medical Center Nijmegen 
were approached for this study. At the time o f the study patients had to have a 
status o f ‘no evidence o f disease’ (NED) or ‘continuing disease-free’ (CDF). 
Furthermore, they had to be between the age o f 18 and 60 at the time o f this 
investigation.
Recruitment procedure
Patients were send a package o f questionnaires, together with a letter o f their 
physician, explaining the purpose o f the study, and an informed consent form. 
Patients were asked to fill out the questionnaires and to send them back together 
with the signed informed consent form, to our medical center. Two years later, all 
patients who had returned the questionnaires at baseline and still had a status of 
NED or CDF, were send a second package o f questionnaires. The ethics committee 
o f our hospital approved with the study.
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Measurement
Fatigue is measured by the Checklist Individual Strength (CIS). This is a 20-item 
questionnaire, which was designed to measure four aspects o f fatigue, namely: 
fatigue severity (8 items), concentration (5 items), motivation (4 items) and 
physical activity (3 items)20,21. Each item is scored on a 7-point Likert scale. High 
scores indicate a high level o f fatigue, a high level o f concentration problems, low 
motivation and a low level o f physical activity. Based on research with Chronic 
Fatigue Syndrome Patients, a score o f 35 or higher on the subscale fatigue severity 
indicates severe experiences o f fatigue20. Based on scores o f healthy controls, a 
score between 27 (mean score for healthy adults plus one sd) and 35 indicates 
heightened experience o f fatigue21,22.
Psychological well-being is measured by the Symptom Checklist-90 (SCL-90)23. 
This 90-item indicator of psychopathology screens for anxiety, agoraphobia, 
depression, somatisation, obsessive-compulsive behaviour, interpersonal 
sensitivity, hostility and sleep disturbances.
Physical limitations are measured by the subscale physical functioning o f the 
RAND-3624,25. This subscale consists o f 10 items on 3-point Likert scale. Scores 
range from 0 to 100. Persons with lower scores are more severely limited with 
respect to physical functioning.
Optimism is measured by the Life Orientation Test (LOT)26,27. This questionnaire 
is a measure o f dispositional optimism. It consists o f 8 items (plus 4 filler items). 
The higher the scores, the more optimistic (range 0-32).
Quality o f life is measured by the Quality o f Life Questionnaire o f the European 
Organisation for research and treatment o f cancer (EORTC QLQ-C30)28. The 
content areas covered by this questionnaire reflect the multi-dimensionality o f the 
quality o f life construct. For this study, the five functional scales (physical-, role-, 
cognitive-, emotional-, and social functioning), and a general health status scale 
were used. Higher scores represent higher functioning and quality o f life (range 0­
100).
Acceptance o f the experience o f cancer is measured by the Cancer Acceptance 
Scale (CAS), a questionnaire of 7 statements (1 not at all applicable, 2 not 
applicable, 3 applicable, 4 very applicable). These statements are 1) I find it hard to 
believe that I had a bone tumour, 2) I often think back to the time that I had a bone 
tumour, 3) Treatment for my bone tumour has changed my life in a negative way, 
4) I am worried about a tumour relapse, 5) I am angry about what happened to me 
6) I am anxious about my health, 7) I am not able to forget about the period that I 
was treated for a bone tumour. A total score can be derived (range 7 to 28). High 
scores are indicative o f low acceptance. Internal consistency is good (Chronbach’s 
alpha=0.85).
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Statistical analysis
Data analysis was performed using SPSS (version 8.0). Descriptive statistics have 
been used for description of the sample. T-tests, Chi-square and GLM-general 
factorial have been performed testing differences between groups. Pearson 
correlation analyses have been used to test the association between fatigue severity 
and demographic, psychological and/or physical variables. Finally, in order to 
examine the contribution o f psychological-, physical- and disease- and treatment 
related variables to severe and heightened fatigue two years later, logistic 
regression was performed.
RESULTS
Description of the sample
We sent a package o f questionnaires to 226 patients. The questionnaires were filled 
out and returned by 170 patients (75%). From these 170 patients 99 were treated 
for a benign tumour and 71 for a malignant tumour.
Two years later, the second package o f questionnaires was send to 155 o f these 170 
patients (15 did no longer have the status o f NED or CDF). Hundred and thirteen 
o f these 155 patients returned the questionnaires (73%), from which 63 were 
treated for a benign tumour and 50 for a malignant tumour. Demographic 
characteristics o f the sample are listed in Table 1. Patients treated for a benign 
tumour are significantly younger, and significantly less often receive disablement 
insurance act. Probably because o f these differences, they are less often married, 
have received higher education and more often work outside the house.
Part 1 baseline measurement
1) What is the prevalence o f  severe fatigue after treatment for malignant and 
benign bone and soft tissue tumours?
The mean CIS-fatigue severity score o f the total sample is 26.3 (sd=14.4). Forty- 
eight patients (28%) meet the cut-off criteria for severe fatigue (i.e., CIS-fatigue>= 
35) while an additional 30 patients (18%) have heightened fatigue scores (i.e., CIS- 
fatigue between 27 and 35). Fatigue scores are not significantly different for 
patients treated for malignant and benign tumours. Patients who were treated for a 
malignant tumour have a CIS-fatigue score o f 26.8 (sd=14.0). For patients who 
were treated for a benign tumour this score is 25.9 (sd=14.7). Percentages of 
patients with severe fatigue are respectively 27 and 29.
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Table 1. Demographic characteristics
Benign
(n=99)
Malignant
(n=71)
p-value
Gender 52 male (53%) 38 male (54%) 0.899
Age 34* 43** <0.001
Married 57 (58%) 49 (70%) 0.032
Education (1=low; 7=high) 4.2 3.5 0.014
Work outside the home 67% 45% 0.005
Household work 12% 17% 0.340
Studying 19% 13% 0.282
Disablement insurance act 8% 29% 0.001
* sd=13, range=18-62, 68% <40 years 
** sd=15, range=18-65, 39% <40 years
Table 2. Mean baseline CIS-fatigue scores and percentages o f  severe fa tigue fo r  different
tumour types
n Mean CIS-fatigue 
baseline (sd)
% severe 
fatigue
Malignant tumours
grades 1,2 chondrosarcoma (lgM)* 34 26.6 (14.6) 26
classical Osteosarcoma (hgM) 9 25.7 (10.0) 22
ewing’s sarcoma (hgM) 7 24.4 (15.9) 29
synovial sarcoma (hgM) 6 29.2 (13.3) 17
other1 15 29.1 (15.2) 33
Benign tumours
aneurysmal Bone Cyst 20 24.2 (15.3) 30
aggressive Enchondroma 15 33.7 (16.0) 53
giant cell tumour 14 23.5 (13.3) 21
osteoid osteoma 10 23.9 (15.2) 20
exostosis 9 21.9 (11.2) 11
chondroblastoma 6 25.8 (14.5) 17
fibrous dysplasia 6 18.7 (..8.5) 0
bone cyst 6 22.2 (18.5) 33
other2 13 29.9 (15.22) 46
1 chordoma (n=2), lymphoma (n=2), grades 1,2 fibrosarcoma (n=1), clear cell chondrosarcoma (n=1), 
parosteal osteosarcoma (n=1), plasmacytoma (n=1), malignant schwannoma of bone (n=1), none bone 
tumour meta (n=1), liposarcoma (n=1), malignant fibrous histiocytoma (n=1), high grade 
hemangioendothelioma (n=1), hemangiopericytoma (n=1), malignant mesenchymoma (n=1)
2 fibromatosis (n=3), osteoblastoma (n=2), histiocytic fibroma (n=1), chondroma (n=1), hemangioma 
(n=1), histiocytosis (n=1), schwannoma of bone (n=1), desmoid tumour (n=1), epithelioid 
hemangioma (n=1), neurofybroma (n=1)
* results on functional outcome according to the MSTS functional scoring system (Enneking, 1993) of 
this group of patients are reported in van de Geest et al., Journal of Surgical Oncology31.
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2) Is fatigue severity associated with former disease and treatment characteristics? 
Mean fatigue severity scores and percentages o f severe fatigue for the different 
diagnoses (only those with n>=5) are given in Table 2. Within the group o f patients 
who were treated for malignant tumours mean fatigue severity scores range from 
24.4 to 29.2. Within the benign tumours, mean fatigue scores range from 18.7 to 
33.7. The highest mean fatigue score was in the group o f patients who were treated 
for aggressive enchondroma (Enneking stage 3).
The association between post-treatment fatigue and the area o f operation has been 
investigated. Three subgroups were identified: lower girdle (n=100; 24 hip, 66 
knee, 10 ankle), upper girdle (n=39; 29 shoulder, 10 elbow) and axial skeleton 
(n=31; 21 pelvis, 10 spine). Within these three groups, mean fatigue scores are 
respectively 26.8 (sd=14.8), 23.6 (sd=14.4) and 27.8 (sd=12.9) (GLM-general 
factorial, p<0.406).
To analyse the association between post-treatment fatigue and the number of 
former operations, the group was divided into two groups, those who underwent 
only one operation (n=126), and those who had to undergo two or more operations 
(n=44). Mean baseline fatigue scores o f these two groups are respectively 24.9 
(sd=14.2) and 29.8 (sd=14.3). The relation between post-treatment fatigue and 
number of former operations almost reached significance (t-test, p<0.053). 
Percentages o f severe fatigue for the two groups mentioned above are respectively 
24 and 41 (Chi- square, p<0.034).
Table 3. The association between fatigue and type o f  procedure (t-tests)
Yes No
n
mean CIS-fatigue 
baseline (SD) n
mean CIS-fatigue 
baseline (SD)
P-
value
Procedure
inc. biopsy 107 27.4 (14.6) 63 24.3 (13.8) 0.185
exc. biopsy 10 29.3 (15.9) 160 26.0 (14.3) 0.488
needle biopsy 1 - 169 - -
curettage 74 26.9 (15.5) 96 25.7 (13.5) 0.625
debulking 5 22.6 (14.1) 165 26.3 (14.4) 0.567
en bloc resec. 81 26.1 (13.2) 89 26.4 (15.4) 0.889
amputation 9 21.9 (10.1) 161 26.5 (14.6) 0.352
mod amputation 1 - 169 - -
cryosurgery 78 27.3 (15.0) 92 25.3 (13.9) 0.355
exploration 3 27.0 (15.6) 167 26.2 (14.4) 0.926
thoracotomy 5 28.2 (14.1) 165 26.2 (14.4) 0.757
osteosynthesis 16 29.9 (11.8) 154 25.9 (14.6) 0.280
cementation 2 14.5 (2.12) 168 26.4 (14.4) 0.246
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To test the association between post-treatment fatigue on one hand and type of 
procedure during treatment on the other hand, several t-tests were performed. In all 
t-tests the dependent variable was the CIS-fatigue score at baseline. Independent 
variables were the different procedures. None o f the t-test revealed significant 
differences in fatigue severity between those patients who underwent a certain 
procedure, and those who did not undergo that certain procedure (Table 3).
The association between post-treatment fatigue and former adjuvant therapy has 
been tested with a t-test. Dependent variable was the CIS-fatigue at baseline. 
Independent variable was former adjuvant therapy (no adjuvant therapy (n=145) 
versus adjuvant therapy (n=25; 6 radiotherapy, 13 chemotherapy and 6 both 
radiotherapy and chemotherapy). Mean baseline fatigue scores for these two 
groups are respectively 26.0 (sd=14.6) and 27.4 (sd=13.2). Results indicate that 
there is no effect o f adjuvant therapy on the severity o f fatigue (t-test, p<0.673). 
Finally, we investigated the association between post-treatment fatigue and the 
prevalence o f oncological complications after initial treatment. The total sample 
has been divided into two groups, those who did not have any oncological 
complications after initial treatment (n=146) and those who did have any 
oncological complications after initial treatment (n=24; 11 local recurrence, 9 
residual tumour, 3 lung metastases and 1 node metastases). Mean baseline fatigue 
scores for these two groups are respectively 25.8 (sd=14.4) and 28.8 (sd=14.2) (t- 
test, p<0.348). Percentages o f severe fatigue are respectively 27 and 38 (chi- 
square, p<0.277).
3) Are patients who finished treatment relatively recently more severely fatigued 
than patients who finished treatment longer ago?
The total sample has been divided into six groups: patients who finished treatment 
between 1 and 2 year ago (n=28), between 2 and 3 years ago (n=38), between 3 
and 4 years ago (n=22), between 4 and 5 years ago (n=19), between 5 and 10 years 
ago (n=46) and more than 10 years ago (n=17). Mean baseline fatigue scores (sd) 
and percentages of severe fatigue for these six groups are shown in Table 4.
Table 4. Mean CIS-fatigue scores and percentages o f  fatigue fo r  patients who finished  
treatment within a different time period____________________________________________
Mean CIS-fatigue (sd) % of severe fatigue
Patients who finished treatment . . .
... between 1 and 2 year ago (n=28) 31.6 (15.5) 43
... between 2 and 3 years ago (n=38) 27.1 (15.4) 34
... between 3 and 4 years ago (n=22) 22.5 (15.0) 18
... between 4 and 5 years ago (n=19) 25.3 (13.0) 21
... between 5 and 10 years ago (n=46) 26.7 (13.2) 26
. . .  more than 10 years ago (n=17) 20.1 (11.9) 18
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Table 5. Correlations between fa tigue severity (CIS-fatigue baseline) and demographic, 
psychological and physical factors_________________________________________________
Pearson correlation p-value
Age -0.009 0.912
Gender 0.017 0.830
Education -0.052 0.509
Psychological well-being (SCL)
depression 0.550 <0.001
anxiety 0.441 <0.001
somatisation 0.561 <0.001
agoraphobia 0.305 <0.001
obsessive-compulsive behaviour 0.430 <0.001
interpersonal sensitivity 0.364 <0.001
hostility 0.343 <0.001
sleep disturbances 0.276 <0.001
Physical functioning (RAND) -0.393 <0.001
Optimism (LOT) -0.398 <0.001
Quality of life (EORTC QLQ-C30)
emotional functioning -0.629 <0.001
physical functioning -0.409 <0.001
role functioning -0.417 <0.001
cognitive functioning -0.319 <0.001
social functioning -0.469 <0.001
general health status -0.687 <0.001
AccePtance 0.337 <0.001
Statistical analyses indicate that there are no significant differences in mean fatigue 
scores (GLM-general factorial, p<0.110) and in percentages o f severe fatigue (Chi- 
square p<0.283). However, results indicate that patients who finished treatment 
between one and two years ago are more severely fatigued than the rest o f the 
patients (t-test, 31.6 (15.5) versus 25.2 (13.9), p<0.029). In addition, the correlation 
between the CIS fatigue score and time since treatment is -.146, and almost reaches 
significance (p<0.057).
4) Is fatigue severity associated with demographic, psychological and/or physical 
variables?
Fatigue severity is not correlated with age, gender or education. On the other hand, 
fatigue severity is negatively correlated with psychological well-being, physical 
well-being, optimism, quality o f life and acceptance (Table 5).
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Part 2 follow-up measurement
5) What is the course o f  fatigue during a two year period?
A t follow-up CIS-fatigue severity score o f the total sample is 25.7 (13.9). Twenty- 
six percent o f all patients meet the cut-off criteria for severe fatigue (i.e., CIS- 
fatigue>=35) while an additional 16 percent experiences heightened fatigue (i.e., 
CIS-fatigue between 27 and 35). In accordance with baseline results, fatigue scores 
at follow-up are not significantly different for patients treated for malignant (CIS- 
fatigue=25.8 (sd=13.6)) and benign tumours (CIS-fatigue=25.1 (sd=13.9)).
The correlation between baseline and follow-up CIS-fatigue scores is 0.72 (p 
<0.01) for the whole sample. From the 48 patients who were identified as severely 
fatigued at baseline, 30 percent (n=14) is missing at second measurement. From the 
other 34 patients, 65 percent (n=22) is still identified as severely fatigued at follow- 
up. Thirty-five percent (n=12) is not severely fatigued anymore at second 
measurement. However, within this group that is not severely fatigued anymore at 
second measurement, 58 percent (n=7) still experiences heightened fatigue in 
comparison to healthy adults.
In addition, from the 122 patients who were identified as non-severely fatigued at 
baseline, 37 percent (n=45) is missing at second measurement. From the other 77 
patients, 91 percent (n=70) is also identified as non-severely fatigued at follow-up, 
while 9 percent (n=7) has become severely fatigued at second measurement.
6) Which variables are able to predict severe fatigue and heightened fatigue at 
follow-up?
Two logistic regression analyses were performed. One with severe fatigue (CIS- 
fatigue>=35 versus CIS-fatigue<35), the other with heightened fatigue (CIS- 
fatigue>=27 versus CIS-fatigue<27) at follow-up as dependent variables. As 
predictors were entered the following disease and treatment characteristics: number 
o f operations, adjuvant therapy (yes/no), number o f oncological complications and 
time since treatment (in days). Also were entered the following baseline 
psychological and physical variables: Physical functioning (RAND), optimism 
(LOT) and acceptance (CAS). In addition, depression and somatisation (SCL) were 
entered to represent the construct o f psychological well-being. Finally, general 
health status (EORTC QLQ-C30) was entered to represent the quality o f life area. 
We have chosen for these specific subscales o f the SCL and the EORTC QLQ-C30 
because o f their high correlations with the CIS-fatigue score at baseline (Table 5). 
Results indicate severe fatigue at follow-up is predicted by more oncological 
complications after initial treatment, more somatisation and less optimism (Table 
6). Heightened fatigue is predicted by the same variables, but also by lower general 
health status and less acceptance o f the experience with a bone or soft tissue 
tumour.
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Table 6. Logistic regression analysis (enter) to predict severe and heightened fa tigue at 
follow -up______________________________________________________________________
Dependant variables (follow-up):
severe fatigue heightened fatigue
Beta p-value Beta p-value
Independent variables (baseline)
former adjuvant therapy -0.562 0.497 -0.158 0.868
number of operations -0.931 0.154 -1.209 0.113
number of onc. complications 2.010 0.032 2.310 0.044
time since treatment 0.000 0.515 0.000 0.219
general health status (EORTC QLQ-C30) -0.027 0.193 -0.101 0.001
physical functioning (RAND) -0.001 0.473 -0.011 0.481
optimism (LOT) -0.207 0.009 -0.259 0.003
acceptance (CAS) -0.120 0.111 -0.197 0.015
depression (SCL) 0.002 0.978 -0.065 0.314
somatisation (SCL) 0.189 0.002 0.250 <0.001
DISCUSSION
In this study we found that about one third (28%) o f a population o f survivors o f a 
bone or soft tissue tumour can be considered as severely fatigued long (mean=3.3 
years) after they have finished treatment. This percentage is considerably higher 
than the prevalence o f fatigue in a control group o f persons without a cancer 
history (11%)22. Furthermore, this percentage is about equal to percentages of 
fatigue in several samples o f cancer survivors, as reported in the literature. In a 
sample o f Hodgkin’s survivors 26% had substantial fatigue for 6 months or longer. 
This percentage was significantly higher than the percentage o f 11 found among 
2,214 controls representative o f the general Norwegian population18. Within a 
sample o f breast cancer survivors, 30 percent did report heightened levels of 
fatigue relative to women in the general population16. In another sample o f breast 
cancer survivors, this percentage is even 38 percent22. Finally, in mixed samples of 
former cancer patients, 30% experiences fatigue on a daily basis19, and 29% 
experiences heightened fatigue complaints in comparison to adults without a 
cancer history17.
Surprisingly, we did not find any differences in fatigue scores between patients 
who were treated for a malignant or a benign tumour in the past. However, we 
found that patients who were treated for a malignant tumour were less often 
working outside their homes and did more often receive disablement insurance act 
than patients who were treated for a benign tumour. In addition, we also found
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differences in physical functioning (measured with the RAND and the EORTC 
QLQ-C30) between patients who were treated for malignant tumours and benign 
tumours. Patients in the malignant group experience significant more physical 
limitations than patients who were treated for benign tumours. Finally, patients in 
the malignant group also score significantly more problematic on the statement 
‘treatment for my bone tumour has changed my life in a negative way’.
On second thought, the similarity between fatigue scores o f patients who were 
treated for malignant or benign tumour might thus be explained by the absence of 
work-related challenges that require either physical endurance, motivation or the 
ability to concentrate. It could be that not-working patients perceive themselves as 
less fatigued because they are not confronted with the consequences o f their severe 
fatigue complaints in their jobs.
Furthermore, fatigue scores did not differ considerably between groups o f patients 
with various diagnoses, with the exception o f patients who were treated for 
aggressive enchondroma. A strikingly high fatigue severity score was found in this 
group. An explanation for this high fatigue score might be due to the fact that 
patients who are treated for aggressive enchondroma score significantly higher on 
the statements ‘I am worried about a tumour relapse’ (p<0.01) and ‘I am anxious 
about my health’ (p<0.05) than patients treated for other diagnoses. This may be 
explained by the fact that these patients know that although the chance o f a relapse 
is low, it will most probably occur after a long observation period (5-10 years). 
None o f the 15 aggressive enchondroma patients had experienced a recurrence 
after initial treatment, at the time o f this study. Another possible explanation for 
the high fatigue severity within this group o f former aggressive enchondroma 
patients could be that these patients finished treatment significantly less long ago 
(2.7 years) than the rest of the patients (4.9 years) (p<0.001).
One could think that the high fatigue severity scores within the group of aggressive 
enchondroma patients could be the reason why we failed to find a difference in 
fatigue severity between patients who were treated for a malignant tumour and 
patients who were treated for a benign tumour. However, this is not the case. When 
patients with aggressive enchondroma are excluded in the analysis, the mean CIS- 
fatigue score for patients with benign tumours is 24.3 (sd=14.1) and the mean CIS- 
fatigue score for patients with malignant tumours is 27.0 (sd=13.9) (t-test, 
p<0.226).
Except for the number o f operations, no relations were found between post­
treatment fatigue and former treatment. This result is consistent with results in the 
literature29. However, it is important to note that some o f these negative results 
might be explained by small numbers o f patients in several analyses. In addition, 
there is a trend for patients who did have oncological complications after initial 
treatment versus those who did not have oncological complications. The first group 
seems to experience more severe fatigue. In addition, results indicate that patients 
who finished treatment between 1 and 2 years ago experience more severe fatigue
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than patients for whom this was already longer ago.
It is important to note that the variables mentioned above are related to each other. 
Not surprisingly there is a high correlation between the number o f oncological 
complications and the amount o f operations (0.424, p<0.001). Furthermore, there is 
a moderate correlation between the amount o f operations and time since last 
treatment (-0.219, p<0.004). This is why certain results are not always 
unambiguous to interpret. For instance, we concluded that patients who underwent 
only one operation experience less severe fatigue than those patients who had to 
undergo two or more operations. However, further analysis indicates that these 
groups also differ significantly with regard to time since treatment. For patients 
who underwent only one operation, time since treatment was 1867 days versus 
1298 days for patients who had to undergo two or more operations (t-test, 
p<0.005).
Results with regard to the association between fatigue severity and psychological 
and physical variables indicate that fatigue is negatively correlated to 
psychological well-being, physical well-being, optimism, quality o f life and 
acceptance. Highest correlations are found between fatigue and depression, 
somatisation, emotional functioning and general health status. These results are 
also similar to results found in various other studies in which these relations have 
been investigated in samples o f disease-free cancer patients29.
Finally, an important characteristic o f this study is its longitudinal design. This 
enables us to discuss the course o f fatigue and the perpetuating factors of fatigue. 
Results from this study indicate that fatigue complaints are more or less stable. 
Mean fatigue scores and percentages o f severe fatigue and heightened fatigue of 
the total sample are about equal at baseline and follow-up. In addition, the majority 
o f the patients who were identified as severely fatigued at baseline are still severely 
fatigue two years later. In our opinion the stability in fatigue complaints is due to 
the fact that the majority o f patients were not in the first years after the completion 
o f treatment anymore. Literature study shows that up to 99 percent o f all cancer 
patients have to deal with some degree of fatigue during their treatment. We think 
that fatigue complaints wear off during the first years after treatment. For patients 
that still experience severe fatigue about 3 years later, there is a good chance that 
they continue to experience severe fatigue. Evidence for this early decrease in the 
fatigue incidence is found in the current study. As indicated above, patients who 
had finished treatment between one to two years prior to the study were 
significantly more severely fatigued than patients who had finished treatment 
considerably earlier.
With regard to these results, one could expect that those patients that are not 
severely fatigued anymore at follow-up, are patients who finished treatment only a 
short time ago. Analyses indicate that patients who were both severely fatigued at 
baseline and at follow-up, finished treatment 4.8 (sd=3.3) years ago, while patients 
who were severely fatigued at baseline, but not anymore at follow-up finished
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treatment 3.7 (sd=2.7) years ago. However, this difference does not reach 
significance (t-test, p<0.341).
With respect to the perpetuating factors o f fatigue, severe fatigue seems to be 
predicted by more oncological complications after initial treatment for a bone or 
soft tissue tumour, less optimism and more somatisation ( a high tendency to focus 
on bodily symptoms. These findings are important with respect to the development 
o f interventions to reduce fatigue. For patients with Chronic Fatigue Syndrome 
(CFS), cognitive behaviour therapy has proven to be successful in reducing fatigue
30 31 31complaints ’ . In one o f these studies , cognitive behaviour therapy was based on 
a statistically tested model o f perpetuating factors in CFS32. In this model focussing 
on bodily symptoms, low physical activity, and low sense o f control contributed to 
increasing severity o f fatigue. Based on the results o f the current study we might 
expect that, similar to the model for CFS patients, a strong focus on bodily 
symptoms might play a role in a model for severely fatigued survivors o f bone and 
soft tissue tumours. In addition, oncological complications and low optimism may 
be other important perpetuating factors.
In summary, results from this study indicate that fatigue is a severe problem for 
more than a quarter o f a sample o f patients who were treated for malignant or 
benign bone and soft-tissue tumours in the past. Fatigue complaints seem to be 
most severe for patients who finished treatment only 1 to 2 years ago, and for 
patients who had to undergo more than one operation. Fatigue is not related to 
other former treatment modalities and demographic variables. Furthermore, it is 
associated with several psychological and physical variables. Finally, fatigue 
severity at follow-up is predicted by oncological complications after initial 
treatment, less optimism and more somatisation.
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ABSTRACT
In a previous cross-sectional study we concluded that severe fatigue was a problem 
for nearly 40 percent o f a sample o f disease-free breast cancer patients1. In the 
present article we report the results o f a follow-up study. We investigated whether 
fatigue is a persistent problem, and whether persistent fatigue is related to former 
treatment modalities. In addition, we studied the predictors o f persistent fatigue.
A t baseline and at follow-up (two years later) patients were asked to fill out several 
computerised questionnaires on psychological, physical, social, cognitive and 
behavioural aspects and to perform two standardised tests to assess 
neuropsychological functioning. In addition they were asked to fill out a daily Self 
Observation List and to wear an actometer during a period o f 12 days. During the 
two years in between patients were asked to fill out a fatigue questionnaire (CIS - 
fatigue) at the end o f every month.
Results indicate that twenty-four percent o f the disease-free breast cancer patients 
experienced persistent severe fatigue complaints during the two year observation 
period. Persistent fatigue seemed to be related to the duration o f former treatment 
but unrelated to type o f surgery, type o f adjuvant therapy and time since treatment 
finished. High anxiety, high impairment in role functioning and low sense of 
control over fatigue symptoms at baseline were predictors o f persistent fatigue.
We conclude that fatigue is a persistent problem for a quarter o f a sample of 
disease-free breast cancer patients. It is important to be aware o f the predictors of 
persistent fatigue.
INTRODUCTION
Based on many cross-sectional studies, we may conclude that fatigue is a frequent 
complaint in former cancer patients even up to ten years after successful treatment 
for cancer2-9. So far, the only longitudinal studies that have been published 
focussed on fatigue complaints in cancer patients while they were undergoing 
active treatment for cancer10,12,13 and in the year after completion o f treatment11,1416 
Up until now, no longitudinal studies have been performed in which fatigue is 
examined over a longer period o f time in cancer survivors.
In one o f our previous publications we investigated and discussed the prevalence 
and correlates o f severe fatigue in a group o f disease-free breast cancer patients1. 
Results indicated that severe fatigue was a problem for nearly 40 percent o f a 
sample o f 150 breast cancer survivors who completed cancer treatment a mean of 
29 months earlier, compared to 11% in a matched sample o f women without a 
cancer history. In addition, severe fatigue appeared to be negatively related to 
psychological well-being, physical activity, neuropsychological functioning, social 
functioning, social support and self-efficacy. Furthermore, fatigue was positively 
related to functional impairment, sleep disturbances, and causal attributions.
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The present study focuses on the follow-up o f the same cohort o f women during a 
two-year period. In this article we will answer three questions:
1. Is severe fatigue a persistent problem in disease-free breast cancer patients long 
after treatment for cancer?
2. Is persistent fatigue related to former treatment modalities?
3. To what extent are psychological well-being, functional impairment, sleep 
disturbances, physical activity, neuropsychological functioning, social 
functioning, social support, self-efficacy and causal attributions able to predict 
persistent fatigue?
Furthermore, we will exploratory describe the course o f fatigue for those patients 
that had a disease recurrence during the two years o f our study.
METHODS
Sample
A relative homogeneous group o f patients was selected for this study. All patients 
had to be treated according to the protocol o f the Comprehensive Cancer Center 
East for premenopausal breast cancer patients. Furthermore, they had to be 
younger than 50 by the time o f primary diagnosis and had to have completed 
treatment for breast cancer a minimum o f 6 months and a maximum o f 60 months 
before. Finally, they had to have no evidence o f disease recurrence at the beginning 
o f this study. During the two years of this study patients went to their own 
oncologist for medical follow-up. Patients that were found to have a disease 
recurrence during this two-year follow-up period dropped out of the study.
Recruitment procedure
Patients were recruited from one university hospital and 6 regional hospitals. At 
the university hospital and three regional hospitals, all patients who met the 
eligibility criteria were initially informed about the study by mail with an 
introductory letter from their oncologist. At the other three regional hospitals, 
patients were informed by their oncologist during control-visits. In the following 
week, patients were contacted by telephone by the psychologist-researcher (P.S.). 
Those patients who agreed to take part in the study were invited to the department 
o f Medical Psychology o f the University Hospital Nijmegen. Two years later, all 
patients that were still disease-free were invited to the department again for follow- 
up assessment. The ethics committee o f all participating hospitals agreed with this 
study.
Measurement
A t baseline and at the end o f the study we investigated fatigue severity, 
psychological well-being, functional impairment, sleep disturbances, physical
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activity, neuropsychological functioning, social functioning, social support, self­
efficacy and causal attributions by validated questionnaires. Furthermore, patients 
performed two standardised tests to assess neuropsychological functioning. In 
addition, they were asked to fill out a daily Self Observation List and to wear an 
actometer during a period o f 12 days at home. Finally, patients were asked to fill 
out a fatigue questionnaire (Checklist Individual Strength) at the end o f every 
month, during the two-year period between baseline and follow-up assessment.
All measures are mentioned below. The fatigue scales and the measures that are 
not standard are extensively described. For a more detailed description o f the other 
measures we refer to the articles in which the baseline data o f the present study are 
described1,17.
Fatigue severity has been measured by the fatigue severity subscale (CIS-fatigue) 
o f the Checklist Individual Strength (CIS)18. The CIS is a 20-item questionnaire 
which was designed to measure four aspects o f fatigue during the last two weeks, 
namely: fatigue severity (8 items), concentration (5 items), motivation (4 items) 
and physical activity (3 items). Each item is scored on a 7-point Likert scale. High 
scores indicate a high level o f fatigue, a high level o f concentration problems, low 
motivation and a low level o f physical activity. Based on research with Chronic 
Fatigue Syndrome Patients, a score o f 35 or higher on the subscale fatigue severity 
indicates severe feelings o f fatigue18. Based on scores o f healthy controls, a score 
between 27 (mean score for healthy adults plus one SD) and 35 indicates 
heightened experience o f fatigue20. In addition fatigue has been measured with the 
Daily Observed Fatigue score (DOF) o f the Self Observation List19. Daily 
Observed Fatigue is reported four times a day on a 5-point scale (0-4). Total scores 
range from 0 to 16.
Because patients filled out the CIS at the end o f every months during the two years 
o f our study we calculated a mean CIS-fatigue score over 24 months, which we 
refer to as the ‘persistent fatigue score’. Patients with a persistent fatigue score of 
35 or higher are referred to as persistently severely fatigued.
Psychological well-being has been measured with the Beck Depression Inventory
21 22,23for primary care (BDI-pc) , the Spielberger Trait Anxiety Inventory (STAI) , 
and the Rosenberg Self Esteem Scale (RSE)24. Furthermore, the anxiety, 
agoraphobia, depression, somatisation, interpersonal sensitivity and hostility 
subscales o f the Symptom Checklist (SCL-90) were used25. Finally, the emotional 
functioning subscale o f the Quality o f Life Questionnaire-C30 o f the European 
Organisation for Research and Treatment o f Cancer (QLQ-C30) was included26.
Functional impairment has been measured with the subscales home management, 
work, and recreation and pastimes from the Sickness Impact Profile (SIP)27. 
Furthermore, the role functioning subscale o f the QLQ-C30 was used. In addition,
142 Chapter 8
hours o f work (outside the home and household activities) are registered in the Self 
Observation List.
Sleep disturbances have been measured with the Groninger Sleep Quality Scale 
(GSQS)28. In the present study we decided to delete two items because these items 
strongly overlap with fatigue complaints (GSQS-2). Furthermore, the sleep/rest 
subscale o f the SIP and the sleep subscale o f the SCL were used. Finally, quality of 
sleep (general quality o f sleep, difficulties falling asleep, restless sleep and early 
awakenings) is registered daily in the Self Observation List.
Physical activity has been measured with the physical functioning subscale o f the 
QLQ-C30, the physical activity subscale o f the CIS, and the mobility and 
ambulation subscales o f the SIP. In addition, physical activity is registered once a 
day in the Self Observation List. Finally, actual physical activity has been 
measured with the actometer29,30. This is an apparatus about the size o f a matchbox 
that was worn around the ankle both day and night during a 12-day period. 
Specialised software was used to calculate several parameters. A general physical 
activity score reflected the physical activity level over the 12-day period and was 
expressed as the average number o f accelerations per 5-minute period. 
Furthermore, the program calculated the 10 largest activity peaks. Both the average 
peak duration o f these 10 largest peaks, and the average duration of rest periods 
after these 10 largest peaks were calculated.
Neuropsychological functioning has been measured with the cognitive functioning 
subscale o f the QLQ-C30, the concentration subscale o f the CIS and the alertness 
behaviour subscale o f the SIP. Furthermore, actual neuropsychological functioning 
is measured by the Complex Reaction Time task (CRT)31 and the Symbol Digit 
subtest of the WAIS32.
Social functioning and Social support have been measured with the social 
functioning subscale o f the QLQ-C30, the social interaction subscale o f the SIP 
and the van Sonderen Social Support Inventory (SSL)33.
Self-efficacy has been measured with the subscale internal locus o f control o f the 
Multidimensional Health Locus o f Control (MHLC)34,35 and the Self Efficacy 
Questionnaire (SEQ)36. The SEQ consists o f five questions that measure sense of 
control with respect to fatigue complaints. A total score ranges from 5 to 25, a 
higher score reflecting more sense o f control. Cronbach’s alpha coefficients range 
from 0.70 to 0.7736,37,40.
Causal attributions with regard to fatigue complaints have been measured with the 
Causal Attribution List (CAL). This questionnaire consists o f 9 items divided over
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two subscales, psychological (e.g. ruminate, sleep problems) and breast cancer 
related attributions (e.g. surgery for breast cancer, adjuvant therapy for breast 
cancer). For each item, patients were asked to indicate their opinion regarding the 
cause o f their fatigue complaints on a 4 point scale (1 very applicable to 4 not at all 
applicable). Internal reliability o f this questionnaire is good. The subscales 
psychological- and breast cancer related attributions respectively have alpha’s of
0.81 and 0.79.
Statistical analysis
Data analysis was performed using SPSS (version 8.0). Paired sample T-tests were 
performed to analyse differences between baseline and follow-up percentages of 
severe fatigue. Pearson correlation was used to analyse the relation between fatigue 
at baseline and at follow-up. In addition, it was used to analyse the relation 
between the persistent fatigue score and the baseline measures. T-tests, and general 
linear model (GLM)- general factorial have been performed to test differences 
between groups. Finally, in order to examine the contribution of the baseline 
measures to persistent fatigue, linear regression analyses (enter-method) were 
performed.
RESULTS
Description of the sample
A t baseline, 150 disease-free breast cancer patients participated in this study. 
Numbers and reasons for non-participation have been described in our previous 
publication1. From these 150 participating patients, 10 patients dropped out for 
several reasons during the 2-year period o f this study (e.g. taking part in research 
takes too much time, family circumstances). Furthermore, 19 women had a disease 
recurrence during the 2-year period. Hundred-twenty-one patients thus completed 
the study. Compliance with respect to the completion o f the monthly fatigue 
questionnaires was high. Fifty-six percent o f the patients returned all 24 monthly 
questionnaires. Twenty-seven percent o f the patients returned 20 to 23 
questionnaires, and 17 percent returned 16 to 19 questionnaires.
Information on baseline demographic and medical characteristics o f the patients 
can be found in Table 1. A division has been made between those women who 
stayed disease-free, those who had a disease recurrence during our study and those 
who dropped out for other reasons. The only significant difference between the 
three groups is that the first group is older than the third group.
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Table 1. Baseline demographic characteristics and medical characteristics
Disease-free Drop-outs Drop-outs
breast cancer because of a for other
patients tumour relapse reasons
(n=121) (n=19) (n=10)
Mean age* 46.7 (5.9) 43.3 (6.2) 41.8 (8.3)
Marital status
married 106 88% 16 84% 8 80%
unmarried 4 3% 2 11% 1 10%
divorced 8 7% 1 5% 1 10%
widowed 3 2% - -
Higher education (>= 12 years) 45 37% 8 42% 4 40%
Employment
paid work outside home 75 62% 10 53% 7 70%
home management 106 %%88 15 79% 7 70%
disablement insurance act 15 12% 1 5% 2 20%
Surgery
mastectomy 78 65% 12 63% 5 50%
lumpectomy 43 35% 7 37% 5 50%
Adjuvant therapy
no adjuvant therapy 18 15% 1 6% -
only radiotherapy 24 20% 5 26% 2 20%
only chemotherapy 28 23% 4 21% 1 10%
radiotherapy and 51 42% 9 47% 7 70%
chemotherapy
Duration of treatment (months)*’1 6 (3) 6 (3) 6 (2)
< 1 month 16 13% - 2 20%
> 1 month, < 6 months 38 32% 12 63% 5 50%
> 6 months 67 55% 7 37% 3 3%
Time since treatment (months)*’2 30 (18) 25 (13) 26 (18)
between 6-12 months ago 12 10% 2 11% 1 10%
between 13-24 months ago 44 36% 10 52% 4 40%
between 25-36 months ago 26 22% 3 16% 1 10%
between 37-48 months ago 17 14% 3 16% 3 30%
between 49-60 months ago 11 9% - 1 10%
more than 60 months ago 11 9% 1 5% -
data are numbers and percentages of participants or * mean (sd).
1 defined as the period from the time of surgery until the end of adjuvant therapy.
2 defined as the period from the end of adjuvant therapy until the day of participation in the current 
study.
The course of severe fatigue in disease-free breast cancer patients 145
Research questions
Is severe fatigue a persistent problem in disease-free breast cancer patients long 
after treatment fo r  cancer?
For the total group o f disease-free breast cancer patients the mean CIS-fatigue 
score at baseline was 28.9 (sd=13.5), and at follow-up 25.0 (sd=13.2) (paired 
sample T-test, p<0.001). The mean Daily Observed Fatigue score (DOF) at 
baseline was 2.9 (sd=2.2) and 2.9 (sd=2.5) at follow-up. The correlation between 
baseline and follow-up CIS-fatigue scores is 0.65 (p<0.01) and 0.73 (p<0.01) 
between baseline and follow-up DOF scores. Both the mean baseline and follow- 
up CIS-fatigue and DOF scores are significantly higher than the mean scores of 
healthy women without a cancer history (CIS-fatigue 19.4 (sd=11.0); DOF 1.6 
(sd=1.3))1.
The number of severely fatigued disease-free breast cancer patients was 47 (39%) 
at baseline. In addition, 21 patients (17%) experienced heightened fatigue. At 
follow-up, the number of severely fatigued patients was 28 (23%) and 26 patients 
experienced heightened fatigue (22%). The percentage o f women who experienced 
heightened or severe fatigue had thus decreased from 56 to 45 percent (paired 
sample T-test, p<0.01).
In the left part o f Table 2 we indicated the number (and percentages) o f patients 
that were classified as severely, heightened or not fatigued at follow up, on basis of 
their classification as severely, heightened or not fatigued at baseline. Most 
important is the results that almost half o f the patients (49%) that were identified as 
severely fatigued at baseline were also identified as severely fatigued at follow-up.
Table 2. Numbers (and percentages) o f  patients that were classified as severely, heightened 
or not fa tigued at fo llow  up, on basis o f  their classification as severely, heightened or not 
fa tigued at baseline (left part o f  table) and persistent fatigue scores and numbers o f  
persistently severely fa tigued women (right part o f  table)
n
persistent
fatigue
score
persistently 
severely fatigued 
women
Severe fatigue at baseline (n=47)
severely fatigue at follow-up 23 49% 39.5 17
heightened fatigue at follow-up 13 28% 33.8 7
no fatigue at follow-up 11 23% 28.2 2
Heightened fatigue at baseline (n=21)
heightened fatigue at follow-up 8 38% 29.5 1
no fatigue at follow-up 11 52% 23.7 -
severe fatigue at follow-up 2 10% 35.9 1
No fatigue at baseline (n=53)
no fatigue at follow-up 45 85% 15.4 1
heightened fatigue at follow-up 5 9% 27.7 -
severe fatigue at follow-up 3 6% 31.2 -
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In addition, 28 percent o f these patients was identified as heightened fatigued at 
follow-up. Furthermore, most patients (85%) that were identified as not fatigued at 
baseline were also identified as not fatigued at follow-up.
The monthly CIS-fatigue scores o f the total sample are depicted in Figure 1. In 
addition, the monthly CIS-fatigue scores are displayed for those women who were 
severely fatigued at baseline, and for those who were not severely fatigued at 
baseline. Results indicate that the monthly fatigue score dropped a little within a 
two year period. For the total group o f 121 disease-free breast cancer patients, the 
monthly fatigue score dropped from 27 at first measurement to 25 at last 
measurement. This descent is due to the descent o f fatigue scores in patients who 
were severely fatigued at baseline. Their monthly fatigue score dropped from 38 to 
34. Monthly fatigue scores of patients who were not severely fatigued at baseline 
remained equal.
months
Figure 1. Mean CIS-fatigue scores over 24 months
The persistent fatigue score, which is the mean o f all monthly fatigue scores, was 
25.9 (sd=11.1) for the total sample. Further, the number o f patients with a 
persistent fatigue score higher o f 35 or higher was 29 (24%). In addition, 25 
patients (21%) had a persistent fatigue score between 27 and 35. In the right part of 
Table 2 you can see that the highest persistent fatigue scores, and the greatest 
amount of persistently severely fatigued women, are within the categories ‘severe 
fatigue at baseline and severe fatigue at follow-up’ and ‘severe fatigue at baseline 
and heightened fatigue at follow-up’.
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Is persistent fatigue related to form er treatment modalities?
The mean persistent fatigue score did not differ significantly for those patients who 
underwent mastectomy (24.8 (sd=11.6)) and those who underwent lumpectomy 
(28.1 (sd=10.4)) (T-test; p=0.130).
Also for patients with different types o f adjuvant therapy the mean persistent 
fatigue score was not statistically different, although patients who did not receive 
any kind of adjuvant therapy at all had a relatively low persistent fatigue score. The 
mean persistent fatigue score was 28.2 (sd=11.4) for patients who received 
radiotherapy, 24.9 (sd=11.4) for patients who received chemotherapy, 27.1 
(sd=11.1) for patients who received both radiotherapy and chemotherapy, and 21.7 
(10.5) for patients who did not receive adjuvant therapy (GLM-general factorial; 
p=0.244). Patients that used tamoxifen during a two year period (n=11) had equal 
fatigue scores to patients that did not use tamoxifen. Their fatigue score were 
respectively 23.5 (sd=11.8) and 26.2 (sd=11.2) (T-test; p=0.436).
Furthermore, there appeared to be a relation between persistent fatigue and the 
duration of cancer treatment. The mean persistent fatigue score was 19.5 (sd=8.7) 
for patients who finished treatment within one month, 27.0 (sd=11.3) for patients 
who finished treatment within 6 months and 27.0 (sd=11.3) for patients who were 
treated for cancer for more than 6 months (GLM-general factorial; p=0.045). 
Finally, we found no relation between persistent fatigue and time since treatment 
finished. Patients who finished treatment 6-12, 13-24, 25-36, 37-48, 49-60, or more 
than 60 months ago had equal persistent fatigue scores (GLM-general factorial; 
p=0.997).
To what extent are psychological well-being, functional impairment, sleep 
disturbances, physical activity, neuropsychological functioning, social functioning, 
social support, self-efficacy and causal attributions able to predict persistent 
fatigue?
In Table 3, correlations between the baseline scores (of all measures from the 
dimensions of psychological well-being, functional impairment, sleep disturbances, 
physical activity, neuropsychological functioning, social functioning, social 
support, self-efficacy and causal attributions) and the persistent fatigue score are 
depicted.
Results indicate that within all different dimensions one or more baseline measure 
correlated significantly with the persistent fatigue score. In summary, women with 
higher persistent fatigue scores report more psychological distress, functional 
impairment, sleep disturbances, physical impairment, neuropsychological 
impairment and more problems with regard to social functioning and social 
support. Furthermore these women have a lower sense o f control and stronger 
psychological and breast cancer related attributions with respect to their fatigue 
complaints.
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Table 3. Pearson correlations between baseline measures and the persistent fatigue score
persistent fatigue score
persistent fatigue score
PSYCHOLOGICAL WELL-BEING
emotional functioning (QLQ-C30) -0.507***
depression (BDI- PC) 0.476***
trait anxiety (STAI) 0.612***
self-esteem (RSE) -0.424***
depression (SCL) 0.560***
anxiety (SCL) 0.452***
agoraphobia (SCL) 0.375***
somatisation (SCL) 0.563***
interpersonal sensitivity (SCL) 0.375***
hostility (SCL) 0.206*
FUNCTIONAL IMPAIRMENT IN DAILY LIFE
role functioning (QLQ-C30) -0.537***
home management (SIP) 0.282**
work (SIP) 0.095
recreation and pastimes (SIP) 0.445***
number of days working (SOL) -0.100
hours of work a day (SOL) -0.099
number of days with household activities (SOL) -0.061
hours of household activities a day (SOL) -0.187
SLEEP DISTURBANCES
sleep disturbances (GSQS-2) 0.412***
sleep/ rest (SIP) 0.379***
sleep (SCL) 0.438***
daily general quality of sleep (SOL) -0.361***
daily difficulties falling asleep (SOL) 0.226*
daily restless sleep (SOL) 0.303**
daily early awakenings (SOL) 0.121
PHYSICAL ACTIVITY
physical functioning (QLQ-C30) -0.477***
physical activity (CIS) 0.512***
mobility (SIP) 0.011
ambulation (SIP) 0.302**
daily activity score (SOL) -0.224*
mean activity (Actometer) -0.194*
peak duration (Actometer) -0.166
rest after peak (Actometer) 0.272**
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Table 3. continued
NEUROPSYCHOLOGICAL FUNCTIONING
cognitive functioning (QLQ-C30) -0.514***
concentration (CIS) 0.470***
alertness behaviour (SIP) 0.454***
concentration (symbol digit) 0.059
reaction time (CRT1) 0.240**
reaction time (CRT2) 0.022
reaction time (CRT3) 0.164
SOCIAL FUNCTIONING
social functioning (QLQ-C30) -0 444***
social interaction (SIP) 0.304**
SOCIAL SUPPORT
amount of social support (SSL-I) 0.063
amount of negative interactions (SSL-N) 0.337***
discrepancies social support (SSL-D) 0.279**
SELF-EFFICACY
self-efficacy (SEQ) -0.489***
internal locus of control (MHLC-I) -0.044
CAUSAL ATTRIBUTIONS
psychological attributions (CAL) -0.476***
breast cancer related attributions (CAL) -0.448***
* p < 0.05 
** p < 0.01 
*** p < 0.001
To examine the contribution o f the baseline measures mentioned above to 
persistent fatigue, a regression analyses was performed (Table 4). Independent 
variables were the CIS-fatigue score at baseline and those measures that correlated 
highest with the persistent fatigue score within the different dimensions. Results 
indicate that 51% of the persistent fatigue score was predicted by the baseline CIS- 
fatigue score. The other selected measures predicted an additional 11%. Results 
indicated that apart from a high baseline CIS-fatigue score, high persistent fatigue 
was also predicted by low self-efficacy. Thus, less perceived control over 
symptoms predicted higher persistent fatigue.
Because the CIS-fatigue score at baseline had the largest contribution to the 
prediction o f the persistent fatigue score, a second regression analysis was 
performed without the baseline CIS-fatigue score. Results indicated that 53% of 
the persistent fatigue score was predicted by the selected measures. Higher 
persistent fatigue scores were significantly predicted by lower self-efficacy, more 
anxiety and more limitations in role functioning at baseline.
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Table 4. Linear regression analyses to predict the persistent fa tigue score (range 8-56); with 
baseline CIS-fatigue score (A) and without baseline CIS-fatigue score (B)________________
A B
Beta adj R2 2RdjaateB
fatigue (CIS) 0.413*** 0.510
trait anxiety (STAI) 0.121 0.286**
role functioning (QLQ-C30) -0.170 -0.258*
sleep (SCL) 0.106 0.130
physical activity (CIS) -0.002 0.117
cognitive functioning (QLQ-C30) -0.130 -0.128
social functioning (QLQ-C30) 0.075 0.162
amount of negative interactions (SSL-N) 0.080 0.073
self-efficacy (SEQ) -0.199** -0.306***
psychological attributions (CAL) -0.105 0.113 -0.096 0.534
total adj R2 0.623 0.534
* p < 0.05 
** p < 0.01 
*** p < 0.001
Description o f  the course offatigue fo r  those women that had a disease recurrence. 
The mean CIS-fatigue score at baseline for those women who had a disease 
recurrence within the two year period o f our study was 23.9 (sd=14.5) at baseline. 
The mean Daily Observed Fatigue score (DOF) at baseline was 2.8 (sd=2.3). 
Further, the number o f severely fatigued patients at baseline was five (26%). In 
addition, one patient (5%) experienced heightened fatigue.
In Figure 2 mean monthly fatigue scores are depicted for the 19 women who had a 
disease-recurrence during the study period. The CIS-fatigue scores rose from 23 
(12 months before the diagnosis o f a disease recurrence) to 31 in the month that the 
disease recurrence was diagnosed. In the same figure, mean monthly fatigue scores 
are depicted for a matched group o f women who did not have a disease recurrence. 
The groups were matched on the baseline CIS-fatigue score. In addition, the two 
groups were comparable with respect to type o f surgery, age, adjuvant therapy, 
duration o f treatment and time since treatment. There was no clear rise of the 
monthly CIS-fatigue scores in this control group o f persistent disease-free women. 
Their monthly CIS-fatigue score varied from 19 to 26.
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months before the diagnosis of a recidive
Figure 2. Mean monthly fatigue scores fo r  women who developed a tumour relapse (n=19) 
in the 12 months before this was diagnosed
(n=19 at time 0, n=16 at time -3, n=14 at time -6, n=11 at time -9, n=10 at time -12)
DISCUSSION
The unique quality o f this study lies in the fact that we studied fatigue in disease- 
free breast cancer patients during a longer period o f time. Because o f that we were 
able to take a closer look at the course o f fatigue complaints and we were able to 
identify those patients that experienced persistent fatigue complaints. Based on the 
monthly fatigue scores we concluded that severe fatigue is a persistent problem for 
24 percent o f a group o f disease-free breast cancer patients. For these women 
fatigue is thus a continuous severe problem, even years after treatment for cancer, 
and is associated with severe limitations in several areas o f daily life. This 
percentage is comparable to percentages found in other samples o f disease-free 
cancer patients38.
To provide a measure for persistent fatigue we calculated the mean CIS-fatigue 
score over the 24 months that patients filled out the fatigue questionnaire. Patients 
with a persistent fatigue score o f 35 or higher were referred to as ‘persistently 
severely fatigued’. We realise that this technique has some shortcomings, for 
example, a few months o f very high fatigue might place a person in the 
‘persistently severely fatigued’ category even if  most o f her monthly scores fell 
below the cut point o f 35. Because o f this shortcoming we additionally calculated 
the persistent fatigue score according to another approach. We calculated the 
percentage o f times that scores fell above the cut-point o f 35. However, this 
technique has some shortcomings as well. For example, a person that has many 
fatigue scores just under 35, will not be labelled as persistently fatigued, while this
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is probably untrue. In spite of the shortcomings o f both techniques it is reassuring 
to know that the Pearson correlation between these differently obtained persistent 
fatigue scores turned out to be very high; 0.90 (p<0.001).
Considering the relation to former treatment modalities, we can conclude that 
patients who did not receive any kind of adjuvant therapy and who did not 
experience any kind o f complications during treatment, i.e. those patients that 
completed treatment for cancer within one month, are at lower risk for persistent 
fatigue. Furthermore, persistent fatigue seemed to be unrelated to type o f surgery, 
type of adjuvant therapy and to time since treatment finished.
A possible explanation for the low persistent fatigue scores in patients whose 
treatment duration was short may be due to the fact that they had not been 
subjected to the harmful effects o f adjuvant therapy and/or multiple operations 
(and anaesthetics) because o f complications. In addition, for this group o f patients 
the period of great uncertainty had been limited and they had been spared many 
hours of travelling to and from the hospital, which can cause exhaustion as well. O f 
course, there may be other explanations.
Furthermore, persistent fatigue was very well predicted by the questionnaires that 
we used to measure psychological well-being, functional impairment, sleep 
disturbances, physical activity, neuropsychological functioning, social functioning, 
social support, self-efficacy and causal attributions. With use of several selected 
baseline measures, the percentage o f explained variance was 62 percent. These 
findings are important with respect to the development o f interventions to reduce 
fatigue. For patients with Chronic Fatigue Syndrome (CFS), cognitive behaviour 
therapy has proven to be successful in reducing fatigue complaints39,40. In one of 
these studies40, cognitive behaviour therapy was based on a statistically tested 
model o f perpetuating factors in CFS36. In this model, focussing on bodily 
symptoms, low physical activity, and low sense o f control contributed to increasing 
severity o f fatigue. Based on the results o f the current study we might expect that, 
similar to the model for CFS patients, a low sense o f control might play a role in a 
model for severely fatigued cancer survivors. In addition, anxiety and impairment 
in role functioning might be important perpetuating factors as well.
With respect to the relation between severe fatigue and disease recurrence it is 
important to note that at baseline severe fatigue was found both in patients who had 
a disease recurrence and in patients who remained disease-free. In our study the 
mean CIS-fatigue score and the percentage o f severely fatigued patients at baseline 
were even lower in the group o f patients who had a disease recurrence than in the 
patients that remained disease-free. In clinical practice severe fatigue complaints 
can thus not be interpreted as an indicator o f a possible disease recurrence. 
However, there seems to be a rise o f the fatigue score in the months preceding the 
diagnosis o f the disease recurrence. Nevertheless, we should be careful in 
interpreting this finding because the group o f women who had a disease recurrence 
is small.
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INTRODUCTION
The results o f the studies reported in the present thesis and o f other studies 
published in the last five years make clear that fatigue (long) after curative 
treatment for cancer is a severe problem for a substantial part o f disease-free 
cancer patients. Complaints o f severe fatigue are often associated with serious 
limitations in daily life, for instance in the areas o f work, household activities, 
social interactions or recreation and pastime. It is important to note that until 
recently the phenomenon ‘post-cancer fatigue’ was not recognised at all. In the 
past the focus within oncology was solely on survival. Often patients had to 
contend with the incomprehension from their physician, their boss, and even from 
family and friends, when they kept on experiencing severe fatigue complaints long 
after they had completed their cancer treatment. Fortunately, this one-sided focus is 
shifting and nowadays quality o f life, and therefore also fatigue, is increasingly 
seen as an important aspect o f (post-)cancer treatment.
In this final chapter we will summarise the results of the studies presented in the 
preceding chapters and place them into perspective, as well as describe the 
limitations o f our investigations. The following topics will be discussed: the 
prevalence and course o f post-cancer fatigue, a description o f ‘the severely 
fatigued disease-free cancer patient’, the relationship between former disease and 
treatment characteristics and post-cancer fatigue, possible perpetuating factors of 
post-cancer fatigue, comparisons between severely fatigued disease-free cancer 
patients and Chronic Fatigue Syndrome (CFS) patients, and, finally, suggestions 
for a cognitive behavioural intervention to reduce post-cancer fatigue.
Prevalence and course of post-cancer fatigue
Our first goal was to assess the prevalence o f fatigue in disease-free cancer patients 
by means o f a validated fatigue questionnaire, the Checklist Individual Strength. It 
has excellent psychometric properties and, based on research o f patients with 
Chronic Fatigue Syndrome and healthy controls, it enables us to determine severe 
and heightened feelings o f fatigue13.
It is important to start with the observation that o f the patients that have been 
successfully treated for cancer not all will be confronted by long-lasting complaints 
o f (severe) fatigue after they have completed treatment. Literature study shows that 
up to 99 percent o f all cancer patients have to deal with some degree o f fatigue 
during their treatment46. Based on the literature and our own experience we can 
conclude that more than one year after successful treatment this percentage is 
considerably lower, but still clinically relevant4,7,8. In the studies we carried out the 
proportion o f severe fatigue varied from 19 to 38 percent in three different samples
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of cancer survivors. The percentage o f heightened and severe fatigue ranged from 
29 to 54 percent (Fig. 1).
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Figure 1. Percentages o f  cancer survivors with severe and heightened fatigue complaints
In two o f these samples patients were assessed a second time after a period of two 
years. In the sample o f patients treated for a bone or soft tissue tumour, the 
percentage o f severe fatigue had remained about equal, namely 26%. However, in 
the sample o f disease-free breast cancer patients the proportion had decreased from 
38 to 23%. A possible explanation for this decrease could be that our breast cancer 
population had completed cancer treatment within a relatively short period (mean 
2.5 years) before taking part in our study. These results seem to suggest that fatigue 
complaints continue to decrease during the first 3 to 4 years after successful 
treatment. Nevertheless, for about a quarter o f the cancer survivors severe fatigue 
complaints are persistent. In the study o f patients treated for a bone or soft tissue 
tumour we found evidence for an early decrease in the fatigue incidence. Here, 
patients who had finished treatment between one to two years prior to the study 
were significantly more severely fatigued than patients who had finished treatment 
considerably earlier.
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There are a few limitations with respect to our conclusions on the prevalence of 
post-cancer fatigue. First, we only investigated patients with specific types of 
cancer, namely breast cancer, bone and soft tissue tumours, and a mixed cancer 
population in which a majority o f the patients had testis carcinoma, colorectal 
carcinoma and sarcoma. However, based on the literature, there is no reason to 
expect that the prevalence will be different in the majority o f other cancer survivor 
populations4. Second, our studies were limited to cancer survivors in a certain age 
category. The rationale was that we wanted to select more or less homogenous 
groups of patients. Mean ages o f the breast cancer patients, the patients with bone 
and soft tissue tumours, and the mixed cancer population were 46 years (sd=6, 
range=28-55), 38 years (sd=14, range=18-65), and 48 years (sd=14, range=21-74), 
respectively. The presented results are thus not applicable to survivors o f other age 
groups. We feel it will be o f particular interest to also investigate fatigue 
complaints in older disease-free patients in the future. After all, fifty percent o f all 
cancer patients are older than 65 years. Finally, our results do not apply to patients 
with advanced cancer. However, based on other research, we know that in the 
palliative setting fatigue is a very important problem as well. In their final stage of 
life the majority o f cancer patients indicate fatigue as a serious complaint that 
interferes with their quality o f life9. In contrast to the fatigue experience of disease- 
free cancer patients, patients with advanced cancer are confronted by numerous 
physical problems, which may aggravate their experience o f fatigue.
Description of ‘the severely fatigued disease-free cancer patient’
Besides the quantitative description o f fatigue (the severity o f fatigue) we have 
studied various qualitative aspects of fatigue in disease-free cancer patients. As 
indicated in Chapter 4, in our research department fatigue has been assessed in 
several samples (e.g. patients with chronic fatigue syndrome, multiple sclerosis, 
pancreatitis, neuromuscular disease and healthy controls) using a multidimensional 
assessment method. In addition to the dimension o f fatigue severity this assessment 
method evaluates eight other dimensions, namely psychological well-being, 
functional impairment in daily life, sleep disturbances, physical activity, 
neuropsychological impairment, social functioning/social support, self-efficacy and 
causal attributions. These dimensions appeared to be relatively independent, 
implying that each dimension uniquely contributes to the description o f a patient 
who experiences severe fatigue.
From the results o f our collective studies we can conclude that severely fatigued 
disease-free cancer patients scored significantly higher on all eight dimensions 
compared to the non-severely fatigued disease-free cancer patients. Furthermore, 
non-severely fatigued disease-free cancer patients were comparable to matched 
healthy controls on most o f the dimensions. It thus seems that fatigue is not an 
isolated problem. Cancer survivors that experienced severe fatigue also 
experienced numerous problems and limitations in several areas o f life.
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None o f our studies yielded significant differences between severely fatigued 
disease-free cancer patients and non-severely fatigued disease-free cancer patients 
on demographic variables. The two groups were similar with respect to age, gender 
and level o f education.
Relations between former disease and treatm ent characteristics and 
post-cancer fatigue
Starting from the hypothesis that post-cancer fatigue is initially caused by the 
cancer itself and/or the treatment for cancer, we were interested in finding out 
whether there are any correlations between post-cancer fatigue and initial disease- 
or treatment-related factors. One o f our first studies had shown that there were no 
differences in severity between fatigued patients who were diagnosed with testis 
carcinoma, colorectal carcinoma, sarcoma or other types o f cancer. Furthermore, in 
our study with patients that had been successfully treated for bone and soft-tissue 
tumours, there proved to be no differentiation in fatigue scores between patients 
treated for various types o f malignant and those treated for benign tumours. 
Neither did we find any dissimilarities in fatigue scores in relation to the area of 
operation (lower girdle (hip, knee, ankle), upper girdle (shoulder, elbow) and axial 
skeleton (pelvis, spine)).
It may seem remarkable that the fatigue scores o f the patients that were treated for 
malignant and those treated for benign tumours were similar. However, when you 
realise that patients with benign tumours also have to go through a period of 
uncertainty surrounding the discovery and diagnosis o f their tumour, that they also 
have to undergo extensive surgery that always carries certain risks and might 
possibly lead to physical limitations, and that they also have to face the chance of 
disease recurrence, the similarity in scores is quite explainable.
With respect to treatment-related variables we did not find any significant relations 
between fatigue and former type o f surgery (mastectomy versus lumpectomy; 
different orthopaedic procedures). In addition, there was no evidence for a relation 
between severe fatigue and type o f adjuvant therapy. For instance, breast cancer 
patients treated with radiotherapy had post-cancer fatigue scores that were 
comparable to the fatigue scores o f patients who had been treated with 
chemotherapy and to patients having received treatment consisting o f a 
combination o f radio- and chemotherapy. However, we did find that patients 
whose surgery had been without complications and who had not received any 
adjuvant therapy were less at risk o f developing severe fatigue than other patients. 
In our longitudinal breast cancer study, patients that had completed treatment for 
cancer within one month, i.e. those patients that had undergone a surgical 
procedure without any complications and without any adjuvant therapy, 
experienced persistent fatigue significantly less often. Furthermore, in our study 
with patients treated for a bone or soft tissue tumour, the percentage of severe 
fatigue was significantly lower in patients that had undergone only one operation
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versus those who had had to undergo two or more procedures. This was relevant 
both for patients treated for malignant tumours and for patients treated for benign 
tumours.
It is our view that the lower fatigue scores in patients whose treatment duration was 
short may be due to the fact that they had not been subjected to the harmful effects 
o f radiotherapy, chemotherapy, or multiple operations (and anaesthetics). In 
addition, the fact that for this group o f patients the period o f great uncertainty had 
been limited and that they had been spared many hours o f travelling to and from 
the hospital, which can cause exhaustion as well, may have played a role here as 
well. This does not mean to say that these are the only reasons; there may be other 
explanations.
In conclusion, type o f cancer, type o f surgery and type o f adjuvant treatment were 
not related to persistent fatigue complaints after treatment for cancer. However, 
patients that did not have to undergo adjuvant treatment at all, and for whom 
surgery was without complications, seemed to experience persistent fatigue less 
often than other patients.
Perpetuating factors of post-cancer fatigue
As described above, we did not find clear evidence for relationships between 
former disease and the majority o f treatment characteristics on the one hand and 
post-cancer fatigue on the other hand. We therefore think that it is important to 
make a distinction between initiating factors and perpetuating factors o f fatigue 
after cancer. We assume that post-cancer fatigue complaints originate in the 
diagnostic and treatment stages. In several reviews various factors have been 
pointed out as possible initiating factors o f fatigue during active treatment for 
cancer. First, there is the primary influence o f the tumour on the organs involved. 
Second, secondary effects o f the tumour, like anaemia, can play a role. Third, the 
actual treatment (surgery, chemotherapy, radiotherapy) could be an important 
cause o f fatigue, and finally, psychological factors like anxiety and depression 
could lead to complaints o f fatigue1012. After successful treatment for cancer 
fatigue complaints disappear in most cases. However, for a substantial part of 
cancer survivors they continue to exist. The factors that are responsible for these 
persistent complaints o f fatigue are referred to as perpetuating factors. Because our 
studies o f fatigue were all conducted some years after treatment had been 
completed, our investigations were restricted to the perpetuating factors o f fatigue. 
From our longitudinal studies we can conclude that low self-efficacy, elevated 
feelings o f anxiety, serious limitations in role functioning, low sense o f optimism 
and high tendency to focus on bodily symptoms seem to be perpetuating factors of 
fatigue complaints after successful treatment for cancer. It thus seems that patients 
that experience little control with respect to their fatigue complaints, patients that 
tend to be anxious, patients that experience difficulties in resuming their former 
roles at home and/or at work, patients that tend to be pessimistic and patients that
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tend to focus on bodily symptoms, are the ones that are most likely to experience 
persistent fatigue. Two o f these factors, i.e. strong focus on bodily symptoms and 
low self-efficacy, have also been identified as perpetuating factors in a statistically 
tested model o f perpetuating factors in Chronic Fatigue Syndrome13.
In addition to these perpetuating factors o f fatigue, the extent to which patients 
have come to terms with their disease (i.e. the acceptance o f having been 
confronted with cancer), might be an important perpetuating factor as well. 
Initially, we assumed that for patients assessed more than one year after treatment 
completion, acceptance o f their experience would no longer play an important role. 
However, based on the clinical knowledge acquired during the last few years and 
the literature1417 we now conclude that this assumption may not apply to all 
patients. It has become clear that some patients still experience difficulties with 
respect to the acceptance o f the fact that they have had cancer, even years after 
treatment has been finished. In the study assessing patients treated for a bone or 
soft tissue tumour we reported data on the relationship between acceptance and 
fatigue (Chapter 7). The results indicated that heightened fatigue was predicted by 
lower levels o f acceptance o f the experience with cancer. This finding is consistent 
with unpublished results in our breast cancer population. Severely fatigued disease- 
free breast cancer patients had significantly lower acceptance scores than non- 
severely fatigued disease-free breast cancer patients.
Another possible perpetuating factor o f fatigue after treatment for breast cancer is 
the menopause. Breast cancer patients often become menopausal as a result of 
chemotherapy. Although there still is an ongoing debate about exactly what 
symptoms are attributable to the menopause, most researchers consider the 
following symptoms to be menopausal in nature: vasomotor symptoms (e.g. hot 
flashes), symptoms related to vaginal atrophy (e.g. pain during intercourse), 
psychological symptoms (e.g. irritability) and other symptoms such as joint pains, 
trouble sleeping and heart palpitations18. In view o f these assumed menopausal 
associations, it is very likely that these symptoms are additional perpetuating 
factors in the fatigue breast cancer survivors experience after they have become 
menopausal. This is all the more likely given that menopausal symptoms seem to 
be both more prevalent and severer in cancer survivors than in healthy women, and 
because physicians may be reluctant to prescribe hormone replacement therapy 
because of the potential increased risk o f cancer recurrence19,20.
Because of this likely influence o f menopausal complaints we decided to include 
an item about the intensity o f hot flashes in the self-observation list (Daily 
Observed Hot Flashes, DOHF). Patients were asked to report the intensity o f hot 
flashes four times a day on a 5-point scale (0-4) during a 12-day period. Total 
DOHF scores ranged from 0 to 16. Because 41 patients had already completed the 
study by the time we included DOHF in the self-observation list, only 80 o f  our 
breast cancer patients filled out this question. The results do indeed suggest a 
relation between fatigue and hot flashes. Disease-free breast cancer patients with
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persistent, severe fatigue (n=21) had a mean DOHF score o f 2.90 (sd=3.71) while 
the rest o f the patients (n=59) had a mean DOHF score o f 1.27 (sd=1.77). This 
difference approached significance (t-test p<0.071).
What we did not investigate in our studies were organic perpetuating factors of 
post-cancer fatigue because at the time we started our research there were no 
indications at all that organic factors could be o f importance in disease-free cancer 
patients. However, in a recent article Bower21 reported that fatigued breast cancer 
survivors had significantly higher serum levels o f several markers associated with 
proinflammatory cytokine activity than non-fatigued survivors, including 
interleukin-1 receptor antagonist, soluble tumour necrosis factor receptor type II, 
and neopterin. Furthermore, they had significantly lower serum levels o f cortisol 
than the non-fatigued group. Comparison with two lymphocyte populations also 
yielded differences.
As explained above, due to our study design we were only able to investigate the 
perpetuating factors o f fatigue. However, we think it is important to also 
investigate the initiating factors o f cancer-related fatigue in the future. This 
requires that patients are included in a longitudinal study from the moment of 
diagnosis and are assessed at various points in time for approximately 4 years. 
Such a research design will allow an evaluation o f both the initiating and the 
perpetuating factors o f fatigue during and long after treatment for cancer. Up until 
now, only a few longitudinal studies have been published in which patients were 
included from the moment o f diagnosis22-26. Initiating factors of fatigue during 
and/or shortly after treatment were cancer diagnosis23,25, depression23,24,26, 
functional disability, quality o f sleep and psychological distress23. However, none 
o f these studies had a sufficient duration to allow an investigation of possible 
perpetuating factors o f persistent fatigue complaints.
Similarities and differences between severely fatigued disease-free 
cancer patients and patients with Chronic Fatigue Syndrome
A comparison o f severely fatigued disease-free cancer patients and CFS patients is 
o f importance to determine whether a cognitive behavioural intervention designed 
to reduce fatigue in CFS patients would also be appropriate for severely fatigued 
disease-free breast cancer patients. In Chapters 3 and 6 o f this thesis we 
investigated possible similarities and differences between severely fatigued cancer 
survivors and CFS patients. In Chapter 3 this was done on the basis of several 
general self-report questionnaires only, while in Chapter 6 we used a large battery 
o f general and daily self-report questionnaires as well as measures o f actual 
behaviour. The discussion below is therefore mainly based on the results described 
in Chapter 6 and thus on the results o f our study involving severely fatigued former 
breast cancer patients.
With respect to the onset o f the fatigue complaints it needs to be pointed out that 
there is an important difference between former cancer patients and CFS patients.
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For patients with fatigue after cancer there is a distinct starting point, namely the 
period in which they were diagnosed and treated for cancer. For patients with CFS 
the onset differs per patient and is often vague or unknown. This automatically 
implies that the attributions relating to the causes o f  the fatigue are different for 
both groups. Severely fatigued disease-free cancer patients often attributed their 
fatigue complaints to the fact that they were diagnosed and treated for cancer, 
while CFS patients attribute their fatigue complaints to several other, mostly 
physical, factors. Another important difference in this respect is that cancer 
patients, besides their high cancer-related attributions, also had high 
psychologically related attributions. For instance, they attributed their fatigue 
complaints to their fear o f a relapse, or to the fact that they tend to ruminate. By 
contrast, CFS patients often exclude the possibility o f psychologically based causes 
o f their fatigue complaints27,28.
Furthermore, although many o f the cancer survivors in our studies experienced 
severe fatigue, in general, they were less severely fatigued and less restricted in 
several areas o f daily life than the CFS patients. Also, severely fatigued cancer 
survivors experienced fewer problems with respect to physical activity, 
concentration and pain and they reported to have more control over their fatigue 
complaints. However, the two groups seemed to have the same amount of 
problems as regards social support and sleep. And finally, levels o f depression and 
anxiety tended to be somewhat heightened for severely fatigued cancer survivors in 
comparison to patients with CFS, which is also in line with our clinical experience. 
Some patients interpreted their persistent feelings o f severe fatigue as a sign of 
disease recurrence, which was associated with anxiety and depression resulting in 
increasing fatigue.
Cognitive behavioural intervention to reduce post-cancer fatigue
Based on the above described results, and because differences within the group of 
severely fatigued cancer patients proved to be larger than within the group o f CFS 
patients, it is likely that a model o f perpetuating factors for former cancer patients 
differs from the CFS model, which has implications for therapeutic interventions 
aimed at reducing fatigue after treatment for cancer. Our findings indicate that the 
following aspects need to be taken into account when considering a cognitive 
behaviour therapy for fatigue after cancer: acceptance of the experience with 
cancer, cognitions associated with fatigue (attributions relating to the causes of 
fatigue, self-efficacy), sleep disturbances, regulation o f physical, mental and social 
activities and social support and interactions. What the large differences we 
observed within the group o f severely fatigued cancer patients have clearly shown 
is that cognitive behaviour therapy to reduce fatigue after successful treatment for 
cancer should, in any event, be adapted to each individual former cancer patient.
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Summary
This thesis consists o f seven articles on the subject o f fatigue complaints in cancer 
survivors.
In Chapter 1 we briefly describe the history o f the Expert Centre Chronic Fatigue 
o f the University Medical Centre Nijmegen. Furthermore, we report that the 
research that is described in this thesis focuses on fatigue complaints in cancer 
survivors. With ‘cancer survivors’ we refer to persons who have received a 
curative treatment for cancer and are disease-free at the time o f participation in our 
studies. Chapter 1 is completed with an outline o f the contents o f Chapters 2 to 9.
In Chapter 2 we review the literature on the topic o f fatigue complaints during and 
after treatment for cancer. Based on studies that were published between 1980 and 
2001 we conclude that prevalence estimates o f fatigue during cancer treatment 
range from 25% to 99%. For cancer survivors, it is found that for different samples 
o f disease-free patients in 17% to 30% o f the cases fatigue is an important 
problem. The majority o f the studies on fatigue during and after cancer, fails to 
find relationships between fatigue on the one hand, and demographic variables and 
disease and treatment characteristics on the other hand. Nevertheless, fatigue seems 
to be related to psychological distress, sleep disturbance and limitations in physical 
functioning. Studies that focus on interventions to reduce fatigue are limited to 
interventions during or shortly after cancer treatment. These studies report positive 
effects on fatigue complaints immediately after the intervention.
In the reviewed articles a wide variety o f instruments to measure fatigue have been 
used. Many o f these instruments have not been tested on validity and reliability, 
and often reference scores are lacking. In addition, most o f the instruments are 
unidimensional, i.e. they solely measure fatigue intensity, rather than 
multidimensional. In the latter case, the nature o f the symptoms as well as their 
severity are gauged. Because of these shortcomings we state in the discussion of 
this article that it is important to use valid and reliable multidimensional fatigue 
instruments in future research, for which reference scores o f healthy subjects 
and/or other patient populations are available. It is only with such instruments that 
that it can be ascertained whether fatigue is any different for cancer patients than 
for healthy individuals or for patients with diseases other than cancer. Furthermore, 
we suggest that it is important to conduct longitudinal studies that will allow the 
identification o f initiating and perpetuating factors of fatigue complaints during 
and after treatment for cancer.
The goal o f the article in Chapter 3 was to assess fatigue with the use o f a 
validated multidimensional fatigue questionnaire, i.e. the Checklist Individual 
Strength, in a mixed sample o f 85 disease-free cancer patients. Reference scores
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recorded in several groups of patients and healthy controls are available for this 
questionnaire. We also wished to investigate whether relationships exist between 
severe fatigue on the one hand, and former treatment modalities, problems of 
concentration, motivational problems, decreased physical activity, functional 
impairment, depression and anxiety on the other hand. Finally, we were interested 
in finding out in what way(s) severely fatigued disease-free cancer patients were 
comparable with patients with Chronic Fatigue Syndrome (CFS). The disease-free 
cancer patients had completed cancer treatment 6 months to 12.5 years prior to our 
study. Nineteen percent o f the disease-free cancer patients appeared to experience 
severe fatigue. No relationships were found between fatigue and type o f cancer, 
type o f former treatment modalities, duration o f treatment and time since treatment 
completion. We did find correlations between severe fatigue and depression, 
anxiety, concentration problems, reduced motivation and reduced physical activity. 
Finally, severely fatigued cancer patients were comparable with a group of patients 
with CFS, matched for age and gender, with regard to depression, reduced 
motivation and reduced physical activity. CFS patients reported more 
concentration problems.
In Chapter 4, the results o f a cross-sectional study o f 150 disease-free breast cancer 
patients are reported. The aim o f this study was also to assess severe fatigue, but 
this time in a larger, more homogeneous group of disease-free cancer patients. All 
women had undergone treatment for breast cancer, had been younger than 50 years 
at the time o f primary diagnosis and had completed their treatment 6 to 70 months 
before participating in the study. We made use o f a multidimensional assessment 
method consisting o f nine dimensions, namely fatigue severity, psychological well­
being, functional impairment in daily life, sleep disturbance, physical activity, 
neuropsychological impairment, social functioning/social support, self-efficacy and 
causal attributions. Thirty-eight percent o f the sample turned out to be severely 
fatigued, compared with 11% in an age-matched sample o f women without a 
history o f cancer. Fatigue severity scores did not differ significantly for those 
patients who had undergone mastectomy and those who had had lumpectomy. 
Neither did we find differences in fatigue scores between patients who had 
received radiotherapy or chemotherapy or both. In addition, we did not find any 
differences between these three patient groups and patients who had not received 
adjuvant therapy at all. We elaborate on this latter finding in Chapter 8. The 
‘severely fatigued disease-free breast cancer patient’ scored higher on several 
dimensions compared to the ‘non-severely fatigued disease-free breast cancer 
patient’. Severely fatigued patients reported more psychological distress, 
experienced more functional impairment at home or at work, they more often had 
sleep disturbances and neuropsychological problems, were less physically active, 
and perceived to receive less social support. Finally, severe fatigue was highly 
related to a low sense o f control with respect to the fatigue complaints and strong
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cancer- and psychologically related attributions with regard to the causes o f the 
fatigue.
In Chapter 5 a study is described in which the same 150 disease-free breast cancer 
patients participated. The goal o f this study was to analyse the relationship between 
fatigue, neuropsychological functioning and physical activity. The results 
described in Chapter 4 had already shown that severe fatigue is related to self­
reported problems o f concentration, memory and physical functioning. However, it 
remained unclear whether this is truly the case. In the present study we therefore 
measured both neuropsychological functioning and physical activity in three ways: 
1) with general self-report questionnaires, 2) with daily self-report questionnaires, 
and 3) by measures o f actual behaviour. Neuropsychological tests were performed 
to measure speed o f information processing and actual ability to concentrate. 
Actual physical activity was measured with the actometer, which is an apparatus 
about the size o f a matchbox that was worn around the ankle both day and night 
during a 12-day period. Results indicated that fatigue was strongly related with 
general and daily self-reported neuropsychological functioning, but not with actual 
neuropsychological functioning in a laboratory setting. Furthermore, fatigue was 
strongly related with general self-reported physical activity but not with daily self­
reported and actual physical activity.
The purpose of the study that is described in Chapter 6 was to examine to what 
extent a patient who experiences severe fatigue after treatment for breast cancer 
resembled a patient with CFS. In this article we compared 57 severely fatigued 
disease-free breast cancer patients with 57 gender- and age-matched patients with 
CFS on the dimensions o f fatigue severity, functional impairment, self-efficacy, 
psychological well-being, sleep disturbances, neuropsychological impairment, 
physical activity, social support, and pain. The CFS patients had higher fatigue 
scores, experienced more functional impairment, were less physically active, 
experienced more pain and had lower self-efficacy, in comparison to the severely 
fatigued disease-free breast cancer patients. However, a subgroup of the latter 
patient sample reported the same amount o f psychological distress, sleep 
disturbances and concentration problems as the CFS patients. Finally, both the CFS 
and severely fatigued breast cancer patients had the same amount o f problems with 
respect to social support. Based on these results, and because differences within the 
group o f severely fatigued cancer patients seemed to be larger than the differences 
within the group o f CFS patients, we assume that the model o f perpetuating factors 
for the former cancer patients probably differs from the CFS model, which has 
implications for therapy aimed at reducing fatigue after treatment for cancer. 
Because o f the large differences within the group o f severely fatigued cancer 
patients it is concluded that cognitive behaviour therapy to reduce fatigue after 
cancer treatment should be adapted to each individual former cancer patient.
In Chapter 7 the results o f our longitudinal study on fatigue complaints in 170 
patients who had received treatment for malignant and benign bone and soft tissue
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tumours 1 to 15 years prior to our study, are reported. One o f the aims o f this study 
was to investigate whether patients who were treated for malignant tumours 
experienced severe fatigue more often than patients treated for benign tumours. 
Because treatment for bone and soft tissue tumours differs from treatment for 
breast cancer, our second goal was to investigate the relationships between 
treatment characteristics and post-cancer fatigue in this population. In addition, 
because time since the end o f treatment varied more widely within this patient 
population than in the populations we studied earlier, we were able to establish 
whether patients who had finished treatment relatively recently were more severely 
fatigued than patients for whom treatment completion was less recent. Finally, the 
longitudinal design o f this study enabled us to investigate the perpetuating factors 
o f fatigue. Severe fatigue complaints appeared to be a problem for 28 percent of 
the patients investigated. Percentages o f severe fatigue were equal for patients who 
had been treated for malignant tumours and those treated for benign tumours. 
Fatigue complaints proved to be most severe for those patients who had finished 
treatment between 1 to 2 years ago, and for patients who had undergone more than 
one operation. At a two year follow-up the majority o f the patients who had been 
severely fatigued at baseline were still severely fatigued. Oncological 
complications after initial treatment, low optimism and high somatisation appeared 
to be predictors o f severe fatigue at follow-up.
Chapter 8 is a sequel o f our cross-sectional breast cancer study o f which the results 
were presented in Chapters 4 and 5. The sequel study was aimed at investigating 
whether severe fatigue after treatment for breast cancer was a persistent problem. 
In addition, we wished to find out whether persistent fatigue was related to former 
treatment characteristics. After baseline measurements, the patients were asked to 
fill out a monthly fatigue questionnaire during a two year period after which they 
were invited to our hospital for an extensive follow-up assessment. O f the 150 
participating patients 121 women completed the study. Nineteen women had a 
disease recurrence during the 2 -year period and 10 patients dropped out for several 
other reasons. Based on the monthly fatigue questionnaires we concluded that 24% 
of the disease-free breast cancer patients experienced persistent severe fatigue 
complaints. Persistent fatigue complaints were less severe in the patients that had 
not received any kind o f adjuvant therapy and for whom, at the same time, surgery 
(mastectomy or lumpectomy) had been without complications. High anxiety, high 
impairment in role functioning and low sense o f control over fatigue symptoms at 
baseline appeared to be predictors o f persistent fatigue.
Finally, in Chapter 9 we place the results of the studies presented in this thesis into 
perspective and discuss their shortcomings and implications. We conclude that for 
approximately 25 percent o f all cancer survivors severe fatigue complaints are 
persistent. These severe fatigue complaints are associated with problems and 
limitations in different areas o f life. Patients that had completed treatment within a 
relatively short time experienced persistent fatigue less often. None o f these
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patients had had to undergo adjuvant treatment, and for all surgery had been 
without complications. Factors responsible for the perpetuation o f severe fatigue 
were low self-efficacy, high feelings o f anxiety, serious limitations in role 
functioning, low sense o f optimism and high tendency to focus on bodily 
symptoms. Furthermore, our various findings indicate that it is plausible that 
menopausal complaints and difficulties in coping with the experience o f having 
had cancer (i.e. acceptance) are important perpetuating factors as well.
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Samenvatting
Dit proefschrift bestaat uit zeven artikelen over ernstige vermoeidheidsklachten bij 
ziekte-vrije kankerpatiënten.
In Hoofdstuk 1 wordt in het kort de geschiedenis beschreven van het 
vermoeidheidsonderzoek dat we sinds 1990 binnen het Universitair Medisch 
Centrum St. Radboud doen. Verder geven we hier aan dat het in dit proefschrift 
gepresenteerde onderzoek zich richt op ziekte-vrije kankerpatiënten. Hiermee 
doelen we op patiënten die een curatieve behandeling voor kanker hebben 
afgesloten en bij wie op het moment van het onderzoek geen tekenen van een 
recidief aanwijsbaar waren. Tenslotte wordt in dit hoofdstuk kort aangegeven wat 
de inhoud is van de hoofdstukken 2 tot en met 9.
Hoofdstuk 2 bestaat uit een overzicht van de literatuur over vermoeidheidsklachten 
tijdens en na behandeling voor kanker. Gebaseerd op studies die tussen 1980 en 
2001 zijn gepubliceerd, concluderen we dat de prevalentie van vermoeidheid 
tijdens behandeling voor kanker varieert van 25 tot 99 procent. Voor 17 tot 30 
procent van de patiënten die de behandeling voor kanker reeds achter de rug heeft 
blijft vermoeidheid een belangrijk probleem. Dit is onderzocht in verschillende 
ziekte-vrije kankerpopulaties. In de meerderheid van de besproken onderzoeken 
naar vermoeidheid tijdens en na behandeling voor kanker wordt geen relatie 
gevonden tussen vermoeidheid aan de ene kant en demografische variabelen en 
ziekte- en behandelingskarakteristieken aan de andere kant. Wel blijkt dat 
vermoeidheidsklachten gerelateerd zijn aan psychische klachten zoals angst en 
depressie, problemen op het gebied van slaap en verminderd fysiek functioneren. 
Studies die zich richten op interventies om vermoeidheidsklachten te verminderen 
beperken zich tot interventies tijdens de behandeling voor kanker o f vlak na het 
beëindigen van de behandeling. Deze studies rapporteren een positief effect op 
vermoeidheid, gemeten vlak na de interventie.
In de besproken artikelen werd gebruik gemaakt van een groot aantal verschillende 
vragenlijsten om vermoeidheid te meten. Veel van deze vragenlijsten zijn niet 
getoetst op validiteit en betrouwbaarheid en vaak waren er geen normgegevens 
beschikbaar. Bovendien zijn de meeste van deze vragenlijsten een-dimensioneel 
(ze meten slechts de intensiteit van vermoeidheid) in tegenstelling tot de 
multidimensionele vermoeidheidsvragenlijsten. Vanwege deze tekortkomingen 
stellen we in de discussie van dit artikel dat het belangrijk is om in toekomstig 
onderzoek gebruik te maken van valide en betrouwbare multidimensionele 
instrumenten om vermoeidheid te meten, voor welke normgegevens van gezonde 
controles en/of andere patiëntenpopulaties beschikbaar zijn. Alleen dan is het 
mogelijk om te kunnen vaststellen o f de vermoeidheidsbeleving van (ziekte-vrije)
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kankerpatiënten, gezonde controles en andere patiëntengroepen verschilt. Tenslotte 
geven we aan dat het belangrijk is om longitudinale studies uit te voeren om 
initiërende en in stand houdende factoren van vermoeidheid tijdens en na 
behandeling voor kanker te achterhalen.
Het doel van het artikel in Hoofdstuk 3 was het meten van vermoeidheid aan de 
hand van een gevalideerde multidimensionele vermoeidheidsvragenlijst, in een 
groep van 85 ziekte-vrije kankerpatiënten met uiteenlopende kankerdiagnoses. Van 
deze vragenlijst, de Checklist Individuele Spankracht, zijn normgegevens van 
gezonde controles en verschillende patiëntenpopulaties beschikbaar. Verder wilden 
we in deze studie de relatie onderzoeken tussen ernstige vermoeidheid enerzijds en 
eerdere behandeling voor kanker, concentratieproblemen, motivationele 
problemen, fysieke activiteit, functionele beperkingen, depressie en angst 
anderzijds. Tenslotte wilden we bekijken in hoeverre de ernstig vermoeide ziekte- 
vrije kankerpatiënten leken op patiënten met het Chronisch Vermoeidheids 
Syndroom (CVS). De ziekte-vrije kankerpatiënten hadden de behandeling voor 
kanker 6 maanden tot 12,5 jaar geleden afgesloten. Negentien procent van de 
ziekte-vrije kankerpatiënten bleek te kampen met ernstige vermoeidheidsklachten. 
Geen relaties konden worden aangetoond tussen ernstige vermoeidheid enerzijds 
en het soort kanker, type behandeling, duur van de behandeling en tijd sinds 
beëindiging van de behandeling, anderzijds. Wel vonden we dat ernstige 
vermoeidheid gepaard ging met concentratieproblemen, lage motivatie, afgenomen 
fysieke activiteit, depressie en angst. Tenslotte toonden we aan dat ernstig 
vermoeide ziekte-vrije kankerpatiënten vergelijkbaar waren met een op leeftijd en 
geslacht gematchte groep patiënten met CVS, voor wat betreft de hoogte van 
depressie, verminderde motivatie en afgenomen fysieke activiteit. CVS patiënten 
rapporteerden meer concentratieproblemen.
In Hoofdstuk 4 worden de resultaten beschreven van een cross-sectioneel 
onderzoek waaraan 150 ziekte-vrije borstkankerpatiënten deelnamen. Het doel van 
dit onderzoek was eveneens het meten van ernstige vermoeidheid, maar nu in 
grotere, meer homogene groep ziekte-vrije patiënten. De patiënten in dit onderzoek 
waren allen behandeld voor borstkanker, waren jonger dan 50 jaar bij de diagnose 
en hadden hun behandeling voor borstkanker 6 tot 70 maanden geleden afgesloten. 
In dit onderzoek is gebruik gemaakt van een meetmethode om negen verschillende 
dimensies te meten, namelijk: ernst van de vermoeidheid, psychisch welbevinden, 
beperkingen in het dagelijks leven ten gevolge van de vermoeidheid, 
slaapproblemen, fysieke activiteit, concentratieproblemen, sociaal functioneren en 
sociale steun, attributies (waar de patiënt zijn klachten aan toeschrijft) en de 
verwachtingen over de eigen beïnvloedingsmogelijkheden van de vermoeidheid 
(self-efficacy). In de onderzochte groep bleek 38 procent ernstig vermoeid te zijn, 
vergeleken met 11 procent in een op leeftijd gematchte groep vrouwen die in hun 
leven nooit voor kanker waren behandeld. Vermoeidheidsscores waren niet 
significant verschillend voor patiënten die een borstbesparende operatie o f een
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borstamputatie hadden ondergaan. Evenmin vonden we verschillen tussen de 
patiëntengroepen die radiotherapie, chemotherapie o f een combinatie van 
radiotherapie en chemotherapie nodig hadden gehad na de operatie. Bovendien 
vonden we geen verschil tussen deze 3 patiëntengroepen en patiënten die geen 
nabehandeling hadden ondergaan, maar hier komen we in Hoofdstuk 8 op terug. 
De ‘ernstig vermoeide ziekte-vrije borstkankerpatiënt’ bleek op verschillende 
dimensies hoger te scoren dan de ‘niet ernstig vermoeide ziekte-vrije 
borstkankerpatiënt’. Zo rapporteerden de ernstig vermoeide patiënten meer angst 
en depressie. Ze ervoeren meer problemen met betrekking tot het uitvoeren van 
hun dagelijkse activiteiten thuis o f op hun werk. Ze hadden vaker last van slaap-, 
geheugen- en concentratiestoornissen, waren minder fysiek actief en ervoeren 
minder sociale steun. Tenslotte was ernstige vermoeidheid in sterke mate 
gerelateerd aan lage self-efficacy en aan sterke attributies met betrekking tot de 
behandeling voor borstkanker en psychische oorzaken, zoals piekeren.
In Hoofdstuk 5 wordt een onderzoek beschreven dat is uitgevoerd bij dezelfde 150 
ziekte-vrije borstkankerpatiënten. Het doel van dit onderzoek was het analyseren 
van de relatie tussen vermoeidheid enerzijds en neuropsychologisch functioneren 
en fysieke activiteit anderzijds. Uit het onderzoek van Hoofdstuk 4 wisten we al 
dat ernstige vermoeidheid samenging met zelfgerapporteerde problemen op het 
gebied van concentratie, geheugen en fysiek functioneren, maar onduidelijk blijft 
o f dit ook werkelijk zo is, o f dat dit slechts de beleving van de patiënt is. Daarom 
werden in het huidige onderzoek neuropsychologisch functioneren en fysieke 
activiteit op drie manieren gemeten: 1) aan de hand van algemene zelfrapportage 
vragenlijsten; 2) met dagelijkse zelfrapportage lijsten waarop patiënten 4 keer per 
dag aangeven of ze concentratie en/of geheugen problemen hebben ervaren en in 
welke mate ze fysiek actief zijn geweest; en 3) aan de hand van meetinstrumenten 
van het werkelijke gedrag. Neuropsychologisch testen werden afgenomen om 
concentratie en reactievermogen te meten. Bovendien droegen patiënten gedurende 
een periode van 12 dagen, een aktometer om hun enkel om werkelijke fysieke 
activiteit te meten. De aktometer is een apparaat ter grootte van een luciferdoosje, 
dat bewegingen registreert. Uit de resultaten bleek dat vermoeidheid in  sterke mate 
gerelateerd is aan algemeen en dagelijks geregistreerd neuropsychologisch 
functioneren. Vermoeidheid bleek echter niet samen te hangen met de scores op de 
neuropsychologische testen. Met betrekking tot de relatie tussen vermoeidheid en 
fysieke activiteit, bleek er alleen een verband te zijn met de rapportage op 
algemene vragenlijsten. Vermoeidheid bleek niet gerelateerd aan dagelijks 
geregistreerde fysieke activiteit en aan werkelijke fysieke activiteit, gemeten met 
de aktometer.
Het doel van de studie in Hoofdstuk 6 was om te onderzoeken in hoeverre ernstig 
vermoeide ziekte-vrije kankerpatiënten vergelijkbaar zijn met patiënten met het 
Chronisch Vermoeidheids Syndroom (CVS). In dit artikel werden 57 ernstig 
vermoeide ziekte-vrije borstkankerpatiënten vergeleken met 57 op leeftijd en
176 Samenvatting
geslacht gematchte CVS patiënten, op de dimensies ernst van vermoeidheid, mate 
van beperkingen in het dagelijks leven, self-efficacy, psychisch welbevinden, 
slaap, concentratie, lichamelijke activiteit, sociale steun en pijn. CVS patiënten 
bleken hogere vermoeidheidsscores te hebben, meer beperkingen te ervaren in het 
dagelijks functioneren, minder fysiek actief te zijn, meer pijn te ervaren en in 
mindere mate het idee te hebben dat ze zelf invloed kunnen uitoefenen op hun 
vermoeidheid, dan de vermoeide ziekte-vrije borstkankerpatiënten. Er was echter 
wel een subgroep binnen de groep ziekte-vrije kankerpatiënten die even hoog 
scoorde als de groep CVS patiënten op psychisch onwelbevinden, slaapproblemen 
en concentratiestoornissen. Tenslotte ervoeren de ziekte-vrije kankerpatiënten en 
de CVS patiënten evenveel problemen met betrekking tot de ervaren sociale steun. 
Gezien de hierboven genoemde verschillen en gezien het feit dat er binnen de 
groep kankerpatiënten een grotere spreiding is op de genoemde dimensies dan bij 
CVS patiënten, is het zeer waarschijnlijk dat een model van in stand houdende 
factoren voor vermoeidheid na kanker op enkele belangrijke punten zal verschillen 
van het CVS-model, hetgeen implicaties heeft voor de behandeling van 
vermoeidheid na behandeling voor kanker. Cognitieve gedragstherapie voor 
vermoeidheid na behandeling voor kanker zal in ieder geval, vanwege de grote 
spreiding in deze groep, in sterkere mate moeten worden aangepast aan elke 
individuele ex-kankerpatiënt dan bij CVS het geval is.
In Hoofdstuk 7 wordt een longitudinaal onderzoek beschreven waaraan 170 
patiënten, die 1 tot 15 jaar geleden behandeld waren voor een kwaad- of 
goedaardige bottumor, deelnamen. Een van de doelen van dit onderzoek was om te 
onderzoeken o f vermoeidheid vaker voorkwam na behandeling van een 
kwaadaardige tumor dan na behandeling van een goedaardige tumor. Omdat de 
behandeling voor bottumoren verschilt van de behandeling voor borstkanker, 
wilden we in ook deze patiëntengroep onderzoeken o f vermoeidheid gerelateerd 
was aan eerdere behandeling voor kanker. Bovendien was er in deze groep een 
groter bereik wat betreft de tijd sinds de beëindiging van de behandeling dan in 
onze borstkankerpopulatie. Dit gaf ons de mogelijkheid om te onderzoeken of 
patiënten die hun behandeling recent hadden afgesloten ernstiger moe waren dan 
patiënten voor wie dit langer geleden was. Tenslotte konden we vanwege het 
longitudinale karakter van deze studie de instandhoudende factoren van 
vermoeidheid onderzoeken. Ernstige vermoeidheidsklachten bleken voor te komen 
bij 28 procent van de 170 onderzochte ziekte-vrije patiënten. Er werden geen 
verschillen in vermoeidheidsscores gevonden tussen de groep die voor een 
kwaadaardige en de groep die voor een goedaardige tumor was behandeld. 
Vermoeidheidsklachten waren het meest ernstig voor patiënten die de behandeling 
voor kanker slechts 1 tot 2 jaar geleden hadden afgesloten en voor patiënten die 
meer dan 1 operatie hadden moeten ondergaan. Twee jaar na de eerste meting 
bleek dat de meerderheid van de patiënten die ernstig vermoeid was nog steeds 
ernstig vermoeid was. Oncologische complicaties na de primaire behandeling,
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weinig optimisme en gerichtheid op lichamelijke sensaties bleken voorspellers van 
ernstige vermoeidheid.
In Hoofstuk 8 wordt het vervolg op de cross-sectionele borstkankerstudie 
(hoofdstuk 4 en 5) gepresenteerd. Het doel van dit vervolg was om te onderzoeken 
o f ernstige vermoeidheid na behandeling van borstkanker een aanhoudend 
probleem was. Bovendien wilden we weten o f aanhoudende vermoeidheid 
misschien wel gerelateerd was aan eerdere behandeling. En tenslotte wilde we 
onderzoeken welke factoren bijdroegen aan de instandhouding van ernstige 
vermoeidheidsklachten. Na de baseline-meting werd de groep ziekte-vrije 
borstkankerpatiënten gedurende een periode van 2 jaar gevraagd om elke maand 
een vermoeidheidsvragenlijst in te vullen en om na 2 jaar terug te komen voor een 
uitgebreide follow-up meting. Van de 150 patiënten hebben 121 patiënten de studie 
volledig afgerond. Negentien patiënten ontwikkelde een recidief tijdens de 2 
onderzoeksjaren en 10 patiënten zijn voortijdig gestopt met het onderzoek om 
diverse redenen. Gebaseerd op de maandelijkse vermoeidheidsvragenlijsten 
vonden we dat 24 procent van de ziekte-vrije borstkankerpatiënten aanhoudende 
klachten van ernstige vermoeidheid ervoer. Deze aanhoudende vermoeidheid bleek 
minder voor te komen bij patiënten die geen nabehandeling (radiotherapie en/of 
chemotherapie) hadden ondergaan en bij wie tevens de operatie (borstbesparende 
operatie o f amputatie) zonder complicaties was verlopen. Angst, beperkingen met 
betrekking tot het uitvoeren van dagelijkse activiteiten thuis o f op het werk en het 
idee weinig controle te hebben over de vermoeidheidsklachten bleken voorspellers 
van aanhoudende vermoeidheid te zijn.
In Hoofdstuk 9 tenslotte volgt een discussie omtrent de resultaten die in dit 
proefschrift genoemd worden. Bovendien worden er beperkingen en implicaties 
van het door ons uitgevoerde onderzoek besproken. We concluderen dat voor 
ongeveer 25 procent van de ziekte-vrije kanker patiënten ernstige vermoeidheid 
een aanhoudend probleem is, dat gepaard gaat met problemen en beperkingen op 
diverse terreinen. Aanhoudende vermoeidheidsklachten kwamen minder vaak voor 
bij patiënten voor wie de behandeling relatief kort had geduurd. Dit waren de 
patiënten die slechts 1 operatie zonder complicaties hadden ondergaan en bij die 
geen nabehandeling nodig was geweest. Factoren die verantwoordelijk waren voor 
de instandhouding van ernstige vermoeidheid waren lage self-efficacy, angst, 
beperkingen in het dagelijks functioneren, weinig optimisme en gerichtheid op 
lichamelijke sensaties. Verder is het aannemelijk dat ook menopausale klachten en 
moeite met de verwerking van de ervaring met kanker een rol spelen.
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